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Abstract
Biofilms are structured microbial communities where microorganisms are em-
bedded in a matrix of extracellular polymers (EPS) and can adhere to inert and
living surfaces. The interfaces where biofilms can form include several medical de-
vices, such as heart valves, catheters and implants. The failure of medicine to treat
emergent infectious diseases caused urgent seeking for alternative therapies. Fur-
thermore, pathogens organized in biofilms are much more resistant to antibiotics
than planktonic ones. Biofilms are recognized to be involved in more than 80% of
all microbial infections, being characterized by persistent inflammation and tissue
damage. These infections are caused by pathogenic or opportunistic microorgan-
isms combined with a chronic disease.
A number of essential elements, indispensable for biofilm formation and mainte-
nance have been evaluated as targets for the development of new drugs. As a
result of an ancient co-existence with prokaryotes, it is reasonable to hypothesize
that some eukaryotes, such as plants and fungi, have developed protection systems
based on secondary metabolites capable of modulating biofilm formation and QS
systems. Therefore, fungi collected in Germany were subjected to a screening for
biofilm modulators.
Within this work, a small lactone produced by Coprinus comatus was purified and
its structure elucidated. This compound, comatuslactone, showed a broad spectrum
bacteriostatic activity. When biofilms of Pseudomonas aeruginosa and Staphylococ-
cus aureus were treated with comatuslactone a severe damage as well as P. aerugi-
nosa biofilm dispersal could be visualized using confocal laser scanning microscopy
with live/dead®staining. Although no inhibition on biofilm formation could be
proved, experiments carried out using reporter strains based on homoserine-lactone
quorum sensing systems, revealed that this compound influences bacterial commu-
nication by blocking quorum sensing in the homoserine-lactone pathway. Addition-
ally, this compound inhibited pyocyanin and rhamnolipid B production. Moreover,
6 roridins and fusidic acid were purified from Calcarisporium arbuscula cultivation.
Their structures were solved using NMR and their biological activities have been
assessed.
Zusammenfassung
Biofilme sind strukturierte mikrobielle Gemeinschaften, in denen die Mikroor-
ganismen in einer Matrix aus extrazellulären Polymeren eingebettet sind und die
an unbelebte und belebte Oberflächen binden können. Die Oberflächen, an de-
nen sich Biofilme bilden können, umfassen auch viele Medizinprodukte wie Herzk-
lappen, Katheter oder Prothesen. Die zunehmenden Probleme der Medizin, neu
auftretende Infektionskrankheiten zu bekämpfen, verursacht eine breite Suche nach
neuen Therapiemöglichkeiten. Hinzu kommt, dass in Biofilmen organisierte Patho-
gene viel resistenter gegenüber Antibiotika sind als planktonische. Bei etwa 80%
aller mikrobiellen Infektionen nimmt man an, dass Biofilme beteiligt sind, was zu
persistierenden Entzündungen und Gewebeschäden führt. Solche Infektionen wer-
den durch pathogene oder opportunistische Mikroorganismen in Kombination mit
chronischen Erkrankungen verursacht.
Eine Reihe essentieller Mechanismen, unerlässlich für die Biofilmbildung oder dessen
Erhaltung wurden als Ziele für die Entwicklung neuer Medikamente untersucht.
Es ist vernünftig anzunehmen, dass einige Eukaryoten wie Pflanzen oder Pilze als
Ergebnis der uralten Ko-existenz mit Prokaryoten Schutzmechanismen entwickelt
haben, welche auf Sekundärmetaboliten beruhen, die Biofilmbildung und quorum-
sensing Systeme beeinflussen. Daher wurden in Deutschland gesammelte Pilze auf
solche Biofilm-Modulatoren untersucht.
In dieser Arbeit wurde ein kleines, von Coprinus comatus gebildetes Lakton aufgere-
inigt und in seiner Struktur charakterisiert. Diese Verbindung, Comatuslakton,
zeigte ein breites Spektrum von bakteriostatischen Aktivitäten. Wenn Biofilme von
Pseudomonas aeruginosa oder Staphylococcus aureus mit Comatuslakton behandelt
wurden, wurden schwere Schäden, bzw. bei P. aeruginosa auch die Auflösung des
Biofilms im konfokalen Laser-Rastermikroskop bei live/dead®Färbung beobachtet.
Obwohl keine Inhibierung der Biofilmbildung beobachtet wurde, zeigten Experi-
mente mit Reporter-Stämmen, dass die Verbindung die bakterielle Kommunikation
über die Blockade des quorum-sensing auf dem Homoserinlakton-Wege bewirkt.
Weiter blockiert Comatuslakton die Pyocyanin und rhamnolipid B Produktion.
Ausserdem wurden sechs Roridine und Fusidinsäure aus Calcarisporium arbuscula
Kulturen gereinigt, die Strukturen mittels NMR aufgeklärt und die biologischen
Aktivitäten bestimmt.
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Chapter 1
Introduction
1.1 Biofilms
Bacteria are frequently found living in highly organized and complex communities instead
of single cells. In fact, most of them show a preference in existing in these peculiar associa-
tions and are capable to switch among two different lifestyles: individual cells (planktonic
state) and biofilms. Transition between one state to the other is regulated by a variety of
physiological and environmental features, such as bacterial cell density, shear forces and
nutrients availability [1, 2].
Biofilms are defined as microbial cells, attached irreversibly to biotic or abiotic surfaces.
They usually occur as communities and are enclosed in a highly hydrated self-produced
slime matrix, named extracellular polymeric substances (EPS matrix), constituted of ex-
opolysaccharides, proteins, surfactants, glycolipids, membrane vesicles, extracellular DNA
and ions such as Ca2+. Bacterial biofilms are composed of a dry volume of approximately
10% of cells and 90% of the EPS matrix varying with environmental conditions. They
represent a protected mode of growth that allows bacterial survival in a hostile environ-
ment and can involve a single microbial species or several species. Global transcriptomic
profiling has shown that growing in biofilms cause bacteria to change their gene expression
and behavior when compared to the planktonic cells [1, 2, 3, 4, 5].
Solid-liquid interfaces provide optimal environmental conditions for the attachment, col-
onization and growth of microorganisms. Therefore, bacteria growing on biofilms are
recognized as a severe threat to the medical, industrial, engineering and agricultural sec-
tors of the economy, causing billions of dollars losses annually [4, 5, 6, 7]. On the other
hand biofilms are very useful, e. g. in cleaning rivers, processing our wastewater in sewage
plants, degrading our food in the gut or in protecting our skin against pathogens.
1.1.1 Biofilm structure and development
The structure of a biofilm shows a substantial complexity, even resembling tissues of eu-
karyotic organisms. Knowledge about the biofilm complex architecture was first achieved
through confocal scanning laser microscopy (CSLM) experiments. Hereby, bacterial cells
growing inside the EPS matrix, interspersed with water channels could be observed [2, 5].
A biofilm development is a high elaborated process, which starts from surface recognition,
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is regulated by bacterial communication and ends on colonization of new environments.
This process undergoes several steps, which are commonly seen to occur in the following
sequence (Fig. 1.1):
• Step 1. Initial cellular attachment to the surface (reversible attachment) - this
stage is characterized by a loose interaction between cells and surface. The cells
are surrounded by a small amount of EPS, and independent movement can still be
noticed, such as twitching and gliding. Some cells leave the surface again and adopt
the planktonic lifestyle [3, 8, 9].
• Step 2. Irreversible attachment. Here the cells produce a higher amount of EPS
matrix, which is a variable element and its composition differs according to the
species of microorganisms and environmental factors. In a general aspect, the EPS
matrix
– promotes cellular adhesion to the colonized surfaces
– enables bacterial cells assemblage and maintains biofilm stability
– captures organic and inorganic nutrients
– digests exogenous macromolecules, as also the EPS matrix itself, due to its
enzymatic activity
– improves genetic information exchange
– retains water by hydrogen bonding, protecting the biofilm against dehydration
– shields the biofilm, conferring protection against oxidants, pH shifts, toxins,
predators, host defenses during infection, antimicrobial agents and disinfectants
[8, 9].
• Step 3. Development of biofilm architecture. After the irreversible attachment, the
biofilm starts to grow acquiring either a flat or a mushroom shape [9].
• Step 4. Biofilm maturation. During this stage, the development of the typical
complex architecture of biofilms is achieved, containing water channels and pores,
together with the further spreading of bacteria inside the EPS matrix, away from
the surface. The architecture of mature biofilms can vary from flat, homogenous to
highly structured biofilms, characterized by empty spaces and towers of cells con-
fined in the EPS matrix. Water channels improve organic and inorganic nutrient
uptake and transport and assure metabolic waste and toxic products removal. Sev-
eral factors have been shown to influence biofilm architecture, including motility,
EPS matrix components and surfactant (e. g. rhamnolipid) production [8, 9, 10].
• Step 5. Dispersion. Mechanical damage or physiological processes, such as quorum
sensing can induce biofilm detachment. Essentially, biofilm dispersal is a natu-
ral mechanism which allows the bacteria to colonize other environments. Three
particular biofilm dispersal patterns can be recognized: a) swarming dispersal: in-
dividual bacterial cells simply leave the biofilm after dissolving the EPS, adopting
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the planktonic lifestyle until another surface is recognized; b) clumping dispersal:
bacterial aggregates are released and start a new colonization (sloughing) and c)
surface dispersal: biofilm moves over the already colonized surface, increasing its
area [6, 8, 9, 10].
Cells growing in biofilms are physiologically distinct from planktonic cells, and also vary
from each other according to the biofilm development. In a mature biofilm, exclusive
niches can be established, which arise from nutrients chemical gradients, metabolic activ-
ities of bacteria, waste and toxic products, as also signaling compounds. Bacteria living
inside a biofilm change their gene expression and physiological processes. Hence, they
adapt to particular regions within the biofilm, and are able even to select for advan-
tageous mutant phenotypes that can preferably survive under a certain environmental
condition [1].
Figure 1.1: Steps of biofilm formation. Source: Monroe et al. 2007 [11].
1.1.2 Quorum sensing (QS)
In 1970, Nealson et al. [12] after studying bacterial bioluminescence, showed that light
emission does not initiate immediately after media inoculation, but after the presence
of a considerable number of bacterial cells. Afterwards, in 1981, Eberhard et al. [13],
isolated and identified the compound N-(3- oxododecanoyl)-L-homoserine lactone, postu-
lating that this molecule could work as a specific genetic regulator, which acts after its
own excretion and accumulation into the culture medium. The terminology quorum sens-
ing (QS) was proposed by Fuqua et al. 1994 [14], to explain the phenomenon of bacterial
cooperative behavior. QS is a communication mechanism used by many bacterial species
to perceive and respond to a multitude of environmental factors. Among the several QS
systems known to date, the QS mediated by the production and subsequent recognition
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of the small molecules called autoinducers - e. g. N-acyl homoserine lactone (AHL), for
Gram-negative and small oligopetides for Gram-positive bacteria - are the most studied
(Fig. 1.2) [15].
Figure 1.2: Bacterial (QS) systems. A. Gram-negative QS. AHLs are secreted to the
environment, initiating the expression of target genes after the achievement of a thresh-
old concentration. B. Gram-positive bacteria QS systems. Small peptides are used as
autoinducers [16].
Concerning the AHLs structures, the homoserine lactone ring is conserved and binds to
the acyl moiety through an amine. Differences occur in the length and in the substituents
at the 3-position of the acyl chain, which varies between 4 and 16 carbons, generally by
addition of two-carbon moieties. The acyl chain can bear at C-3 a carbonyl, a hydroxyl
group or be fully reduced. This AHL diversity arises from an abundance of AHL syn-
thases in the bacterial world, therefore some microorganisms produce only one type of
AHL, while other species produce a large variety of these compounds [17, 18].
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Figure 1.3: Structure of AHLs. Adapted from Churchill et al. 2011 [18].
Small, linear or cyclic peptides, are used in QS systems of Gram-positive bacteria (Fig.
1.3). These peptides are secreted actively via an ATP-Binding Cassette (ABC) trans-
porter complex. When a threshold concentration is achieved in the environment, the
autoinducer peptides bind to a histidine kinase sensor, located on the bacterial mem-
brane, causing its auto-phosphorylation. Next, the phosphate group is transferred to a
regulator response protein, which has the capability of binding to DNA, therefore initiat-
ing the expression of QS controlled genes [19, 20].
Figure 1.4: Example of an oligopeptide autoinducer, used by Staphylococcus aureus [20].
Changing gene expression allows bacteria to perform particular behaviors only when ex-
isting in a community but not when living alone as a single cell. The majority of the
behaviors controlled by QS systems are productive only when a group of bacteria express
them in synchrony; these behaviors include bioluminescence, EPS matrix production,
sporulation, conjugation, pigment and antibiotic production [14, 15, 16]. However, in
pathogenic microorganisms these changes in gene expression allow bacteria also to co-
ordinate the expression of virulence factors, such as enzymes and toxins. A number of
molecules, produced via QS systems have the ability of minimizing the impact of the host
immune system until a proper number of microorganisms develops in order to establish
infection [15, 21].
1.1.3 Clinical relevance of biofilms
Biofilms are recognized to be involved in more than 80% of all microbial infections, being
characterized by persistent inflammation and tissue damage. These infections are caused
by pathogenic or opportunistic microorganisms combined with a chronic disease. A large
number of diseases are related to the presence of biofilms, and some examples are dental
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caries, periodontitis, chronic infection of the middle ear, chronic rhinosinusites, chronic
tonsillitis, endocarditis, fasciite, wound infections in burned patients, urinary and biliary
tract infections, osteomyelitis, pneumonia, including the majority of cases of patients with
cystic fibrosis [22, 23, 24, 25]. Macfarlane and Dillon 2007 [26] and Rosenvinge et al. 2013
[27] discussed in reviews the role and implications of biofilms on gastrointestinal conditions
and cited several diseases which could be related to biofilm formation and persistence.
Bacteria growing as biofilms are often associated with medical devices, characterizing a
new disease named chronic polymer-associated infection. Staphylococcus spp. followed by
Pseudomonas aeruginosa are commonly related with infections on artificial bone implants,
intravenous catheters, heart valves, pacemakers, ventricular assist devices, synthetic vas-
cular grafts and stents, urinary and orthopedic prostheses and contact lenses [3, 28].
One of the major challenges in the clinics is providing an assertive diagnosis between
an infection caused by a biofilm or by planktonic cells. Culture dependent methods are
often not sufficient to detect chronic biofilm infections, occasionally showing a negative
result even when severe symptoms related to bacterial infections are diagnosed. Molecular
methods, which are demonstrated to be high sensitive to accurate cases of a biofilm infec-
tion, should be conducted always when an infection suspicion is present [23, 24, 25, 28].
Therefore, several criteria were proposed by Hall-Stoodley and Stoodley 2009 [24], Parsek
and Singh 2003 [25] and Fux et al. 2003 [29] to a better distinction between infections
caused by planktonic cells or biofilms. According to these criteria, an infection caused by
a biofilm, should: a) be caused by microorganisms associated to biotic or abiotic surfaces,
including several types of epithelium and/or medical devices; b) show the presence of
aggregated cells in clusters or inside a EPS matrix, visible through direct examination of
the infected tissue; c) be restricted to a particular site in the host; d) be recalcitrant to
antibiotic treatments; e) show culture-negative results despite strong infection symptoms;
e) have an ineffective host clearance, evidenced by the presence of bacterial aggregates
associated with inflammatory cells in the host tissue.
Since bacterial presence stimulates immune response, biofilm infection symptoms may be
present, although they usually originate from planktonic cells or microbial metabolites,
such as toxins. The immune mediated response leads to damage of the surrounding tis-
sues, but generally the host defense mechanisms fail to resolve biofilm infections [24, 25].
Conventional antibiotics therapy typically shows some efficacy against biofilms infections,
usually improving the symptoms caused by detached cells or aggregates. Nevertheless,
eradication of biofilm infections using conventional antibiotic therapies generally fails,
and recurrent symptoms are common, even after cycles of antibiotic therapy. The results
of this colonization are persistent infections that are hard and even impossible to treat,
leading to severe health complications and longer hospital stays [29, 30].
1.1.4 Antibiotic resistance of biofilms
Antibiotic sensitive bacteria can extremely reduce their susceptibility when growing inside
a biofilm. Experiments of biofilms grown in vitro , also demonstrated an elevated reduc-
tion on antibiotic susceptibility, suggesting that resistance is not achieved through muta-
tions or mobile genetic elements, nor connected with host factors. When bacteria restore
the planktonic lifestyle, the sensitivity against antibiotics is also rapidly restored, show-
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ing that biofilms possess peculiar resistance mechanisms. Compared with free-swimming
cells, biofilms resist clearance by the host immune system and display increased resistance
to antimicrobial agents. Up to 1000-fold resistance (compared to planktonic cells) against
antibiotics, heavy metals and disinfectants have been reported. Hence, the necessary
doses of antibiotics to eradicate a biofilm infection will frequently exceed the maximum
tolerable doses, making the treatment, in most of the cases, not feasible [3, 5, 28].
Several concomitant factors occur in order to confer biofilm resistance against antibiotics:
- the biofilm EPS matrix may work as an adsorbent or reactant, reducing the amount
of antibiotic available for interaction with the bacterial cells, mostly with the bac-
teria that are located in the center of a biofilm. As biofilms are mainly constituted
by water, relatively small compounds, with the molecular weight of antibiotics can
freely pass through the matrix. However, antibiotics can be inactivated by enzymes
present in the EPS matrix, such as beta-lactamases, or be sequestered by binding,
in the case of aminoglycosides [31, 32].
- reduced metabolic and growth rates exhibited by bacteria which are growing in
biofilms, particularly those deep inside the community. On the surface of a biofilm,
the oxygen concentration is higher than in its core. This induces the generation
of chemical gradients, which leads to an increase of slow growing and persistent
cells. Under convenient environmental conditions, persistent cells can repopulate
a biofilm. Moreover, gradients in pH, caused by accumulation of acidic metabolic
products may have a negative impact on antibiotic efficacy [32, 33].
- biofilm cells are physiologically distinct from planktonic bacteria, and express spe-
cific protective factors, such as multidrug eﬄux pumps, upregulation of porin pro-
teins expression and stress responses. Bacterial cells adapt themselves to local
variations inside a biofilm, changing their gene expression and consequently their
physiological activities. Cell growth, protein synthesis, and metabolic activities are
stratified within a biofilm and mutation or recombination arises [1, 32].
Therefore, the majority of antibiotics which are capable to eradicate actively growing and
dividing bacterial cells failed completely against persistent and slow growing cells. This
coupled with the protection that the EPS matrix displays may explain the failure of most
of the available antibiotics treatment on clearing a biofilm infection.
1.1.5 Preventing and treating a biofilm
Preceding aggressive antibiotic administration and impregnation of medical devices with
antimicrobial agents are conventional approaches used in the clinics to prevent bacte-
rial attachment to surfaces and subsequent biofilm formation. For example chlorhex-
idine/silver sulfadiazine showed to decreased microbial medical devices colonization in
clinical trials [33, 34].
When a biofilm is already established in the host, chronic suppressive antibiotic treat-
ment and removal of the infected device are the main strategies used in the clinics to
control the infection. In particular cases, medical devices removal is possible, but mone-
tary investments and complication risks of a surgery have to be carefully evaluated. On
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the other hand, prostheses, pacemakers and cardiac implants are difficult and sometimes
even impossible to replace, putting emphasis on the need of optional and more effective
therapies. Moreover, the treatment of a biofilm infection requires combinations of multi-
ple antibiotics, which are administrated in elevated doses for a prolonged period of time,
often causing severe side effects. A short treatment with minimal antibiotic doses, usu-
ally applied to control acute infections, is greatly discouraged due to the risk of resistance
induction. Within this statement, a correct diagnostic, differentiating a biofilm from
an infection caused by planktonic microorganisms, is crucial to a successful treatment
approach decision [31, 32, 33, 34].
1.1.6 Research Strategies for controlling biofilm infections
A number of essential elements, indispensable for biofilm formation and maintenance have
been evaluated as targets for the development of new drugs [35, 36, 37]. Therefore, sev-
eral approaches have been proposed to control such infections: a) use of antimicrobial
peptides - several peptides have the property of disrupting membrane stability, showing a
potential to target the slow growing cells which are found inside the biofilms; b) antiad-
hesion agents - some compounds possess the ability of blocking bacterial attachment to
surfaces, consequently preventing biofilms formation (e. g. pilicides); c) bacterial polysac-
charides - a number of bacterial exopolysaccharides have the characteristic of inhibiting
and/or dispersing biofilms assembled by other species; d) quorum sensing inhibition, a
phenomenon called quorum quenching (QQ) - interrupting bacterial communication pre-
vents the expression of virulence factors, biofilm architecture and maintenance and in
some bacterial species, even biofilm formation. A combined administration of an antibi-
otic for killing the dispersed organisms and a quorum sensing inhibitor could be successful;
e) chelating agents destabilize biofilm architecture; f) D-amino acids and norspermidine
- both are shown to work synergistically to disassemble biofilms, acting through different
mechanisms; g) phage therapy - specific phages lyse bacterial cells and produce enzymes,
more specifically, polysaccharide depolymerases which have the ability on degrading the
biofilm EPS matrix; h) vaccines and antibodies - both are being evaluated aiming the
prevention of biofilm infections. Many antibodies are in distinct stages of clinical trials; i)
high-throughput screening (HTS) processes and chemical libraries screening are also be-
ing performed in order to identify new candidates which display activity against biofilms
[35, 36, 37, 38, 39, 40].
In addition already approved antibiotics also have shown to inhibit elements necessary
for biofilm formation. One example is azithromycin, which is inactive against plank-
tonic P. aeruginosa, but is able to delay biofilm development and to affect bacterial cell
communication. Gentamicin was proved to be effective against persistent cells, but only
when administrated in combination with fructose, glucose, manitol and pyruvate. A gen-
tamicin and mannitol, when applied synergistically, showed to be effective on treating
urinary biofilms infections in a mice model. Combinations of rifampicin and vancomycin,
daptomycin or levofloxacin have been successfully evaluated in vitro , but the high doses
necessary to eradicate a biofilm remain a constant concern [41, 42, 43, 44].
The currently available methods used for the treatment of biofilm infections are insuf-
ficient and demonstrate a high failure rate. Improvements in this field, including new
therapies which specifically prevent biofilm formation or actively eradicate already exist-
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ing biofilms, are urgently needed. Besides these numerous interesting research strategies,
infections caused by biofilms still prevail as a critical threat to human health. Further-
more, no small molecules targeting formation and/or eradication of biofilms are currently
on clinical trials [38, 39].
1.2 Natural products
The discovery of bioactive microbial secondary metabolites and their introduction into the
clinic caused a revolution in the medical field. In the past decades, population longevity
increased and pain and suffering caused by several diseases diminished. Numerous natural
products and their respective synthetic derivatives were successfully generated for medical
use, covering many therapeutic fields. They are the most important agents applied on
the treatment of infectious diseases, providing a multitude of chemical structures cou-
pled with an abundance of biological activities. Due to co-evolution processes, the lead
molecules originated from natural products frequently display an increased activity and
adaptation to biological systems than the ones arising from pure laboratorial synthetic
chemistry approaches [39, 40, 45, 46, 47, 48].
Although new chemical entities and promising bioactive lead molecules candidates are
being continuously discovered, most of the big pharmaceutical companies have restraint
their programs on natural products discovery. Synthetic combinatorial chemistry allied
with HTS technologies were believed to be a preferred strategy to discover unknown and
useful molecules for medicinal use. A number of companies invested heavily in these
approaches, and, without the expected success, finished their activities on natural prod-
ucts development. The result we have nowadays is a crisis in the field of anti-infective
agents, with a lower rate of this type of medicines introduced in the market combined
with a higher rate of bacterial resistance. Notably, the research on anti-infective agents is
still being performed by a few pharmaceutical companies, small biotechnology companies,
research institutes and academic laboratories worldwide [48, 49, 50, 51].
1.2.1 Eukaryotes as a natural source of biofilm modulators
As a result of an ancient co-existence with prokaryotes, it is reasonable to hypothesize that
some eukaryotes, such as plants and fungi, have developed protection systems based on
secondary metabolites capable of modulating biofilm formation and QS systems. Follow-
ing this rational, a number of natural products which exhibit the capacity of inhibiting or
dispersing bacterial biofilms were already identified [52, 53, 54]. In 1993, de Nys et al. [55]
isolated halogenated furanones from the macroalga Delisea pulchra (Rhodophyta). These
compounds possess several biological activities and are capable of inhibiting a number
of QS-controlled phenotypes, including swarming motility of Serratia liquefaciens, toxin
production of Vibrio harveyi and bioluminescence of Vibrio fischeri. Furanones (Fig. 1.5)
can also inhibit QS systems in P. aeruginosa, and it has been demonstrated that a deriva-
tive (C-30) (Fig. 1.2B) downregulates expression of more than 80% of the QS-regulated
genes, many of them encoding virulence factors [53, 54, 55]. The marine alga Laminaria
digitata produces and secretes the oxidized halogenated compounds hypochlorous and hy-
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pobromous acids, which react with AHLs, destroying the signaling molecule [57].
Figure 1.5: Chemical structures of furanones. A. Natural furanone, isolated from the
algae D. pulchra; B and C. Synthetic furanone derivatives [55, 57].
Plants such as carrots, garlic, habanero (chili), and water lily produce compounds that
interfere with bacterial QS systems. Garlic extracts were demonstrated to be able to clear
pulmonary P. aeruginosa infections in mouse models, and ajoene was recognized as the
major QS inhibitor. Allicin, a very well-known antibacterial compound extracted from
garlic, did not show any interference with QS systems of P. aeruginosa. The result of
interference with QS systems are dispersed and thinner biofilms, more accessible to antibi-
otic therapies and to the host immune system. Moreover, a decrease in the production of
virulence factors such as pyocyanin and rhamnolipids was demonstrated in the presence of
QQ compounds. Furthermore, cranberry extracts were also shown to inhibit biofilm for-
mation of Gram-positive and Gram-negative bacteria [52, 58, 59, 60, 61, 62, 63, 64, 65].
Furanones, compounds from garlic, polymers and many other molecules capable of in-
hibiting QS systems have been used as a scaffold for synthetic combinatorial chemistry
libraries. Modifications on the acyl chain substituents, on the lactone ring and synthe-
sis of analogues are the most common used approaches to generate compounds effective
against QS systems of bacteria [66].
1.2.2 Bioactive metabolites from fungi
Fungi are capable of producing a broad range of molecules, which vary from simple to
high complex structures. Normally, these metabolites are biosynthesized for specialized
physiological, social or protective reasons, conferring environmental advantages to the
producer. Mycelia and fruiting bodies contribute differently to the life cycle of a fungus,
where the vegetative mycelia responsible for substrata colonization and nutrient uptake
and the fruiting bodies, usually short-lived forms, for the reproduction. Mycelia are ex-
posed to nutrient and space competitors, including bacteria and other fungi, whereas the
fruiting bodies need protection against parasites, insects, mammals and other kind of
predators. Consequently, these both entities need to secure themselves against environ-
mental animosities. Therefore, fungi have evolved several chemical defense mechanisms,
which confer protection against the threats of the environment [67, 68, 69, 70].
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Since the discovery of penicillin the importance of fungal metabolites in the search for
new drugs has been demonstrated. Beside the enormous biodiversity of fungi, they pos-
sess peculiar and uncommon biosynthetic pathways, generating complex and new chem-
ical scaffolds. A number of products from these pathways are important compounds
used in the clinics and are also lead molecules for a semisynthetic approach: (i) beta-
lactams antibiotics, such as penicillins, cephalosporins, monobactams and carbapenems;
(ii) antifungal agents, like griseofulvin, echinocandins and pneumocandins; (iii) the an-
tihelmintic PF1022A; (iv) antilipidemic statins, such lovastatin, mevastatin and their
synthetic analogs and the immune-supressive cyclosporine [71, 72, 73].
Besides these molecules which are used for medical treatments, numerous others struc-
tures, belonging to diverse chemical classes and displaying several kinds of biological ac-
tivities have been isolated from fungal sources. Here, a few examples, grouped according
on their building blocks, leading to three classes, are given [45, 74].
• Polyketides
Polyketides comprise the most abundant class of secondary metabolites produced
by fungi, possessing from simple to highly diverse and complex structures. They
are synthesized by sequential reactions catalysed by polyketide synthases, assem-
bling carboxylic acids monomers, usually acetate and propionate. Alterations on the
carbon skeleton can develop previously, on the course and subsequently of chain as-
semblage, giving rise to the vast array of fungal polyketide structures. The outcome
compound depends mostly on type and amount of biosynthetic precursors applied
in the reactions [46, 71, 75, 76].
Both beneficial, used for human health and agricultural proposals, and harmful
compounds, such mycotoxins are present in this class. Moreover, several secondary
metabolites displaying a variety of biological activities have been continuously iso-
lated from fungal sources, such as polyacetylenes, styrylpyrones, lactones and aza-
philones (Fig. 1.6) [71, 75, 76, 77, 78, 79].
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Biformin 10-Hydroxy-undeca-
2,4,6,8-tetraynamide
Agrocybin
Antibacterial activity Antibacterial, antifungal,
cytotoxic activity
Cytotoxic, trypanocidal,
immunosuppressive
Producer: Polyporus bi-
formis a [80, 81].
Producer: Mycena viridi-
marginata [82, 83, 84].
Producer: Agrocybe dura
Marasmius [84, 85, 86].
Frustulosin Hispolon Chrysodin
Antibacterial activity Antiviral activity Antifungal activity
Producer: Stereum frustu-
losum [81, 84, 87, 88].
Producer: Inonotus
hispidus [81, 84, 87].
Producer: Sepedonium
chrysospermum [91, 92].
Strobilurin A Agaricoglycerides A and
B
Bulgarialactones 1 and 2
Fungicide Analgesic properties Antibacterial activity
Producer: Agaricus sp.,
Mycena spp., Strobilurus spp.
[84, 93].
Producer: Agaricus spp.,
Hebeloma spp.Psathyrella
spp.Stropharia spp. [94].
Producer: Bulgaria in-
quinans [95].
L-1 Cinnabarin
Nematocidal activity Antibacterial, antiviral,
antioxidant activities
Producer: Irpex lacteus
[84, 96].
Producer: Pycnoporus san-
guineus [81, 97, 98].
Figure 1.6: Examples of polyketides produced by fungi.
• Nonribosomal peptides (NRPs).
A large number of fungal secondary metabolites are non-ribosomally assembled pep-
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tides, generated by multimodular enzymes, the non-ribosomal peptide synthetases.
NRPs are differentiated from the other chemical classes by the wide range of amino
acids incorporated into their structures. Numerous biological activities, like an-
timicrobial, QS regulators, immunosuppressive (cyclosporine) and antiviral were
linked to compounds from this group of natural products. β-lactam antibiotics,
diketopiperazines, siderophores, peptaibols and the ergot alkaloids comprise some
examples of this type of compounds (Fig. 1.7) [74, 99, 100].
Mca Nebularine Cylindrocyclin A
Antiviral activity Activity against Mycobac-
terium spp.
Cytotoxic activity
Producer: Macrocystidia
cucumis [101].
Producer: Clitocybe nebu-
laris [84].
Producer: Cylindrocarpon
sp. [102].
L-α-aminoadipyl-L-
cysteinyl-D-valine
Epicoccin G Cyclo(Pro-Val)
ÎŠ-lactam antibiotics pre-
cursor
Antiviral activity Antibacterial activity
Producer: Penicillium
chrysogenum (Acremonium
chrysogenum) [74].
Producer: Epicoccum ni-
grum [103].
Producer: Colletotrichum
gloeosporioides [104, 105].
Figure 1.7: Examples of NRPs produced by fungi.
• Terpenoids
Terpenes are composed of C5 isoprene units, linked in a "head-to-tail manner".
Their classification is based on the number of isoprene units: monoterpenes (C10),
sesquiterpenes (C15), diterpenes (C25), triterpenes (C30) and tetraterpenes (C40).
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Their structures can be linear, cyclic, saturated or unsaturated and the isoprene
units can also be linked to another type of carbon skeleton. Terpenes diversity is
due to the large amount of terpene synthases. This class of compounds demon-
strates numerous biological activities, including antibacterial, antifungal, antiviral
and cytotoxic (Fig. 1.8) [74, 106].
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Collybial Wickerol A and B Phellodonic acid
Antiviral and antibacte-
rial activity
Antiviral activity Antibacterial, antifungal,
algicidal
Producer: Collybia conflu-
ens [84, 106, 107].
Producer: Trichoderma
atroviride [108].
Producer: Phellodon
melaleucus [84, 109].
Ganoderic acid Hypnophilin and Desoxy-
hypnophilin
Cheimonophyllal
Antiviral activity Antibacterial and an-
tiparasitic activity
Nematocidal activity
Producer: Ganoderma lu-
cidum [81, 110].
Producer: Lentinus crini-
tus, L. strigosus, Pleurotel-
lus hypnophilus [84, 106, 111,
112, 113].
Producer: Cheimonophyl-
lum candidissimum [84, 114].
Enokipodin C Sterelactone C Lentinellic acid
Antibacterial activity Antibacterial, antifugal
and cytotoxic activity
Antibacterial and cyto-
toxic activity
Producer: Flammulina ve-
lutipes [115].
Producer: Stereum sp.
[116].
Producer: Lentinellus om-
phalodes, L. ursinus [84, 106,
117].
Figure 1.8: Examples of terpenoids produced by fungi.
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1.2.3 Fungi as biofilm modulators
Information about fungi metabolites capable of inhibiting QS and biofilm formation are
scarce in the literature. Following the lessons learned from the past concerning the genus
Penicillium as a prolific source of secondary metabolites, fifty strains were screened for
compounds which could modulate P. aeruginosa QS systems, leading to the identification
of patulin and penicillic acid as inhibitors. In 2012, Scopel et al. [118] showed that Staphy-
lococcus epidermidis biofilm could be inhibited by the presence of the diketopiperazine
cis-cyclo(Leucyl-Tyrosyl), isolated from a marine Penicillium sp. Ophiobolins, sesquiter-
penes isolated from the marine fungus Emericella variecolor could inhibit Mycobacterium
bovis (BCG) and M. smegmatis biofilm formation. Moreover, QS inhibitors were found in
mushrooms extracts, were a screen of crude extracts of 14 Basidiomycotina species was
performed [119, 120].
The proofed ability to produce a wide variety of bioactive compounds, and the lack of
information about metabolites capable to interfere with QS and biofilm formation, makes
fungi obvious candidates for screening for quorum-quenching secondary metabolites. Since
these organisms may produce such compounds to defend themselves against their natu-
ral enemies, it can be expected that this group of organisms produce metabolites which
are capable to inhibit bacterial quorum sensing. Therefore, the task of this work was to
cultivate Basidimycotina collected in Germany and search for compounds able to inhibit
biofilm formation.
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Chapter 2
Hypothesis and rationale
Bacteria growing on biofilms are recognized as a serious menace to human health, caus-
ing chronic and severe diseases. The failure of conventional medical treatments against
emerging infectious diseases together with the increasing incidence and severity of such
infections has urged seeking for alternative therapies. Within this context, several ap-
proaches with the aim of finding more efficient treatments have been discussed.
Since decades, fungi have been demonstrated to be a prolific source of bioactive sec-
ondary metabolites, producing a wide range of chemical structures. Their fruiting bodies
are exposed to rain and moist climate periods, especially in the German fall, offering
an ideal substratum for the establishment of biofilm communities. On the other hand,
fungal vegetative mycelia have to compete with several kinds of organisms present in the
environment for nutrients and space. It is clear that fungi have self-defense mechanisms
which are crucial to efficient substrata colonization and reproduction. Aiming at products
used for chemical defense, we exploited compounds from fungal origin for their possible
applications for controlling bacterial pathogenic biofilms.
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Chapter 3
Objective and specific aims
The main objective of this study was to investigate the biofilm modulatory properties of
fungal secondary metabolites. The specific aims were:
• Assessment of microbial communities on surfaces of Basidiomycotina fungi fruiting
bodies collected in Germany using the SSCP technique.
• Cultivation of these fungi, taxonomic and molecular identification of the isolates.
• Preliminary screening of crude extracts for antimicrobial and antibiofilm activities.
• Purification of active fractions, identification and characterization of these com-
pounds by NMR and mass spectrometry.
• Evaluation of QS systems inhibitory properties of the isolated compound.
• Assessment of the toxicity of active compounds in eukaryotic tissue culture.
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Chapter 4
Material and Methods
4.1 Chemicals
4.1.1 Organic solvents
Acetonitrile (ACN) and methanol (MeOH) - HPLC grade -, acetone, chloroform, dichloro-
methane, ethanol, ethyl acetate (EtOAc), isopropanol and heptane were purchased from
J.T Baker®(Deventer, Holland). Butanol was purchased from Sigma-Aldrich (St. Louis,
Missouri, USA). Deuterated chloroform (CDCl3) and methanol (CD3OD) were purchased
from Deutero GmbH (Kastellaun, Germany), acetic acid and formic acid from Carl Roth
GmbH (Karlsruhe, Germany).
4.1.2 Organic reagents
Bacteriological agar, malt extract, peptone, tryptone and yeast extract were purchased
from Difco (Sparks, Maryland, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), 3-(N-morpholino) propanesulfonic acid (MOPS), 4’,6-diamidino-2-phenyl-
indole (DAPI), bromophenol blue, crystal violet, folic acid, lead citrate, sodium ca-
codylate, uranyl acetate, xylene cyanol were purchased from Sigma-Aldrich®. Biotin,
dimethylsulfoxide (DMSO), ethidium bromide (EtBr), ethylenediamine tetraacetic acid
disodiumsalt dihydrated (Na2- EDTA), formamide (CHONH2), formaldehyde (CH2O),
glycine, paraformaldehyde, sodium carbonate (Na2CO3), tris HCl and Triton were pur-
chased from Carl Roth GmbH. Bind silane and repel silane were purchased from GE
Healthcare life sciences (Uppsala, Sweden). Inositol and thiamine HCl were purchased
from Calbiochem (Darmstadt, Germany). N-3-oxododecanoyl-L-homoserine lactone (3-
oxoC12-HSL), N-oxohexanoyl-L-homoserine lactone (3-oxo-C6-HSL) and pyocyanin were
purchased from Cayman Chemical (Denver, Colorado, USA). Glucose and glutardialde-
hyde came from Merck (Darmstadt, Germany), tetramethylethylenediamine (TEMED)
from Amresco®(Solon, Ohio, USA) and agarose from Lonza (Basel, Switzerland).
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4.1.3 Media and antibiotics
Brain heart infusion (BHI), casein-soya-peptone broth (CASO) and potato dextrose broth
(PDB) were purchased from Carl Roth GmbH, Mueller Hinton (MH) agar and potato
dextrose agar (PDA) from Difco, Dulbecco’s modified Eagle Media (DMEM) from Lonza
and RPMi-1640, gentamycine and tetracycline from Sigma-Aldrich®.
4.1.4 Antibodies and enzymes
Anti- α-tubulin was purchased from Sigma-Aldrich®and anti-mouse Alexa Fluor 488 from
Molecular Probes®, Life Technologies GmbH (Darmstadt, Germany). RNAse was pur-
chased from Macherey-Nagel (Düren, Germany), proteinase K from AppliChem (Darm-
stadt, Germany) and lambda exonuclease from New England Biolabs (Schwalbach, Ger-
many).
4.1.5 Primers
Primer sets used for fungal identification were purchased from Eurofins MWG Operon
GmbH (Huntsville, Alabama, USA). Phosphorylated primer set used for SSCP analysis
was purchased from Invitrogen™, Life Technologies GmbH.
4.1.6 Inorganic reagents
Boric acid (H3BO3), chlorhydric acid (HCl), magnesium chloride, hexahydrated (MgCl2 x
6 H2O), heptahydrated magnesium sulphate and anhydrous (MgSO4 x 7 H2O and MgSO4),
manganese sulphate (MnSO4), silver nitrate (AgNO3), sodium chloride (NaCl), phospho-
ric acid (H3PO4), potassium chloride (KCl), disodium hydrogen phosphate (Na2HPO4),
sodium thiosulfate (Na2S2O3), potassium dihydrogen phosphate (KH2PO4) and sodium
hydroxide (NaOH) were purchased from Carl Roth GmbH. Hexahydrated Ferric chloride
(FeCl3 x 6 H2O), sodium phosphate (Na3PO4), osmium tetroxide (OsO4) and heptahy-
drated zinc sulphate (ZnSO4 x 7 H2O) were purchased from Sigma-Aldrich®. Dihydrated
calcium carbonate (CaCl2 x 2 H2O) was purchased from Merck, ammonium persulfate
(APS) from Amresco®.
All kits used in this work and chemicals which are not listed above are mentioned together
with the supplier in the correspondent method.
4.2 Biological material
4.2.1 Basidiomycotina collection
Fifteen Basidiomycotina species were collected in Braunschweig, Göttingen and Köris,
Germany. A tissue fragment from the inner part and from the skin covering the pilleus
of the fruiting bodies was frozen in Tris EDTA (TE) Buffer (10 mM Tris, 1 mM EDTA,
pH 8.0) for DNA extraction, sequencing and bacterial community analysis.
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4.2.2 Bacterial strains
Bacillus cereus DSM 626, Escherichia coli DSM 498, Micrococcus roseus DSM 20447 and
Staphylococcus aureus DSM 1104 were purchased from the German collection of microor-
ganisms and cell cultures (DSMZ). Streptococcus mutans UA159 was kindly provided by
Prof. Irene Wagner-Döbler, P. aeruginosa PA14 by Dr. Mathias Müsken, E. coli MT102
(pSB403) and Pseudomonas putida F117 (pKR-C12) by Prof. Kathrin Riedel.
4.2.3 Yeast strains
Candida albicans DSM 11225, Candida guilliermondii DSM 70052, Candida krusei DSM
6128, Candida parapsilosis DSM 5784, Candida tropicalis DSM 70151, Rhodotorula gluti-
nis DSM 70398 and Yarrowia lipolytica DSM 70561 were purchased from DSMZ.
4.2.4 Eukaryotic cell line
Mouse fibroblast L-929 DSMZ ACC2 was purchased from DSMZ.
4.3 Isolation of fungi
4.3.1 Isolation and mycelia development in different media
Small tissue fragments from the inner part of the collected fruiting bodies were excised
and placed on three solid medium: a) Melin-Norkrans Modified (MNM); b) biotin aneurin
folic acid agar (BAF) and c) yeast and malt extract agar (YEM), for mycelia isolation.
After fungal growth, small pellets were cut and placed into cryotubes containing PDB
with 20% of glycerol. The stocks were kept at - 80◦C. Mycelia development in four solid
medium (BAF, MNM, PDA and YEM) pH 5.0, 7.0 and 9.0 was measured in order to set
up the screening conditions. BAF, MNM and YEM components are listed in table 5.12.
PDA was obtained commercially.
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Table 4.1: Chemical composition of the media used for fungal isolation.
BAF MNM YEM agar
glucose 30 g 10 g -
malt extract - 3 g 20 g
yeast extract 0.2 g - 3 g
peptone 2 g - -
(NH4)2HPO4 - 0.25 g -
KH2PO4 0.5 g 0.5 g -
MgSO4.7H2O 0.5 g 0.15 g -
FeCl3.6H2O 0.01 g 0.012 g -
NaCl - 0.025 g
ZnSO4.7H2O 0.001 g - -
MnSO4.4H2O 0.005 g - -
CaCl2.2H2O 0.1 g 0.067 g -
thiamin HCl 50 µg 30 µg -
biotin 1 µg - -
folic acid 100 µg - -
inositol 50 µg - -
water 1000 mL 1000 mL 1000 ml
agar 15 g 15 g 15 g
4.4 Molecular methods
4.4.1 Fungal identification
DNA from fungal colonies and fruiting bodies was used for PCR amplification and se-
quencing reaction in order to identify the isolates. DNA was extracted from mycelia
and fruiting bodies fragments (10 - 50 mg) using the kit NucleoSpin®PlantII (Macherey-
Nagel), as recommended for fungal DNA extraction. Fungal material was incubated in
ethanol overnight and cell lysis was performed using sea sand (Merck) and a Fastprep®
(MPbiomedicals, Santa Ana, USA) instrument (running time: 45 s, speed: 4.0 m sec−1).
Samples were incubated with 10 µl of RNase and proteinase K (10 mg ml−1) for 1 h (op-
tional step). The specific fungal primers set ITS1F - CTTGGTCATTTAGAGGAAGTAA
and ITS4 - TCCTCCGCTTATTGATATGC was used for PCR amplification [121].
Amplification was performed in an Eppendorf Mastercycler in a 50 µL reaction mixture
containing 5 µL 10 x PCR buffer, 2.5 mM MgCl2, 10 mM dNTP Mix (2.5 mM each), 1
µM of each primer, 35.5 µL Milli-Q®water, 2 µL (15 ng) of DNA template and 0.5 µL Taq
polymerase (5000 U ml−1). The following program was used: 35 cycles, initial denatura-
tion: 94◦C for 05 min, melting: 94◦C for 40 s, annealing: 55◦C for 45 s, extending: 72◦C
for 1 min 30 s, final extension 72◦C for 07 min. PCR products were run on a 2% agarose
gel for 2.5 h at 100 V using a horizontal gel system (Starlab International, Ahrensburg,
Germany). Molecular weight marker IV (Bioline GmbH, Luckenwalde, Germany) was
used for fragments size determination. The gels were stained in an EtBr bath for 20 min
and visualized under UV light using E.A.S.Y Win32 gel documentation system (Herolab,
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Wiesloch, Germany). The bands were excised and purified with a NucleoSpin®ExtractII
kit (Macherey-Nagel).
A sequence reaction was performed using the DYEnamic ET Terminator cycle sequenc-
ing kit (Amershan Biosciences, Freiburg, Germany) and both primers. The product was
purified with a Dye Ex Spin Kit (Qiagen, Hilden, Germany). Amplicons were sequenced
at HZI on an Applied Biosystems 377 genetic analyser. The software Sequencher 4.10.1
was used to analyse the obtained sequences.
4.4.2 Evaluation of microbial communities on basidiomas using
single strand conformation polymorphism (SSCP) finger-
print
A FastDna®Spinkit for Soil (MPbiomedicals) was used to extract DNA from a frag-
ment of the skin covering the mushroom pilleus. PCR reactions were performed us-
ing the eubacterial primers 27F - AGAGTTTGATCMTGGCTCAG- and 521R - Ph -
ACCGCGGCTGCTGGCAC, in order to access the bacterial communities through SSCP
fingerprint [122, 123]. Amplification was performed in a Eppendorf Mastercycler in a 50
µL reaction mixture containing 05 µL 10 x PCR buffer, 2.5 mM MgCl2, 10 mM dNTP
Mix (2.5 mM each), 1 µM of each primer, 35.5 µL Milli-Q®water, 2 µL of DNA template
(15 ng) and 0.5 µL Taq polymerase (5000 U ml−1). The following program was used: 30
cycles, initial denaturation: 95◦C for 3 min , melting: 95◦C for 1 min , annealing: 56◦C
for 40 s , extension: 72◦C 40 s, final extension 72◦C for 10 min. PCR products were
analysed on a 1.5% agarose gel stained with EtBr.
After purification of PCR reactions using a MiniElute kit (Qiagen) as recommended by
the manufacturer, amplicons were digested according to the following reaction: 10 µl of
amplicons in elution buffer (EB) were incubated with 2.5 µl of lambda exonuclease buffer
(New England Biolabs) and 2.5 µl of lambda exonuclease (5000 U ml−1) at 37◦C for 1
h. The resulting phosphorylated single strand was further purified using the same kit.
A NanoDrop spectrophotometer (PEQLAB GmbH Biotechnologie, Erlangen, Germany)
was used to quantify the DNA obtained from the reaction. A solution containing 100 ng
of the single strand DNA, 4 µl of Milli-Q®water and 4 µl of SSCP loading buffer (47.5%
formamide, 5mM NaOH, 0,12% bromophenol blue and 0.12% xylene cyanol) was sub-
jected to electrophoresis on a polyacrylamide gel (table 5.13).
Table 4.2: Composition of polyacrylamide gels.
Polyacrylamide gel preparation
10 x TBE Buffer 6 mL
(891.5 mM tris-base; 889.5 mM boric acid; 22.4 mM Na2 EDTA)
Bi-destilated water 36 mL
MDE 18 mL
10% APS 240 µL
TEMED 24 µL
Two previous cleaned glass plates were respectively coated with: a) a solution of 3 ml
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ethanol p.a.; 30 µl of acetic acid and 30 µl of Bind-silane) and b) 500 µl of Repel-silane.
The gel was poured between the glass plates and allowed to polymerize for 2.5 h. Gels
were run at 400 V for 16 h at 20◦C in a PEQLAB electrophoresis unit and subsequently
silver stained, according to Bassam et al. 1991 [124]. Briefly, the gel was fixated with a
10% acetic acid solution during 30 min and washed 3 times during 5 min with bi-destilated
water. An aqueous solution of 0.1% AgNO3 and 500µl of formaldehyde was used to stain
the gel, for 30 min. After washing, the gel was developed using a 2.5% Na2CO3 with 500
µl of formaldehyde and 500 µl of a 2% Na2S2O3 solution. To stop the reaction, the gel
was allowed to stand for 10 min in a 2% glycine and 0.5% EDTA aqueous solution. The
last step consisted of gel impregnation, using a solution of 10% glycerol during 10 min.
A polyester backing paper was used to cover the stained gel. All solutions were prepared
using 500 mL of bi-destilated water. Single bands were excised from the polyacrylamide
gels and eluted in an SSCP extraction buffer (10 mM Tris-buffer, 5 mM KCl, 1.5 nM
MgCl2 x 6 H2O, 0.1% Triton x 100, pH 9.0) at 95◦C for 15 min. The DNA template
in this solution was used for a PCR with the 27F-521R primers set. PCR reaction was
cleaned with the MiniElute kit and a sequence reaction was performed in the same fashion
as described in the 4.4.1.
4.5 Screening for bioactive secondary metabolites
4.5.1 Production of secondary metabolites
The fungi strains BS_HZI4, BS_HZI14, BS_BP1, GÖ_W13, GÖ_W19 and KÖ_S3
showed appropriate growth rate in the tested conditions and were chosen for the secondary
metabolites screening. After growth in Petri dishes with YEM agar at 22◦C, 5 x 5 mm
pellets sized were transferred to 100 ml Erlenmeyer flasks filled with 35 ml of BAF, PDB
and YEM broth, pH 9.0, pH 7.0 and pH 5.0. After 14, 21, 28, 35 and 42 days of static
incubation, at 20◦C and 25◦C, in the dark, mycelia were separated from the liquid medium
by filtration under vacuum using a Whatman paper n◦1. The obtained aqueous extracts
were concentrated using a lyophilisator (Martin Christ Gefriertrocknungsanlagen GmbH,
Osterode am Harz, Germany), then resuspended in 1.1 ml of Milli-Q®water and tested
for their biological activities. Freeze dried culture media was used as control. A total of
121 extracts showed biological activity and the compounds were extracted with organic
solvents. Extracts obtained were compared using RP-HPLC/MS and the producing fungi
were incubated in 5 L of media in order to obtain a larger amount of the active compounds
for structure elucidation and testing.
4.5.2 Liquid - liquid extraction
The obtained supernatant was extracted three times with ethyl acetate, followed by wash-
ing with an aqueous sodium chloride saturated solution. In the end, anhydrous MgSO4
was added to the organic fraction, to complete removal of residual water. The remain-
ing aqueous solution was re-extracted using 2-butanol. Extracted fresh autoclaved media
were used as background control.
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4.5.3 Extraction from mycelia and fruiting bodies
Mycelia obtained from the cultivation of the strains BS_HZI4, GÖ_W13 and GÖ_W19
and fruiting bodies from Boletus spp. and Coprinus spp. were freeze dried and macerated.
The obtained powder was scaled and first extracted with heptane during 7 h, followed
by an overnight extraction using ethyl acetate and finishing with an 8 h extraction using
methanol. The volume of organic solvent used corresponded to 20% of sample dry weight.
Extracts obtained according to 4.4.2 and 4.4.3 items were submitted to solvent organic
evaporation at 40◦C, on a rotary evaporator and tested for their biological activities.
4.5.4 Reverse Phase-High Performance Liquid Chromatography
/Mass Spectrometry (RP-HPLC/MS)
RP-HPLC/MS was carried out on an Agilent 1200 series system (Agilent Technologies,
Santa Clara, California, USA), using a C18 analytical column (Nucleosil®125 x 20 mm,
Macherey-Nagel), on a gradient condition. A 6460 TripleQuad with electrospray ionization
(ESI) was used for Mass Spectrometry. The running conditions were: (solvent A) Milli-
Q®water: formic acid (0.1 %) and (solvent B) acetonitrile: formic acid (0.1 %), the
gradient started with 5% B at 0 min and 100% B at 15 min; UV absorbance was detected
using a diode array detector (DAD) at 210, 230, 254, 260 and 400 nm; flow rate: 0.3 mL
min−1. Ionization was performed in the positive and negative modes with the following
ion source parameters: N2 flow 9 L min−1 and temperature 300◦C, nebulizer pressure
25 psi, sheath gas flow 7 L min−1 and temperature 300◦C, capillary voltage 5000 V and
charge voltage 1000 V. The fragmentor voltage was tested from 0 to 150 V, and set on
100 V. An MS scan was performed from 20 to 2000 atomic units. Chromatograms were
analysed using Qualitative Analysis Mass Hunter Software (Agilent Technologies).
4.5.5 Fractionation strategies
4.5.5.1 Fractionation using Reverse Phase-High Performance Liquid Chro-
matography (RP-HPLC)
RP-HPLC fractionation was carried out on an Agilent 1100 series system, coupled with
a fraction collection accessory, using a C18 analytical column (Nucleosil®125 x 20 mm)
on a gradient condition. Fractions were collected each 0.15 s, on a microtiter plate. The
running conditions were set according to 4.5.4. The microtiter plates were allowed to dry
under N2 stream. After complete solvent removal, microbiological tests were performed.
If chromatograms showed a lack of peak separation or if the biological activity was no
further detected, the following fractionation approaches were tested.
4.5.5.2 Fractionation using solid phase extraction (SPE)
C18 (A) and SiOH (B) (Macherey-Nagel) cartridges were eluted using (A) methanol:
water (85 : 15), methanol: water (50 : 50), methanol (100); (B) heptane (100), ethyl
acetate (100), ethyl acetate: methanol (50 : 50) and ethyl acetate: methanol (30 : 70).
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4.5.5.3 Fractionation through molecular weight
The crude extracts were fractionated using Sephadex LH-20 (GE Healthcare) as stationary
phase and eluted with methanol. All obtained fractions were tested for their biological
activities. Active fractions were analysed using RP-HPLC/MS.
4.6 Purification
4.6.1 Thin layer chromatography (TLC)
Pre-coated glass silica plates (silica gel 60 F264 1 mm, 20 x 20 cm, Macherey-Nagel) were
used for normal phase TLC. The solvent system dichloromethane: MeOH (98 : 4) was
used to develop the plates. The chromatographic plates were visualized under UV light at
264 nm. Bands were scraped and the compounds extracted with dichloromethane: MeOH
(90 : 10).
4.6.2 Semi preparative RP-HPLC
Purification of compounds was carried out on an Agilent 1200 series system, using a C18
column (Varian, Agilent Technologies 250 x 100 mm) and a specific guard column. The
method was adjusted according to the results obtained from the analytical experiments
and set as follows: for the extract obtained from BS_HZI4 the running conditions were:
(solvent A) Milli-Q®water and (solvent B) acetonitrile, the gradient starting with 90% of
A at 0 min and 20%B at 20 min. For a fraction obtained from BS_HZI14 a gradient
condition was applied using the following running conditions: (solvent A) Milli-Q®water
and (solvent B) acetonitrile, the gradient starting with 30% of A at 0 min and 100%B
at 15 min. The pure isolated compounds were subject to mass spectrometry and nuclear
magnetic resonance (NMR) to elucidate their structures.
4.7 Structure Elucidation
NMR spectra were recorded on a Bruker 400 MHz spectrometer, in CDCl3 and CD3OD
using a 5mm tube (Norell®, Deutero GmbH). Structures were elucidated with 1H- and
13C-NMR including 1H-1H- and 1H-13C-COSY. The already known structures had their
1H spectra recorded and were compared to data from literature.
4.8 Biological activity
4.8.1 Antimicrobial activity
4.8.1.1 Disk diffusion test
C. albicans, E. coli, P. aeruginosa, S. aureus, were used as target microorganism to
assess the antimicrobial activity of the organic extracts and fractions. Antimicrobial
susceptibility tests were performed using the Kirby-Bauer method [125]. Briefly, bacteria
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were inoculated on Luria Bertani (LB) (10 g.L−1 yeast extract, 5 g.L−1 tryptone and 10
g.L−1 NaCl) and incubated overnight. The broth was further diluted in sterile Phosphate
Buffered Saline (PBS) (NaCl 137 mM, 2.68 mM KCl, 10.1 mM Na2HPO4, 1.76 mM
KH2PO4) and inocula adjusted to 0.5 according to the McFarland scale. With a sterile
swab (Heinz Herenz, Hamburg, Germany), a plate containing MH agar for bacteria and
PD agar for yeasts was uniformly inoculated. A paper disk containing 10 µl of the organic
extracts or fractions diluted in 1 mL MeOH was placed in the center of the plate. A disk
containing 10 µl of MeOH was used as control. The plates were incubated at 37◦C for
bacteria and 30◦C for yeasts and the inhibition zones were measured after 24 h.
4.8.1.2 Minimal inhibitory concentration (MIC)
Minimal inhibitory concentrations were defined for yeasts and bacteria mentioned in sec-
tions 4.2.2 and 4.2.3, using the method of micro-dilution. Briefly, 1x108 cells were inocu-
lated in RPMI-1640 and LB medium, for yeasts and bacteria, respectively. After addition
of the isolated compounds, serial dilutions were performed in round-bottom, non tissue
treated polystyrene microtiter plates (Falcon®Micro Test™). Compound concentrations
ranged from 300 µg mL −1 to 0.3 µg mL −1. MeOH was used as control. After 24 - 48 h
of incubation for yeasts and 16 - 24 h for bacteria, 10 µl of each well was inoculated on
PD and LB agar to determine antibiotic or static activity.
4.8.1.3 Preparation of bacterial cells for transmission electron microscopy
(TEM)
TEM was performed in order to investigate ultrastructural changes in bacterial cells sub-
mitted to the active compound. P. aeruginosa and S. aureus were grown overnight in
LB, at 37◦C. Tubes were centrifuged and the pellet was washed with PBS. Pellets were
resuspended in new media containing the active compound MIC and the controls in a
new media with 5 µl of MeOH. After overnight incubation, the tubes were centrifuged
and pellets washed with PBS. Cells were fixed in 2.5% glutardialdehyde, buffered with
phosphate buffer (PB) (20 mM Na3PO4, 150 mM NaCl, pH 7.2), at room temperature
for 30 min.
4.8.1.4 Embedding and ultrathin sectioning
After washing in 0.1 x PB, the cells were post-fixed with 1 % OsO4, in 0.1 M sodium
cacodylate, pH 7.0, overnight at 4◦C. Cells were immobilized in 2% Difco agar in PB.
Dehydration in an acetone series (30, 50, 70, 90 and 100%) was done at room temperature,
requiring 20 min for each dehydration step. Infiltration with ERL resin [126] as a resin
+ acetone mixture (1 + 1) was done at ambient temperature overnight, followed by pure
resin infiltration overnight again and finally for 4 h. Probes were transferred into a gelatin
capsule and filled with resin monomer. Polymerization was done for 8 h at 70◦C. Ultrathin
sections were cut with a diamond knife using the Leica Ultracut ultramicrotome (Leica,
Heidelberg, Germany) and were picked up with Formvar-coated grids (300 mesh, Cu).
Sections were post-stained for 10 min with 3 % aqueous uranyl acetate and for 5 min with
0.5 % lead citrate [127, 128].
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4.8.2 Inhibition of biofilm formation
P. aeruginosa, S. aureus and S. mutans were used in this assay. The experiments
were performed in 96-well, flat bottom, polystyrene, non tissue treated microtiter plates
(Falcon®Micro Test™, Becton Dickinson labware, Franklin Lakes, USA). After overnight
incubation at 37◦C, P. aeruginosa and S. aureus were inoculated in CASO broth, with
the inocula adjusted to 0.5 according to Mcfarland scale. For S. mutans, BHI broth was
used, and the strain was allowed to grow for 24 h with 5% of CO2 tension. 100 µl of
media containing bacterial cells were pipetted into a microtiter plate with the addition
of 50 µl of the aqueous extracts. 4 wells were employed to each aqueous extract. When
organic extracts and fractions were used, extracts were diluted in 1 mL MeOH and 10 µl
were added to 140 µl of medium. Fresh freeze dried media and media with 5 µl of MeOH
were used as control.
The microtiter plates were covered with a sterile adhesive porous paper (Kisker Biotech
GmbH, Steinfurt, Germany) and incubated at 37◦C for 18 h. After the incubation time,
the medium was discharged, the plates washed with PBS and stained for 15 min with
a 0.1% crystal violet aqueous solution. The residual stain was removed with successive
washing, the plates were air-dried and the biofilm suspended in a solution containing 30%
of acetic acid. A plate reader was used to determine the amount of biofilm in the wells, at
the absorbance of 595 nm [129]. The amount of biofilm was calculated as follows: Biofilm
amount (%) = (Control-Blank)-(Sample-Blank).
4.8.3 Activity on bacterial biofilms
P. aeruginosa and S. aureus were incubated overnight and the cell concentration adjusted
to 1x108, in CASO broth. Inoculated media (200 µL) was pipetted into the wells on
an 8-well glass chamber system (Nunc, Thermo Fisher Scientific, Rochester, New York,
USA) for S. aureus and an 8-well Permanox chamber system (Nunc, Thermo Fisher Sci-
entific) for P. aeruginosa. After 16 h of incubation, wells were washed with PBS and fresh
medium with serial dilutions of the active compound was added. Concentration ranged
from 300 µg mL−1 to 15 µg mL−1 for P. aeruginosa and from 150 µg mL−1 to 15 µg mL−1
for S. aureus. Fresh medium with 10 µL of MeOH was used as control. The chambers
were incubated at 37◦C for 18-20 h.
After this period, medium was discharged and the samples washed with PBS to remove
planktonic cells. Live/dead®BacLight™bacterial viability kit (Invitrogen™) was used ac-
cording to the manufacturer instructions. The chambers were detached and the slides
visualized under a confocal laser scanning microscope.
4.8.4 Quorum sensing inhibition
P. putida F117 (pKR-C12) [130] and E. coli MT102 (pSB403) [131] were used to test
the isolated compounds against QS systems. P. putida F117 (pKR-C12) is based on
the las QS-system of P. aeruginosa, responding to long chain AHLs. E. coli MT102
(pSB403) is a strain reporter for genes lux of Vibrio fischeri, responding to short chain
AHLs. After overnight incubation in LB with the respective antibiotics at 30◦C, 5 mL
of media containing the sensor strains was added to 20 mL of fresh media. Homoserine
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lactones were added to the 20 mL of media (50 nM 3-oxoC12-HSL for F117 and 100 nM
of 3-oxo-C6-HSL for MT102), and 5 mL was used as background control. 100 µl were
added to the wells of a black microtiter plate (Greiner Bio One GmbH, Frickenhausen,
Germany). Serial dilutions of the isolated compounds were performed, within a range of
concentration from 250 µg mL −1 to 0.025 µg mL −1. MeOH was used as control. The
plates were incubated at 30◦C, and fluorescence and bioluminescence were measured on
a multi-mode Synergy 2 plate reader (Bio TeK Instruments GmbH, Bad Friedrichshall,
Germany) after 4 and 8 h of incubation. QS inhibition was calculated relative to the
control.
4.8.5 Pyocyanin and rhamnolipid B quantification
P. aeruginosa PA14 was allowed to grow overnight. Thereafter, 1 x 108 cells were in-
oculated in LB media, in a microtiter plate. Serial dilutions of the isolated compounds
were performed, on a concentration range of 300 µg mL −1 to 0.3 µg mL −1. MeOH was
used as control. After 30 h of incubation, at 37◦C, 1 mL of the treated media was ex-
tracted with EtOAc (3 times). Control was submitted to the same procedure. Pyocyanin
and rhamnolipid B were quantified using HPLC - MS/MS. Here, the target parent ions
(211 m/z [M + H]+ for pyocyanin and 652 m/z [M + H]+ for rhamnolipid B) were se-
lected and fragmented with collision energy of 30 V. The two most intense product ions
from each selected parent ion were monitored in the multiple reaction monitoring (MRM)
mode. Curves using a pyocyanin commercial standard were generated and used to calcu-
late compound concentration by the Quantitative Analysis MassHunter software (Agilent
Technologies). Rhamnolipid B concentration was calculated relative to the control.
4.9 Cytotoxicity assays
4.9.1 MTT test
The cytotoxicity of purified compounds was measured using the mouse fibroblast cell line
L-929 (DSMZ ACC2). First, cells were grown at 37◦C in a humidified 5% CO2 tension
incubator in Dulbecco’s modified Eagle Media (DMEM) supplemented with 10% fetal
bovine serum, during 3 days. Serial dilutions were performed in 96 - well microtiter
plates, inoculated with 5 x 104 cells and a starting concentration of 30 µg mL−1 of the
tested compounds. Blank and solvent controls were incubated under the same conditions.
After five days of incubation at 37◦C, MTT was used to measure growth and viability of
cells, which were capable of reducing it to a violet formazan product. Therefore, MTT
was dissolved in PBS and added to the each well, giving a final concentration of 0.5 g L−1.
The plate was incubated at 37◦C during 2 h, the precipitate of the formazan crystals was
centrifuged, and the supernatant was discarded. The precipitate was washed with PBS
and dissolved in isopropanol containing 0.4% HCl. The microplates were gently shaken
for 20 min to ensure a complete dissolution of the formazan, and finally measured at
595 nm using an ELISA plate reader. All experiments were carried out in two parallel
experiments. Activity values were calculated as the mean with respect to the controls,
which were set to 100% [132].
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4.9.2 Impedance measurements
The impedance measurements were performed with small modifications on a RT-CES
system (xCelligence) from Acea Biosciences (Roche), which has been described previously
[133, 134, 135]. For time-dependent cell response profiling, 60 µL of media was added to a
96-well E-Plate (ACEA biosciences, San Diego, CA, USA) to obtain background readings
followed by the addition of 120 µL cell suspension of L-929 cells. After each step, the
E-Plates were incubated for 30 min at room temperature and then placed on the reader
in the incubator for continuous recording of impedance as reflected by cell index. After
24 h of incubation the cells were treated with the compounds. To prepare the compounds
for screening each stock solution (10 mM in DMSO) was diluted with cell media to get
a final test concentration of the IC90 and less than 0.1 % DMSO. 1 µL of each prepared
solution was then transferred into the 96-well E-Plate. Each E-plate contained also wells
only with DMSO as a solvent control. All measurements were performed in triplicates
and run for 5 d. The time-dependent cellular response profiles (TCRP) were recorded
by the Roche RTCA Software, Version 1.2. Data processing and mining workflow was
implemented in the statistical programming language R, Version 2.12.2 (R Development
Core Team, 2011). The following additional R packages were used in addition: class
[136], gplots [137] and MASS [136]. For the development of the R code the integrated
development environment R Studio, Version 0.94.92, was used. The workflow starts by
importing the raw impedance data which is provided by the RTCA software as cell index
(CI) data. The CI is already background corrected and is calculated as follows (Eq. 1)
[138]:
CI(t) = Rt −Rb
Zn
(4.1)
where CI(t) is the cell index at time point t, Rt is defined as measured electrode impedance
of the well with the cells in the medium at a certain time point and Rb as measured back-
ground impedance of the well with the cell medium alone. Zn is a frequency factor which
corrects for different frequencies of the alternating voltage the xCelligence system can use,
the standard setting is Zn = 15. The raw data were imported into R and normalized as
suggested by Abassi et al. by dividing the cell indices for each time point after compound
addition by the cell index at a reference time point (Eq. 2) [135]. As reference time point,
the last measurement before compound addition was taken. For further analysis, only the
measurements starting at the reference time point (with normalized cell index = 1) and
later were considered.
NCI = CIt
CIt(reference)
(4.2)
The reference compounds and the test compounds with unknown mode of action were
measured as triplicates randomly distributed over the microtiter plates (using sampling
without replacement in R) to avoid batch effects.
Detection and removal of outliers was carried out using the median polishing procedure.
The central idea of the data mining concept is to use cubic smoothing splines for the ap-
proximation of the impedance data and as dimension reduction technique. This approach
has the benefit of avoiding the curse of dimensionality and the Runge phenomenon that
occurs for high polynomials, while keeping the complexity of the data set. The smooth
spline function of R was used for TCRP approximation. As set of descriptors, the basis
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spline coefficients were extracted to construct a distance matrix that was used for hier-
archical cluster analysis. A heatmap was constructed that displays the Z-transformed
values of the 22 descriptors (= basis spline coefficients). Hierarchical cluster analysis of
the reference compounds together with the compound of unknown mode of action was
carried out. Co-clustering of the compound of unknown mode of action with reference
compounds with known activity class label was used to predict the mode of action [139].
4.9.3 Eukaryotic cell staining
Cells were grown on cover slips in 4-well plates, test compounds were added after the
cells had become semi-confluent and incubated for 24 h. Cells were fixed with 3.7%
paraformaldehyde (followed by 0.1% Triton-X 100 treatment for 5 min) or ice cold methanol:
acetone (50:50) for 10 min and then washed with PBS. For α-tubulin staining, anti-α-
tubulin was added, incubated for 45 min and washed with PBS. Afterwards, anti-mouse
Alexa Fluor 488 was added to the cells and incubated for further 45 min. After washing
with PBS, 4,6-diamino-2-phenylindole (DAPI) was added and kept at room temperature
for 5 min. Cover slips were mounted in anti-fade mounting medium (Molecular Probes®,
Life Technologies) and the samples observed under a fluorescence microscope.
4.10 Microscopy methods
4.11 Confocal laser scanning microscopy (CLSM)
CLSM was performed using a Leica TCS SP1 (Leica, Heidelberg, Germany) and Leica
Confocal software, version 2.5, Build 1347d. The instrument was equipped with the
following laser lines: 405 nm UV line, a multiline Argon laser, a 561 nm yellow diode-
pumped solid state laser and a 633 nm HeNe laser, attached to an upright microscope.
Biofilm samples were observed with 20 x 0.5 NA and 63 x 0.9 NA oil immersible lenses,
using the laser lines 488 nm and 561 nm.
Thickness of biofilms were defined using Z-stacking, where the Z values are set for the
beginning and end of a sample. Biofilm damaging was calculated according to the area
covered by green or red cells, using the softwares ImageJ and Fiji.
4.11.1 Transmission electron microscopy (TEM)
The samples were examined using an in-column energy-filter transmission electron mi-
croscope Libra120plus (Zeiss, Oberkochen, Germany), operated in the elastic bright-field
mode with anobjective aperture-set of 60 µm, 120 kV acceleration voltage and an energy-
slit set to 12 eV. Micrographs were recorded with a cooled bottom-mount 2048x2048
CCD-camera (Sharp: Eye; Tröndle, Moorenweis, Germany) within the range of x 3000-
x 30000 magnification.
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4.11.2 Fluorescence microscopy
Images were taken with CCD (charged coupled device) camera attached to a Zeiss Axio-
phot fluorescence microscope (Carl Zeiss GmbH), using appropriate filter sets.
4.12 Statistical methods
Standard deviation was calculated using the software Origin 9 (Originlab Corporation,
Northhampton, MA, USA). Non-parametric multivariate statistical analysis was per-
formed using PRIMER (v.6.1.6, PRIMER-E, Plymouth Marine Laboratory, UK) [140,
141]. A sample-similarity matrix was generated using the modified Bray-Curtis coeffi-
cient by comparing presence/absence of bacterial phylotypes.
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Chapter 5
Results
5.1 Fungal isolates classification
Basidiomycotina fruiting bodies were collected in Braunschweig, Göttingen and Köris,
Germany. Pure cultures were obtained from eleven fungal species. The isolates were
classified according to fruiting bodies macroscopic features and sequence analysis of the
region containing ITS1, ITS2 and the 5.8S rRNA genes. The identities of the consensus
sequence obtained from fungal mycelia were confirmed using BLAST search to known
sequences (table 5.14). The strain BS_HZI14 was classified as Russula emetica, but the
sequence obtained from the mycelia showed 99% of similarity with C. arbuscula. C.
arbusculais a parasitic fungus, being commonly found in the inner tissues of Russula spp.
and Lactarius spp. [142].
Table 5.1: Classification of the Basidiomycotina fungi according to fruiting bodies macro-
scopic features and the sequences obtained with ITS1F-ITS4 primers set.
Isolate Morphological analysis Sequence (ITS1F-ITS4)
BS_HZI4 Coprinus comatus Coprinus comatus
BS_HZI14 Russula emetica Calcarisporium arbuscula
BS_HZI30 Boletus edulis Boletus edulis
BS_HZI23 Boletus aestivalis Boletus aestivalis
BS_HZI27 Boletus luridus Boletus luridus
BS_BP1 Laetiporus sulphureus Laetiporus sulphureus
BS_BP5 Hebeloma incarnatulum
GÖ_W13 Macrolepiota sp. Macrolepiota fuliginosa
GÖ_W19 Pholiota sp. Pholiota lenta
GÖ_W29 Macrolepiota rhacodes Macrolepiota rhacodes
KÖ_S3 Macrolepiota procera Macrolepiota procera
33
5.2 Bacterial communities associated with mushrooms
The rationale of this work was based on fungi self-defense mechanisms to control bacterial
biofilms. Compounds production by these organisms is reported, while there is a lack on
the information about bacterial communities related with Basidiomycotina fruiting bodies.
Thus, within this work, single strand conformation polymorphism (SSCP) fingerprint
was employed to analyze the bacterial composition of those communities. Therefore, 49
fruiting bodies were collected in Braunschweig (BS), Drübeck (DRÜ), Göttingen (GÖ)
and Köris (KÖ) and identified according to their morphological characteristics. One
individual of each fungal species was submitted to ITS region sequencing. The identified
fungi with their respective abbreviation and collection year are shown in table 5.2.
Table 5.2: Fungal species used in the SSCP analysis, to-
gether with their respective abbreviation, venue and year
of collection.
Fungal Species Abbreviation Collection venue/year
Coprinus comatus CC1 BS - HZI/2009
C. comatus CC2 BS - HZI/2010
C. comatus CC3 BS - Bürgerpark/2010
C. comatus CC4 BS - Bürgerpark/201
C. comatus CC5 BS - Bürgerpark/2011
C. comatus CC6 BS - HZI/2012
C. comatus CC7 BS - HZI/2012
C. comatus CC8 BS - HZI/2012
C. comatus CC9 BS - HZI/2012
C. comatus CC10 BS - HZI/2012
C. comatus CC11 GÖ/2010
C. comatus CC12 DRÜ/2012
C. comatus CC13 DRÜ/2012
C. comatus CC14 BS - HZI/2012
C. comatus CC15 BS - HZI/2012
C. comatus CC16 BS - HZI/2012
C. comatus CC17 BS - HZI/2012
Coprinopsis atramentaria CA1 BS - HZI/2012
C. atramentaria CA2 BS - HZI/2012
C. atramentaria CA3 BS - HZI/2012
C. atramentaria CA4 BS - HZI/2012
C. atramentaria CA5 BS - HZI/2012
C. atramentaria CA6 BS - HZI/2012
Coprinopsis picacea CP1 DRÜ/2012
C. picaceus CP2 DRÜ/2012
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Fungal Species Abbreviation Collection venue/year
Macrolepiota fuliginosa MF GÖ/2009
Macrolepiota procera MP KÖ/2011
Macrolepiota rhacodes MR DRÜ/2012
Boletus aestivalis BA1 BS - HZI/2009
B. aestivalis BA2 BS - HZI/2009
B. aestivalis BA3 BS - HZI/2010
B. aestivalis BA4 BS - HZI/2011
B. aestivalis BA5 GÖ /2010
B. aestivalis BA6 GÖ /2010
B. aestivalis BA7 GÖ /2011
B. aestivalis BA8 KÖ/2011
B. aestivalis BA9 KÖ/2011
Boletus aureus BAu BS- HZI/2010
Boletus edulis BE1 BS - HZI/2009
B. edulis BE2 BS - HZI/2010
B. edulis BE3 GÖ/2009
Laetiporus sulphureus LS1 BS - Bürgerpark/2011
L. sulphureus LS2 BS - Bürgerpark/2011
L. sulphureus LS3 BS - Bürgerpark/2011
Amanita sp. AM1 BS - HZI/2010
Amanita sp. AM2 BS - HZI/2010
Stropharia sp. SI BS - HZI/2009
Russula emetica RE1 BS - HZI/2009
R. emetica RE2 BS - HZI/2011
To analyze the bacterial communities associated with the collected fruiting bodies, DNA
was extracted from the skin which covers the mushrooms hat, and quantified using a
NanoDrop spectrophotometer. Herein, DNA concentration varied between 15 ng µl−1 and
50 ng µl−1. A PCR reaction was performed using the bacterial universal primers set 27F-
521R [126], generating a fragment of approximately 500 bp. The reaction was repeated
several times, until the concentration of 100 ng µl−1 was achieved. Although displaying
enough DNA yields, 18 fungal strains did not show any bacterial DNA amplification and
were excluded from the SSCP analysis. With the other 31 samples, a SSCP was performed
and silver stained. From those 31 samples, all the bands observed in the SSCP gels were
numbered and quantified. SSCP fingerprint allowed the quantification of a maximum of
9 bacterial phylotypes among the mushrooms samples (Fig. 5.1). For phylogenetic and
statistical analysis, fungal samples were divided into 5 groups, representing: a) Coprinus
comatus and Coprinopsis spp., b) Boletus spp., c) Macrolepiota spp., Russula emetica and
e) mixed genera.
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Figure 5.1: Number of bacterial phylotypes detected on 31 mushrooms hats. (S) - Sapro-
phytic species and (E) - ectomycorrhizal ones. A detail of a SSCP gel is shown in the
insert.
To identify the members of the bacterial community, SSCP bands were excised and sub-
jected to a new PCR reaction followed by 16 rRNA fragment sequencing. Sequences were
analysed using the software Sequencher 4.10. The identity of the consensus 16S rRNA
obtained sequences was confirmed using the Seqmatch feature available at the RDP-II
database [143]. Multiple sequence alignments were performed using the program Muscle,
provided in the software SeaView 4.0 [144]. MEGA 5.0 was used to construct phylogenetic
trees, using neighbour-joining method together with Jukes-Cantor model and pairwise
deletion of gaps to calculate the evolutionary distance [145]. A total of 1000 bootstrap
replications were executed to test for branch robustness.
The identified phylotypes were grouped into 4 phyla and 10 families: 29 gammapro-
teobacteria (18 Enterobactereaceae, 8 Pseudomonadaceae, 1 Moraxellaceae and 1 Xan-
thomonadaceae), 13 Alphaproteobacteria (8 Rhizobiaceae, 4 Bradyrhizobiaceae and 1
Acetobactereaceae), 3 Betaproteobacteria (2 Burkholderiaceae and 1 Oxalobactereaceae)
and 4 Bacteroidetes/Chlorobi (CFB), all belonging to Flavobacteraceae (Fig. 5.2). No
Gram-positive bacteria sequence was detected within the mushroom samples, using SSCP
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fingerprint.
Figure 5.2: Neighbour joining tree of the 16S rRNA fragments sequences, obtained from
SSCP fingerprint analysis from 31 mushrooms samples together with reference sequences.
Evolutionary distances were computed using the Jukes-Cantor model. The red section of
the circle represents the phyla gammaproteobacteria; the green represents the betapro-
teobacteria; the blue represents the alphaproteobacteria; the brown represents the Bac-
teroidetes / Chlorobi (CFB) and the grey sector represent a sequence with incertae sedis.
The numbers represent bacterial families: 1. Enterobactereaceae; 2. Pseudomonadaceae;
3. Moraxellaceae; 4. Xanthomonadaceae; 5. Oxalobactereaceae; 6. Burkholdereaceae;
7. Acetobactereaceae; 8. Bradyrhizobiaceae; 9. Rhizobiaceae; 10. Flavobacteraceae; 11.
Incertae sedis. The sequence of Archaeoglobus served as outgroup.
The software PRIMER (v.6.1.6, PRIMER-E, Plymouth Marine Laboratory, UK) was used
to perform non-parametric multivariate statistical analysis [143, 144]. A binary matrix
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(presence/ absence) was generated and subjected to a modified Bray-Curtis similarity
measure, in order to compare the presence/absence of each of the 9 bacterial phylotypes
distributed over all the 31 mushroom samples [146].
Figure 5.3: Dendrogram based on modified Bray Curtis similarity analysis. The den-
drogram shows the differences among bacterial communities of 31 mushrooms samples.
Samples were divided in 5 groups, in the following way: A) Coprinus comatus and Co-
prinopsis spp., B) Boletus spp., C) Macrolepiota spp., D) Russula emetica, E) mixed
genera. The codes on the left side indicate the abbreviations to each fungal species.
Those abbreviations are summarized in table 5.2.
Two main clusters can be distinguished according to the obtained dendrogram. The first
one (upper section), is characterized by the presence of group A (24 from 25 samples), all
samples comprising group C and D and group E (4 from 6 samples). Group D exhibited a
very peculiar bacterial community, while samples belonging to group C where randomly
distributed among the cluster. Also, two individuals belonging to group E (Amanita sp.)
shared 100% of similarity (Fig. 5.3). The second dendrogram cluster (lower section)
encloses all the samples belonging to group B. This cluster also included two samples of
group E (L. sulphureus) and one belonging to group A (C. picacea). To provide more
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details about the bacterial communities associated with mushrooms, sequences belonging
to each established group (A - E), were subjected to phylogenetic analysis. Group A -
in this group, 17 specimens of Coprinus comatus, 6 of Coprinopis atramentaria and 2 of
Coprinopsis picacea were analysed. Among the collected C. comatus, bacterial phylotypes
were detected only in 3 individuals. CC4 and CC5 were collected both in 2011 and in the
same location (Bürgerpark, BS) and CC9, in 2012 at the HZI (BS). Bacterial phylotypes
belonging to the Flavobacteraceae family were present in all of the 3 specimens, while a
phylotype similar to Pseudomonas agarici was detected only on the hat of CC5. Moreover,
no more than 2 bacterial phylotypes were identified on the surface of this fungal species.
Additionally, the bacterial communities of 6 specimens of Coprinopsis atramentaria, all
collected at HZI (BS), in 2012, were evaluated. Here, the samples CA1and CA3 showed
the presence of 1 phylotype, sharing similarity with Blastobacter aggregatus and Rhizobium
alamii, respectively. Furthermore, bacterial communities associated with 2 individuals of
C. picacea (CP1 and CP2) were also assessed. On the hats of CP1 four phylotypes were
detected, while on CP2 only 1 phylotype was observed. All of the bacterial phylotypes
associated with C. picacea belong to the Enterobactereaceae family (Fig. 5.4).
Figure 5.4: Neighbour joining tree of the 16S rRNA fragments sequences obtained from
the hats of Coprinus comatus and Coprinopsis spp. individuals analysed using SSCP
fingerprint analysis, together with reference sequences. Evolutionary distances were com-
puted using the Jukes-Cantor model. The sequence of Archaeoglobus served as outgroup.
Group B - comprises thirteen specimens belonging to the genus Boletus spp. (9 speci-
mens of B. aestivalis, 3 of B. edulis and 1 of B. aureus). This group demonstrated the
highest bacterial richness among the 5 analysed mushrooms groups, harboring 2 to 9 of
the detected phylotypes. The obtained 16S rRNA sequences were grouped in 4 fami-
lies: Enterobactereaceae, Pseudomonadaceae, Burkholderiaceae and Acetobactereaceae.
Among these families, only phylotypes related to Enterobactereaceae were found in all
of the 3 Boletus spp. investigated. Between the nine specimens of B. aestivalis collected
during 2009 - 2011, the sample BA1 showed 9 bacterial phylotypes associated. SSCP fin-
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gerprint profiling demonstrated the presence of Enterobactereaceae, Pseudomonadaceae
and Burkholdereaceae associated with this fungal species. Additionally, 3 B. edulis (BE)
individuals used in this study showed the presence of Enterobactereaceae and Acetobac-
tereaceae. Only 1 specimen of B. aureus (BAu) was evaluated according to its bacterial
community analysed. From the obtained sequence the phylotypes associated with this
mushroom shared similarity with Acetobacter diazotrophicus (Fig. 5.5).
Figure 5.5: Neighbour joining tree of the 16S rRNA fragments sequences obtained from
the hats of Boletus spp. individuals analysed using SSCP fingerprint analysis, together
with reference sequences. Evolutionary distances were computed using the Jukes-Cantor
model. The sequence of Archaeoglobus served as outgroup.
Group C - includes 3 Macrolepiota spp. specimens. On the hat of a specimen of M. fuligi-
nosa, 4 phylotypes were detected, 3 belonging to the genera Pseudomonas, Acinetobacter
and Rhodanobacter and 1 to the family Enterobactereaceae. A phylotype, occurring on
the hat of M. rhacodes shares similarity with Enterobacter ludwigii (Fig. 5.6). Bacterial
phylotypes could not be detected on M.procera hat.
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Figure 5.6: Neighbour joining tree of the 16 rRNA fragments sequences obtained from the
hats of Macrolepiota spp. individuals analysed using SSCP fingerprint analysis, together
with reference sequences. Evolutionary distances were computed using the Jukes-Cantor
model. Archeaoglobus profundus was the outgroup used in the calculation.
Group D - encloses two individuals of Russula emetica. SSCP fingerprint analysis of those
two specimens detected 8 phylotypes on RE1 and 7 phylotypes on RE2. Phylogenetic
analysis of the obtained sequences showed that most of the phylotypes belongs to the
Rhizobiaceae family. Only one sequence showed similarity with Flavobacterium hibernum
(Fig. 5.7).
Figure 5.7: Neighbour joining tree of the 16S rRNA fragments sequences obtained from the
hats of Russula emetica. Individuals analysed using SSCP fingerprint analysis, together
with reference sequences. Evolutionary distances were computed using the Jukes-Cantor
model.
Group E - comprises a mixture between fungal genera. Here, a Burkholderia sp. and a
Pseudomonas fluorescens phylotypes were detected associated with Stropharia sp. On the
fruiting bodies of Laetiporus sulphureus (LS1 and LS2) the Enterobactereaceae Duganella
sp. and Rhanella sp. were identified. On the two Amanita sp. samples, Acetobacter
diazotrophicus and an Enterobactreaceae phylotype were found. Moreover, an incertae
sedis sequence was also detected (Fig. 5.8).
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Figure 5.8: Neighbour joining tree of the 16S rRNA fragments sequences obtained from
the hats of fungi belonging to group E, analysed using SSCP fingerprint analysis, together
with reference sequences. Evolutionary distances were computed using the Jukes-Cantor
model. The sequence of Archaeoglobus served as outgroup.
5.3 Screening
In order to determine appropriate conditions for the production of secondary metabolites
with biological activity in liquid media, mycelia of the eleven isolated fungal species were
grown on Petri dishes (90 x 90 mm), containing different solid culture media (BAF, MNM,
PDA and YEM), with pH adjusted to 5.0, 7.0 and 9.0. Growth estimate (in days) was
assessed by fungal colonies measurements, which were recorded during 30 days (table 5.3).
The isolates which showed the ability to grow under the given incubation conditions, faster
than 20 days were preferred for the screening experiments.
Table 5.3: Period of incubation (days) required by the fungal colony to reach the periphery
of a 90 x 90 mm Petri dish. Eleven species were grown using different culture media.
Isolate BAF pH 5.0,
pH 7.0, pH
9.0
MNM pH 5.0,
pH 7.0, pH
9.0
PDA pH 5.0,
pH 7.0, pH
9.0
YEM pH 5.0,
pH 7.0, pH
9.0
Coprinus comatus 13, 13, 15 25, 25, 27 13, 13, 15 13, 13, 15
Calcarisporium arbuscula 10, 10, 10 15, 15, 15 10, 10, 10 10, 10, 10
Boletus edulis 30* 30* No growth No growth
Boletus aestivalis 30* 30* No growth No growth
Boletus luridus 30* 30* No growth No growth
Laetiporus sulphureus 15, 15, 30* 28, 28, 30* 15, 15, 19 15, 15, 19
Macrolepiota fuliginosa 15, 15, 15 26, 26, 26 15, 15, 15 15, 15, 15
Macrolepiota procera 14, 14, 15 24, 24, 24 14, 14, 15 14, 14, 15
Macrolepiota rhacodes 30* 30* 30* 30*
Pholiota lenta 15, 15, 15 24, 24, 24 14, 14, 14 15, 15, 15
Hybeloma incarnatulum 30* 30* 30* 30*
After determining fungal growth, conditions used on the screening could be set as follows:
a) media: BAF, PD and YEMB broth, with pH adjusted to 5.0, 7.0 and 9.0; b) temper-
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ature: 20◦C and 25◦C; c) incubation period: 14, 21, 28, 35 and 42 days. None of isolated
species showed satisfactory growth on MNM, therefore this medium was excluded from
the screening strategy.
C. comatus, M. fuliginosa, M. procera and P. lenta were grown according to the con-
ditions mentioned above, leading to 90 aqueous extracts each. From L. sulphureus, 80
extracts were obtained, since it showed a low growth rate when incubated in BAF broth
adjusted to pH 9.0. Due to its high growth rate, C. arbuscula was incubated for 14, 21
and 28 days, generating 54 extracts. Each aqueous extract was obtained from a 110 mL
filtrated culture. After concentration using lyophilisation, the extracts were resuspended
in Milli-Q®water (1.1 mL), had their pH measured and were tested against P. aeruginosa,
S. aureus and S. mutans, in liquid media for antibacterial and anti-biofilm activity. All of
the 494 obtained extracts had pH defined between 5.0 and 5.5. 160 aqueous extracts were
able to inhibit bacterial growth or biofilm formation from at least one of the microor-
ganisms tested. Autoclaved media followed by lyophilisation and diluted similarly as the
extracts were used as control. The respective fungal species and incubation conditions in
which biological activities were detected are summarized on table 5.4.
Table 5.4: Fungal species and incubation conditions used
for production of biological active secondary metabolites.
C.
comatus
C.
arbuscula
L.
sulphureus
M.
fuliginosa
M.
procera
P.
lenta
BAF media
pH 5.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
pH 7.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
pH 9.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
Not grown A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
Not grown A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
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C.
comatus
C.
arbuscula
L.
sulphureus
M.
fuliginosa
M.
procera
P.
lenta
PDB media
pH 5.0 20◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
pH 7.0 20◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
pH 9.0 20◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
25◦C - A.G+
14, 21
and 28 d
- A.G+
28 d, 35
and 42 d
A.G+
28 d, 35
and 42 d
-
YEM media
pH 5.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
B SA 21 d - - -
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
B SA 21 d - - -
pH 7.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
B SA 21 d - - A.G+
21 d A
- 42 d
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
B SA 21 d - - A.G+
21 d A
- 42 d
pH 9.0 20◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- - - A.G+
21 d A
- 42 d
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C.
comatus
C.
arbuscula
L.
sulphureus
M.
fuliginosa
M.
procera
P.
lenta
25◦C A - 35
and 42 d
A.G+
14, 21
and 28 d
- - - A.G+
21 d A
- 42 d
A - antibacterial activity against all of three bacteria tested.
A.G+ - antibacterial activity against the tested Gram-positive bacteria.
B SA - S. aureus biofilm inhibition.
Aqueous extracts showing identical biological activity were submitted to liquid-liquid
extraction using ethyl acetate followed by 2-butanol and analysed using RP-HPLC-MS.
Chromatograms analyses showed high similarity between the extracts obtained from the
same fungal species, in different media. Therefore, ethyl acetate or 2-butanol extracts
obtained from the same fungal species were combined to proceed with the biological
tests.
5.3.1 Biological activity of organic extracts
Extracts combination yielded 24 samples. Antibacterial activity and inhibition of biofilm
formation were detected only when ethyl acetate extracts were used. 2-Butanol extracts
did not show any of the investigated biological activities.
The antimicrobial spectra of the 12 ethyl acetate extracts were accessed using the disk dif-
fusion method. Crude extracts were diluted with MeOH to 5 mg mL−1 and 25 µL of these
solutions were used per paper disk. C. comatus and P. lenta (incubated during 42 days)
extracts inhibited the growth of all bacteria tested. C. arbuscula and P. lenta (incubated
during 21 days) showed inhibition of growth of Gram-positive bacteria. C. arbuscula was
the only isolate which showed activity against yeasts. Within this method, M. fuliginosa
and M. procera extracts did not show any activity. None of the sporocarps and mycelia
extracts showed activity. The obtained inhibition zones are shown on table 5.5. Extracts
are named according to the media and producer fungi. For P. lenta, incubation period is
also given.
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Table 5.5: Inhibition zone (mm) of the tested ethyl acetate extracts.
Extract S. aureus E. coli P. aeruginosa C. albicans
C. arbuscula BAF 35 - - 23
C. arbuscula PD 36 - - 25
C. arbuscula YEM 33 - - 22
C. comatus BAF 16 12 13 -
C. comatus YEM 15 10 13 -
L. sulphureus YEM - - - -
M. fuliginosa BAF - - - -
M. fuliginosa PD - - - -
M. procera BAF - - - -
M. procera PD - - - -
P. lenta YEM 21d 14 - - -
P. lenta YEM 42 d 16 14 12 -
MICs against P. aeruginosa, S. aureus and C. albicans were also determined, using the
micro dilution method. MBICs were assessed against P. aeruginosa and S. aureus. In
this case, 100 µL of an initial solution (10 mg mL−1) was serial diluted in liquid media.
Herein, the observed activities were comparable to the ones observed for the aqueous
extracts. MICs and MBICs values are found in table 5.6.
Table 5.6: MICs and MBICs (µg mL −1) of the crude ethyl acetate extracts obtained from
fungi.
Extract S. aureus
(MIC)
S. aureus
(MIBC)
P. aeruginosa
(MIC)
P. aeruginosa
(MBIC)
C. albicans
(MIC)
C. arbuscula BAF 62.5 - - - 23
C. arbuscula PD 62.5 - - - 25
C. arbuscula YEM 62.5 - - - 22
C. comatus BAF 250 - 500 - -
C. comatus YEM 250 - 500 - -
L. sulphureus YEM - 125 - - -
M. fuliginosa BAF 500 125 - - -
M. fuliginosa PD 500 125 - - -
M. procera BAF 500 125 - - -
M. procera PD 500 125 - - -
P. lenta YEM 21d 500 - - - -
P. lenta YEM 42 d 500 31.2 500 - -
5.3.2 RP-HPLC Fractionation
Active extracts were submitted to RP-HPLC fractionation. Here, fractions were collected
each 0.15 s in 96 - well microtiter plates. After complete dryness of solvent under N2
stream, the microtiter plates were inoculated with S. aureus, P. aeruginosa or C. albi-
cans, according to the crude extracts verified activities. Peak retention times (RT) were
correlated with the activity observed in the microtiter plate.
Crude extracts obtained from C. arbuscula showed activity against C. albicans and S.
aureus. Fractionation was performed using a C18 column (125 x 20 mm). The fraction
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containing the peaks with the RT ranging between 7.0 and 7.14 min and the peak with
the retention time at 12.31 min inhibited the growth of S. aureus. The fraction collected
between 10.46 and 11 min showed activity against C. albicans (Fig. 5.9).
Figure 5.9: Chromatogram obtained from C. arbuscula ethyl acetate extract. Arrows
indicate fractions with biological activity.
Fractionation of C. comatus extract was performed using a C18 column with the dimen-
sions of 250 x 20 mm. The fraction collected between 9.0 and 9.15 min showed activity
against S. aureus and P. aeruginosa. Within this fraction, only one peak could be ob-
served in the chromatogram, which led to the correlation of the antibacterial activity with
the peak with RT at 9.127 min (Fig. 5.10).
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Figure 5.10: Chromatogram obtained from C. comatus extract fractionation. Arrow in-
dicates the peak which was correlated with antibacterial activity.
L. sulphureus crude extracts inhibited S. aureus biofilm formation. A C18 250 x 20 mm
column was used to fractionate this sample. Activity was correlated with the fraction
obtained at 12 and 12.5 min of elution (Fig. 5.11). No antibiotic activity was observed.
Figure 5.11: Chromatogram obtained from L. sulphureus extract fractionation. Arrow
indicates the fraction with activity against S. aureus biofilm formation.
Organic extracts obtained from M. fuliginosa, M. procera and P. lenta did not show
activities after HPLC fractionation.
All 6 fungal species were incubated in 5 L media, according to the following conditions:
a) C. arbuscula was incubated in YEM broth pH 9.0, during 14 days, at 20◦C; b)C.
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comatus was incubated in BAF broth pH 9.0, during 42 days, at 25◦C; c) L. sulphureus
was incubated in YEM broth pH 5.0, during 21 days, at 20◦C; d) M. fuliginosa and
M. procera were incubated in PDB pH 7.0, during 28 days, at 20◦C and e)P. lenta was
incubated in YEM broth pH 9.0, during 42 days, at 20◦C. Ethyl acetate was used to
extract the compounds from the media in all of the cases.
5.3.3 Crude extracts fractionation and purification
5.3.3.1 C. arbuscula
Approximately 1.7 g of dark orange oil was obtained from C. arbuscula cultivation. The
fractionation was performed using a 300 x 30 mm glass chromatographic column, packed
with 450 g of Sephadex LH-20 resin. Column was eluted using methanol. 15 fractions were
obtained and tested against S. aureus and C. albicans, using the disk diffusion method.
Fractions number 3 and 4 were active against both microorganisms tested, showing in-
hibition zones of 35 mm for S. aureus and 13 mm for C. albicans. Fractions 11 and 12
showed an inhibition zone of 13 mm against S. aureus.
HPLC chromatograms were obtained for all four active fractions. Fractions number 3 and
4 were combined, generating a fraction named CA_A1; fractions 11 and 12 generated the
fraction named CA_B1.
All 7 compounds present in the fraction CA_A1 were purified using a semi-preparative
RP-HPLC, method A, described in the section 4.4.6.2. Compound numbers, retention
times and purified amounts are described in table 5.7. Compounds 1 - 4 and 7 were
purified yielding a white powder. Compounds 5 and 6 were purified as yellow oil.
Table 5.7: Compounds purified from the fraction CA_A1, obtained from the cultivation
of C. arbuscula. Retention time (min) and compounds quantity (mg) are given.
Compound Retention time (min) Quantity (mg)
1 13.5 3
2 13.6 1.5
3 15 0.8
4 12.9 12
5 14.19 0.6
6 13.1 8
7 15.4 1.2
Fraction CA_B1 was purified using normal phase TLC followed by semi-preparative RP
- HPLC. Dichloromethane: methanol (98 : 2) was used to develop the TLC plates. All
bands, visualized under UV light 264 nm, were scraped and tested against S. aureus.
The band with the retardation factor (Rf) value of 0.135 showed activity against the
mentioned bacteria. The active TLC band was further purified using semi-preparative
RP-HPLC, using the method B, described in section 4.4.6.2. The peak with RT of 7.3
min was collected, leading to the isolation of 1.5 mg of compound 8, as yellow oil.
All of the purified compounds were analysed using RP-HPLC/MS and handed over to
NMR measurements.
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5.3.3.2 Coprinus comatus
From C. comatus 5 L cultivation, around 150 mg of crude extract was obtained. The
crude extract was applied on SPE C18 cartridges and eluted with a mixture of MeOH
and H2O, generating 4 fractions. Fraction 1, obtained from an 80: 20 (H2O : MeOH)
mixture inhibited the growth of S. aureus and P. aeruginosa. This fraction was purified
using a semi preparative RP - HPLC, with the method B, described on section 4.4.6.2.
The peak with the RT 9.7 min was collected, leading to the isolation of 7 mg of compound
9.
The purified compound was analysed using RP-HPLC-MS and NMR measurements.
5.3.3.3 Laetiporus sulphureus
About 110 mg were obtained from L. sulphureus cultivation in 5 L medium. C18 cartridges
were used to fractionate the extract, again with a MeOH / H2O mixture. The fraction
obtained from a mixture MeOH / H2O (50 : 50) was active against S. aureus biofilm
formation. The fraction was submitted to further fractionation using a semi-preparative
HPLC, method B described in the section 4.4.6.2, but no activity was detected.
5.3.3.4 Macrolepiota fuliginosa and Macrolepiota procera
From the cultivation M. fuliginosa and M. procera, about 150 mg and 195 mg of crude
extract were obtained, respectively. SPE SiOH cartridges were used to fractionate both
samples. Cartridges were elutes with hexane, followed by ethyl acetate and mixtures of
ethyl acetate and MeOH (80 : 20, 50 : 50, 20 : 80). The fraction obtained after elution
using the mixture 50 : 50 ethyl acetate: MeOH was active against growth (300 µg mL −1)
and biofilm formation (75 µg mL −1) of S. aureus, for both fungi. A TLC using hexane
/ ethyl acetate was performed. Bands with the Rf 0.73 showed activity against S. aureus
growth. From M. fuliginosa 0.4 mg and from M. procera 0.6 mg of yellow oil was obtained.
The samples were directed to NMR measurements.
5.3.3.5 Pholiota lenta
About 2 g oil was obtained after P. lenta cultivation in 5 L media. The extract was
fractionated using Sephadex LH-20, packed in a 600 x 30 mm glass chromatographic col-
umn, generating 65 fractions. Fractions 8 to 22 showed activity against S. aureus growth.
Activity against P. aeruginosa was not detected after this fractionation procedure.
Fractions 8 to 22 were analysed using HPLC-MS, but a broad peak, eluted from 6 to 14
min of run was observed in all chromatograms. Several solvent systems were tested for
TLC, but none of the used techniques was successful in isolating the active compound.
Regarding all the extracts, eight compounds were obtained from C. arbuscula (compound
1 - 8 ) cultivation and C. comatus cultivation led to the isolation of one active compound
(compound 9). In order to identify the compounds, they were submitted to RP-HPLC-
MS analysis, using a C18 column with the dimensions of 125 x 20 mm, and the method
described in section 4.4.4, followed by NMR measurements.
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5.4 RP-HPLC/MS analysis of the purified compounds
5.4.1 Compounds isolated from Calcarisporium arbuscula
Fraction CA_A1, obtained from C. arbuscula 5 L cultivation, yielded 7 compounds (Fig.
5.12). All these compounds were purified using semi preparative HPLC.
Compound 1 was eluted at 13.5 min and showed UV maximum absorbance at 260 nm.
Three ions were detected using mass spectrometry analysis, operated in the positive mode:
m/z 361.2, m/z 515.2 and m/z 1029.5. The m/z of compound 1 was calculated to 514.2
(Fig. 5.12, 1). Likewise compound 1, compound 2 m/z was calculated to 514.2. Com-
pound 2 was obtained at 13.6 min, with UV maximum absorbance also at 260 nm. Three
ions, m/z 361.2, m/z 537.2 and m/z 1029.5, were identified. The ion at m/z 537.2 ac-
quired a sodium ion (m/z 23) from the ionization process, corresponding to [M + Na]+.
The ion of m/z 1029.5 corresponded to [2M + H]+ (Fig. 5.12, 2).
Compound 3 was recovered at 15.05 min, showing an UV maximal absorbance at 260 nm.
The mass spectrum was analysed in the positive mode, revealing two peaks, of m/z 513.2
and m/z 1047.4. An m/z of 512 was calculated for compound 3 (Fig. 5.12, 3).
Compound 4 was obtained at 12.91 min, presenting UV maximum absorbance at 260
nm. Mass spectrometry analysis on the positive mode showed the presence of three ions,
one at m/z 229.2, the second at m/z 529.2 and the third at m/z 1057.5. The m/z of
compound 4 was calculated to 528, the first ion peak corresponding to [M + H]+ and the
second to [2M + H]+ (Fig. 5.12, 4).
Compound 5 showed an RT of 14.19 min, also with the UV maximum absorbance at 260
nm. Mass spectrum, analysed in the positive mode revealed several peaks: m/z 229.1,
m/z 285.2, m/z 511.2, m/z 571.2, m/z 837.4, m/z 1051.4 and m/z 1163.4. The m/z of
compound 5 was calculated to 570 (Fig. 5.12, 5).
Compound 6 was eluted at 13.1 min and showed UV maximum absorbance at 260 nm.
The mass spectrum in the positive mode showed the presence of two ions, one at m/z
529.2 and the second one at m/z 1079.5. The m/z of compound 6 was again calculated
to be 528, the first ion corresponding to [M + H]+ and the second corresponding to [2 M
+ Na]+ (Fig. 5.12, 6).
Compound 7 was obtained at 15.4 min and showed an UV maximum absorbance at 220
nm. The mass spectrum was obtained from the negative-ion mode and two peaks were
observed: m/z 515.3 and m/z 1031.7. The m/z of compound 7 was calculated to 516,
corresponding to [M-H]− (Fig. 5.12, 7).
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Figure 5.12: Retention times, UV absorbance and counts mass to charge ratio (m/z) of
the compounds isolated from the fraction CA_A1.
Compound 7 was subjected to HRMS analysis, in the negative mode, yielding a peak at
m/z 515.2999 (Fig. 5.13).
Figure 5.13: Counts mass to charge ratio (m/z) of compound 7, using a HRMS.
Fraction CA_B1, obtained from C. arbuscula cultivation in 5 L of YEMB, yielded com-
pound 8. This compound was purified using TLC combined with semi preparative HPLC.
HPLC-MS analysis revealed a peak at the RT of 7.72 min, with UV maximum absorbance
at 260 nm. Mass spectrum, analysed in the positive ion mode showed 2 peaks, one at
m/z 181 and the second one at m/z 383. Compound 8 m/z was calculated to 180. The
peak at m/z 383 corresponded to [2M + Na]+ (Fig. 5.14, 8).
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Figure 5.14: Retention time, UV absorbance and ion peaks obtained from RP-HPLC-MS
analysis of compound 8.
5.4.2 Compound isolated from Coprinus comatus
Compound 9 was purified from a C. comatus culture, after growth during 42 days in BAF
medium, with pH adjusted to 9.0. HPLC-MS analysis showed a peak eluted at 9.1 min,
with UV maximum absorbance at 210 nm. Mass spectrum, analysed in the positive mode,
showed a peak at m/z 129. Compound 9 m/z was calculated to 128 (Fig. 5.15).
Figure 5.15: Retention time, UV absorbance and ion peaks obtained from RP-HPLC-MS
analysis of compound 9.
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5.5 Structure elucidation
5.5.1 Compounds isolated from the fraction CA_A1, obtained
from Calcarisporium arbuscula cultivation
5.5.1.1 Roridins
1H NMR spectra from compound 1 showed four methyl groups at δH 0.79 (s), 1.14 (d), 1.71
(s(br)), and 2.26 (s(br)) and an epoxy-methylene with doubletts at 3.14 and 2.82 coupling
with J=4.1 Hz, pointing together with protons of a 1,4-disubstituted diene moiety with δH-
resonances at 7.53, 6.60, 5.89 and 5.82 to a macrocyclic mero-sesquiterpene (Fig. 5.16).
Careful analysis of the NMR spectra led to the conclusion that 1 was one of the four
epimeric roridins E. Comparison with published 1H- and 13C-NMR [147, 148, 149] data of
all four roridins in question showed that in 1 4-H, 11-H, 15A-H, 6’-H, and especially 13’-H
were deshielded, but 15b-H and 2’-H were shielded compared to roridin E and epiroridin
E. All NMR data fitted well to those reported for epiisororidin E and 1 was identified
being this compound (Fig. 5.7, 1). The minor compound 2 also belonged to one of the
epimeric roridins E as judged by its 1H- and 13C-NMR data, very similar to those of 1
(Fig. 5.17 and Fig. 5.18). Again a comparison with the 1H- NMR data of all four roridins
E isomers revealed that in 2 compared to roridin E and epiroridin E 4-, 11-, and 15A-H
were deshielded and 2’- and 7’H were shielded. 13’-H was deshielded against roridin E
but shielded against epiroridin E. Compared to the 1H-NMR data of epiisororidin E (Fig.
5.16) 2’-, 6’-, 7’-, and especially 13’-H were shielded in compound 2. All NMR data fitted
well to those reported for isororidin E leading to the identification of 2 as this compound
(Fig. 5.7, 2).
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Figure 5.16: 700 MHz 1H NMR spectrum from compound 1, in CDCl3. This compound
was identified as epiisororidin E.
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Figure 5.17: 700 MHz 1H NMR spectrum from compound 2, in CDCl3. This compound
was identified as isororidin E.
Figure 5.18: Isororidin E 2 13C-NMR spectrum.
The 1H NMR of compound 3 was similar to the ones seen for the roridin E isomers (Fig.
5.19). However, resonances of the 5’-protons were replaced by a fourfold doublet at δH
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5.53. This and the downfield-shift of the 14’-methyl group to δH 1.33 fitted mostly to the
data reported for roridin H by Traxler and Tamm [150].
After assigning all the resonances of all protons, compound 3 was identified as roridin H
(Fig. 5.7, 3). However, the relative configuration at C-6’ and C-13’ has not been solved
by these authors. A comparison of the 1H NMR data of the closely related 1,3-dioxolanes
of erythro- and threo-10,11-dihydroxy-trans-12-nornerolidol revealed a deshielding of the
13-methyl group to δH = 1.25 ppm in the threo-compound compared to δH = 1.15 ppm in
the erythro-compound and a shielding of 11-H to δH = 3.72 ppm in the threo-compound
(instead of δH = 4.21 ppm in the erythro-compound) [151]. These chemical shifts of the
threo-compound fitted well with the one observed in roridin H, revealing that the stereo-
chemistry of roridin H is that of isororidin E with 6’S,13’S-configuration. This stereochem-
istry was also confirmed by single crystal X-ray crystallography for 8α-acetoxy-roridin H
[152]. Compound 4 was therefore identified as 8α-hydroxy-roridin H, a compound recently
reported from a halotolerantMyrothecium species (Fig. 5.7) [153].1H NMR chemical shifts
for all roridin E isomares are summarized in the table 5.8. 1H NMR chemical shifts for
epiisororidin E 1 and isororidin E 2, together with the corresponding literature, are out-
lined in the table 5.9.
The fourth roridin, compound 4, bore one additional oxygen compared to roridin H.
The diene moiety of the macrocyclic diester at δH 5.80 (H-10’), δH 6.55 (H-9’), δH 7.70
(H-8’) and δH 5.93 (H-7’) showed couplings to a broad double duplet at δH 4.06 (H-6’)
which coupled with a dq at δH 1.32 (H-14’) (Fig. 5.20). The resonance of H-13’ was
considerable deshielded compared to those of the roridin E isomers. Resonances of H-14’
at such positions however are known for macrocyclic trichothecanes carrying acetals be-
tween C-5’ and C-6’. This hypothesis was confirmed by the presence of a resonance at
δH 5.52 (H-5’) indicating the presence of two oxygen substituents. The H-5’ coupled to
two allylic protons at δH 2.61 and 2.26 which coupled allylicly to an olefinic proton at
δH 5.69 (H-2’) and a methyl group at δH 2.26 (H-12’). The diester of the macrocyclic
ring system coupled on the one hand to the proton at δH 5.93 (H-4) which coupled to a
methylene group with resonances at δH 2.48 and 2.17 (H-3). Both H-3 coupled to δH 3.82
(H-2). On the other hand stood H-15 of the oxymethylene group forming an ABq at δH
4.39. The olefinic proton H-10 of the sesquiterpene moiety at δH 5.55 showed couplings
to δH 3.75 (H-11) and allylic couplings to the C-16-methyl group at δH 1.85 and δH 4.11
(H-8). H-8 finally coupled to a methylene group at δH 2.17 and 2.06. The presence of
the epoxy-group found in all roridins so far was revealed by resonances at δH 3.10 and
2.82. The deshielding of H-8 together with the deshielding of H-16 and H-10 pointed to a
C-8-hydroxylation of compound 4. Both 8α- and 8β-hydroxylations are known from nat-
ural products with trichothecane skeleton. While 8α-hydroxylations have been reported
from fungi, 8β-hydroxylations are only known from plants [154]. The shielding of H-15
and the deshielding of H-16 and H-10 in compound 4 compared to roridin H required the
8α-configuration of the hydroxyl-group. An 8β-configuration would have caused almost
no change in the H-15 resonances but a stronger upfield shift of H-16 [155]. 8α-Hydroxy-
roridin H has been reported from Myrothecium sp. GS-17 [153] and from C. arbuscula
[156].
The fifth roridin isolated from this fungus has very similar 1H NMR spectra (Fig. 5.21)
to 8α-hydroxy-roridin H 4 and was identified as its acetate, 8α-acetoxy-roridin H (cal-
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carisporin B1) 5 (Fig. 5.7, 5). This compound has already been reported from two
Myrothecium species [152] but also from C. arbuscula [156]. 1H NMR chemical shifts
for 8α-hydroxy-roridin H 4, 8α-acetoxy-roridin H and roridin H 3, compared with the
corresponding literature, are outlined in table 5.10 and 5.11.
Figure 5.19: 700 MHz 1H NMR spectrum from compound 3, in CDCl3. This compound
was identified as roridin H.
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Figure 5.20: 700 MHz 1H NMR spectrum from compound 4, in CDCl3. This compound
was identified as 8α-hydroxy-roridin H.
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Figure 5.21: 700 MHz 1H NMR spectrum from compound 5, in CDCl3. This compound
was identified as 8α-acetoxy-roridin H.
Finally, a sixth roridin, compound 6, was found. The resonances seen in the 1H-NMR
spectra are again very similar to those of roridin H 3, significant shifts could only be seen
in the lactone ring (Fig. 5.22). Here the 5’-H shifted to lower fields at δH 5.75 and a
slight shift was only seen for 14’-H which moved to δH 1.36. 5’-H was deshielded and
showed a doublet at δH 5.24 with J=6.9 Hz. Of the two 4’-H one is missing and the other
one moved to δH 3.82 and became a double doublet with J=6.9 and 0.5 Hz indicating a
hydroxy group at this site. 4’-Hydroxy roridin H 6 is known as roridin J (Fig. 5.7, 6)
and has been reported from Myrothecium verrucaria [157] and from C. arbuscula [156].
The large coupling constant between 4’-H and 5’-H requires a dihedral angle of close to
180◦ between these two protons. Model inspections showed that this is only possible if the
4’-hydroxy group is in β-position. Its stereochemistry at 4’-H has not yet been determined
and is reported here for the first time being 4’R. 1H NMR chemical shifts for roridin J 6,
together with the corresponding literature, are summarized intable 5.10 and 5.11.
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Figure 5.22: 700 MHz 1H NMR spectrum from compound 6, in CDCl3. This compound
was identified as roridin J.
Table 5.8: 1H NMR chemical shifts reported in the lit-
erature for roridin E, epiroridin E, epiisororidin E and
isororidin E.
Reference [147, 148] [147] [147] [149]
H roridinE
epi
roridin
E
epiiso
roridin
E
iso
roridin
E
2-H 3.84 (1H, d,
J=4.9 Hz)
3.87 (1H, d,
J=5.0 Hz)
3.83 (1H, d,
J=5.0 Hz)
3.84 (1H, d)
3A-H 2.05 (1H, m) 2.03 (1H, ddd)
3B-H 2.53 (1H, m) 2.55 (1H, dd)
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Reference [147, 148] [147] [147] [149]
4-H 6.20 (1H, dd,
J=8.2, 4.0 Hz)
6.15 (1H, dd,
J=8.0, 4.0 Hz)
6.29 (1H, dd,
J=8.0, 4.1 Hz)
6.30 (1H, dd)
7A-H 2.00 (1H, m)
7B-H 1.66 (1H, m)
8A-H 2.02 (1H, m)
8B-H 2.02 (1H, m)
10-H 5.47 (1H, d br,
J=4.3 Hz)
5.44 (1H, d,
J=5.0 Hz)
5.47 (1H, d,
J=5.5 Hz)
5.50 (1H, dm)
11-H 3.89 (1H, d,
J=4.3 Hz)
3.91 (1H, d,
J=5.0 Hz)
4.03 (1H, d,
J=5.5 Hz)
4.09 (1H, d)
13A-H 3.13 (1H, d,
J=4.1 Hz)
3.15 (1H, d,
J=4.0 Hz)
3.13 (1H, d,
J=4.0 Hz)
3.15 (1H, d)
13B-H 2.81 (1H, d,
J=4.1 Hz)
2.83 (1H, d,
J=4.0 Hz)
2.81 (1H, d,
J=4.0 Hz)
2.83 (1H, d)
14-H 0.78 (3H, s) 0.76 (3H, s) 0.77 (3H, s) 0.80 (3H, s)
15A-H 3.93 (1H, d,
J=12.0 Hz)
3.89 (1H, d,
J=12.0 Hz)
4.01 (1H, d,
J=12.5 Hz)
4.06 (1H, d)
15B-H 4.30 (1H, d,
J=12.0 Hz)
4.31 (1H, d,
J=12.0 Hz)
4.17 (1H, d,
J=12.5 Hz)
4.16 (1H, d)
16-H 1.70 (3H, s br) 1.67 (3H, s) 1.68 (3H, s) 1.71 (3H, s br)
18-H
2’-H 5.95 (1H, s br) 5.98 (1H, s) 5.82 (1H, d,
J=1.2 Hz)
5.83 (1H, q)
4’A-H 2.50 (1H, m)
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Reference [147, 148] [147] [147] [149]
4’B-H 2.50 (1H, m) 2.29 (1H, m)
5’A-H 3.56 (1H, m) 3.50 (1H, dt,
J=15.0, 6.0 Hz)
3.56 (1H, ddd,
J=10.1, 7.4, 5.0
Hz)
5’B-H 3.56 (1H, m) 3.69 (1H, dt,
J=15.0, 6.0 Hz)
3.73 (1H, ddd,
J=10.1, 7.5, 7.4
Hz)
6’-H 3.69 (1H, m) 3.89 (1H, m) 3.74 (1H, m)
7’-H 5.90 (1H, dd,
J=15.4, 3.2 Hz)
5.86 (1H, dd,
J=15.0, 3.0 Hz)
5.87 (1H, dd,
J=15.6, 6.1 Hz)
5.71 (1H, dd)
8’-H 7.51 (1H, dd,
J=15.4, 11.4 Hz)
7.45 (1H, dd,
J=15.0, 11.0 Hz)
7.54 (1H, dd,
J=15.6, 11.0 Hz)
7.55 (1H, dd)
9’-H 6.56 (1H, dd,
J=11.4, 11.4 Hz)
6.54 (1H, dd,
J=11.0, 11.0 Hz)
6.60 (1H, dd,
J=11.0, 11.0 Hz)
6.60 (1H, dd)
10’-H 5.74 (1H, d,
J=11.4 Hz)
5.70 (1H, d,
J=11.0 Hz)
5.80 (1H, d,
J=11.0 Hz)
5.82 (1H, d)
12’-H 2.26 (3H, d,
J=1.4 Hz)
2.24 (3H, s) 2.21 (3H, d,
J=1.2 Hz)
2.22 (3H, d)
13’-H 3.63 (1H, m) 3.98 (1H, qd,
J=6.5, 3.0 Hz)
3.70 (1H, m)
14’-H 1.12 (3H, d,
J=6.5 Hz)
1.17 (3H, d)
64
Table 5.9: 1H NMR chemical shifts for epiisororidin E 1
and isororidin E 2, together with their respective refer-
ence.
Reference 1 [147] 2 [149]
H
epi
isororidin
E
epi
isororidin
E
iso
roridin
E
iso
roridin
E
2-H 3.83 3.83 (1H, d,
J=5.0 Hz)
3.84 3.84 (1H, d)
3A-H 2.01 1.99 2.03 (1H, ddd)
3B-H 2.56 2.58 2.55 (1H, dd)
4-H 6.32 6.29 (1H, dd,
J=8.0, 4.1 Hz)
6.37 6.30 (1H, dd)
7A-H 1.51 1.49
7B-H 2.11 2.1
8A-H 2.0 2.0
8B-H 2.0 2.0
10-H 5.50 5.47 (1H, d,
J=5.5 Hz)
5.50 5.50 (1H, dm)
11-H 4.08 4.03 (1H, d,
J=5.5 Hz)
4.08 4.09 (1H, d)
13A-H 3.14 3.13 (1H, d,
J=4.0 Hz)
3.15 3.15 (1H, d)
13B-H 2.82 2.81 (1H, d,
J=4.0 Hz)
2.83 2.83 (1H, d)
14-H 0.79 0.77 (3H, s) 0.79 0.80 (3H, s)
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Reference 1 [147] 2 [149]
15A-H 4.04 4.01 (1H, d,
J=12.5 Hz)
4.06 4.06 (1H, d)
15B-H 4.17 4.17 (1H, d,
J=12.5 Hz)
4.16 4.16 (1H, d)
16-H 1.71 1.68 (3H, s) 1.71 1.71 (3H, s br)
18-H
2’-H 5.84 5.82 (1H, d,
J=1.2 Hz)
5.83 5.83 (1H, q)
4’A-H 2.57 2.55
4’B-H 2.33 2.29 (1H, m) 2.32
5’A-H 3.59 3.56 (1H, ddd,
J=10.1, 7.4, 5.0
Hz)
3.48
5’B-H 3.75 3.73 (1H, ddd,
J=10.1, 7.5, 7.4
Hz)
3.81
6’-H 3.91 3.89 (1H, m) 3.73 3.74 (1H, m)
7’-H 5.89 5.87 (1H, dd,
J=15.6, 6.1 Hz)
5.70 5.71 (1H, dd)
8’-H 7.53 7.54 (1H, dd,
J=15.6, 11.0 Hz)
7.54 7.55 (1H, dd)
9’-H 6.60 6.60 (1H, dd,
J=11.0, 11.0 Hz)
6.60 6.60 (1H, dd)
10’-H 5.82 5.80 (1H, d,
J=11.0 Hz)
5.82 5.82 (1H, d)
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Reference 1 [147] 2 [149]
12’-H 2.21 2.21 (3H, d,
J=1.2 Hz)
2.21 2.22 (3H, d)
13’-H 3.99 3.98 (1H, qd,
J=6.5, 3.0 Hz)
3.71 3.70 (1H, m)
14’-H
Table 5.10: 1H NMR chemical shifts reported in the lit-
erature for 8α-OH-roridin H , 8α-acetoxy-roridin H and
roridin J.
[153] [152] [150] [157]
8α-OH-roridin
H
8α-acetoxy-
roridin H roridin H roridin J
H 3.82 (1H, d,J=5.0 Hz)
3.84 (1H, d,
J=5.0 Hz)
3.8 (1H, d, J=5
Hz) 3.85d
2-H 2.49 (1H, dd,J=15.2, 8.2 Hz) 2.19 (1H, m) 2.1 m
3A-
H 2.17 (1H, m)
2.48 (1H, dd, J=
8.5, 15.5 Hz) 2.48dd
3B-
H
5.94 (1H, dd,
J=8.2, 4.1 Hz)
5.90(1H, dd, J=
4.5, 8.5 Hz) 5.9 (1H, m) 6.0dd
4-H 2.18 (1H, m) 2.11 (1H, m) 2.0 m
7A-
H 2.07 (1H, m) 2.24 (1H, m)
7B-
H
4.12 (1H, d(br),
J=4.8 Hz)
5.19 (1H, d, J=
4.5 Hz) 2.0 m
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[153] [152] [150] [157]
8A-
H - -
8B-
H
5.56 (1H, d(br),
J=5.8 Hz)
5.70 (1H, dt, J=
0.5, 5.5 Hz)
5.42 (1H, d, J=4
Hz) 5.44d
10-
H
3.75 (1H, d, J=
5.8 Hz)
3.76 (1H, d, J=
5.5 Hz) 3.64 (1H, m) 3.63d
11-
H
3.10 (1H, d,
J=4.1 Hz)
2.84 (1H, d, J=
4.0 Hz)
2.96 (1H, ABq,
J=4 Hz) 2.97
13A-
H
2.83 (1H, d,
J=4.1 Hz)
3.11 (1H, d, J=
4.0 Hz)
2.96 (1H, ABq,
J=4 Hz)
13B-
H 0.88 (3H, s) 0.84 (3H, s) 0.85 (3H, s) 0,87
14-
H 4.39 (1H, s(br))
4.36 (1H,d, J=
12.5 Hz)
4.15 (1H, ABq,
J=12 Hz) 4.21
15A-
H 4.39 (1H, s(br))
4.41 (1H, d, J=
12.5 Hz)
4.15 (1H, ABq,
J=12 Hz)
15B-
H 1.86 (3H, m) 1.76 (3H, s) 1.69 (3H, s) 1.74
16-
H 1.93 (3H, s)
18-
H 5.69 (1H, s(br)) 5.64 (1H, s) 5.67 (1H, s) 5.84 d
2’-H 2.63 (1H, m) 2.24 (1H, m) 2.64 (1H, d,J=11 Hz) 3.85 d
4’A-
H 2.26 (1H, m)
2.66 (1H, dd, J=
3.5, 12.0 Hz)
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[153] [152] [150] [157]
4’B-
H
5.52 (1H, dd, J=
8.3, 3.2 Hz)
5.53 (1H, dd, J=
3.5,8.5 Hz)
5.58 (1H, dd,
J=8, 3.5 Hz) 5.24 d
5’A-
H - -
5’B-
H
4.06 (1H, d,
J=8.5 Hz)
4.07 (1H,dt, J=
2.5, 8.5 Hz) 4.03 (1H, m) 3.87
6’-H 5.95 (1H, dd,J=15.3, 15.3 Hz)
5.96 (1H, dd, J=
2.5 Hz) 5.9 (1H, m) 5.80 d
7’-H 7.70 (1H, dd,J=15.3, 11.4 Hz)
7.65 (1H, ddt,
J= 1.0, 11.5,
15.5 Hz)
7.68 (1H, dd, J=
15.5, 11 Hz) 7.70 dd
8’-H 6.56 (1H, t,J=11.4 Hz)
6.57 (1H, dd, J=
11.5 Hz)
6.55 (1H, t,
J=11 Hz) 6.54 t
9’-H 5.80 (1H, d,J=11.4 Hz)
5.80 (1H, dd, J=
1.0, 11.5 Hz)
5.79 (1H, d,
J=11 Hz) 5.9 d
10’-
H 2.27 (3H, s)
2.28 (3H, d, J=
1.0 Hz)
2.27 (3H, d,
J=1.5 Hz) 2.28 d
12’-
H
3.66 (1H, dq,
J=8.5, 6.0 Hz)
3.67 (1H, dq, J=
6.0,8.5 Hz) 3.65 (1H, m) 3.70 q
13’-
H
1.32 (3H, d,
J=6.0 Hz)
1.35 (3H, d, J=
6.0 Hz)
1.32 (3H, d, J=6
Hz) 1.36 d
14’-
H
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Table 5.11: 1H NMR chemical shifts for 8α-OH-roridin
H 4 , 8α-acetoxy-roridin H 5 and roridin J 6 1H NMR
chemical shifts for 8α-OH-roridin H , together with their
respective reference.
[150] 3 [153] 4 5 [152] 6 [157]
roridin
H
roridin
H
8α-OH-
roridin
H
8α-OH-
roridin
H
8α-
acetoxy-
roridin
H
8α-
acetoxy-
roridin
H
roridin
J
roridin
J
H
3.8 (1H,
d, J=5
Hz)
3.83
(1H, d,
J=5.3
Hz)
3.82
(1H, d,
J=5.0
Hz)
3.82
(1H, d,
J=5.2
Hz)
3.82
(1H, d,
J=5.1
Hz)
3.84
(1H, d,
J=5.0
Hz)
3.85
(1H, d,
J=5 Hz)
3.85d
2-H
2.46
(1H, dd,
J=15.3,
8.4 Hz)
2.49
(1H, dd,
J=15.2,
8.2 Hz)
2.49
(1H, dd,
J=15.4,
8.3 Hz)
2.46
(1H, dd,
J=15.3,
8.4 Hz)
2.19
(1H, m)
2.48
(1H, dd,
J=15, 8
Hz)
2.1 m
3A-
H
2.17
(1H, m)
2.17
(1H, m)
2.17
(1H,
ddd,
J=15.4,
5.2, 4.6
Hz)
2.48
(1H, dd,
J= 8.5,
15.5 Hz)
2.1 (1H,
m) 2.48dd
3B-
H
5.9 (1H,
m) 5.92
5.94
(1H, dd,
J=8.2,
4.1 Hz)
5.93
(1H, m)
5.89
(1H, dd,
J=8.2,
4.5 Hz)
5.90(1H,
dd, J=
4.5, 8.5
Hz)
6.00
(1H, dd,
J=8, 4
Hz)
6.0dd
4-H 2.18(1H, m)
2.17
(1H, m)
2.11
(1H, m)
2 (1H,
m) 2.0 m
7A-
H
2.07
(1H, m)
2.06
(1H, dd,
J=15, 14
Hz)
2.24
(1H, m)
2 (1H,
m)
70
[150] 3 [153] 4 5 [152] 6 [157]
7B-
H
4.12
(1H,
d(br),
J=4.8
Hz)
4.11
(1H, m)
5.19
(1H, d,
J= 4.5
Hz)
2 (1H,
m) 2.0 m
8A-
H - - -
2 (1H,
m)
8B-
H
5.42
(1H, d,
J=4 Hz)
5.43
5.56
(1H,
d(br),
J=5.8
Hz)
5.55
(1H, d
J=6 Hz)
5.43
(1H,
ddq,
J=4.8,
1.9, 1.1
Hz)
5.70
(1H, dt,
J= 0.5,
5.5 Hz)
5.44
(1H, d,
J=5 Hz)
5.44d
10-
H
3.64
(1H, m)
3.75
(1H, d,
J= 5.8
Hz)
3.75
(1H, d,
J=5.7
Hz)
3.62
(1H,
d(br),
J=5.8
Hz)
3.76
(1H, d,
J= 5.5
Hz)
3.63
(1H, d,
J=5 Hz)
3.63d
11-
H
2.96
(1H,
ABq,
J=4 Hz)
3.11
(1H, d,
J=4.0,
1.0Hz)
3.10
(1H, d,
J=4.1
Hz)
3.10
(1H, d,
J=4.1
Hz)
3.12
(1H, d,
J=4.0
Hz)
2.84
(1H, d,
J= 4.0
Hz)
2.97
(1H,
AB)
2.97
13A-
H
2.96
(1H,
ABq,
J=4 Hz)
2.81
(1H, d,
J=4.2
Hz)
2.83
(1H, d,
J=4.1
Hz)
2.83
(1H, d,
J=4.1
Hz)
2.81
(1H, d,
J=4.0
Hz)
3.11
(1H, d,
J= 4.0
Hz)
2.97
(1H,
AB)
13B-
H
0.85
(3H, s)
0.85
(3H, s)
0.88
(3H, s)
0.88
(3H, s)
0.84
(3H, s)
0.84
(3H, s)
0.87
(3H, s) 0,87
14-
H
4.15
(1H,
ABq,
J=12
Hz)
4.31
(1H, d,
J=12.6
Hz)
4.39
(1H,
s(br))
4.39
(1H, m)
4.38
(1H, d,
J=12.4
Hz)
4.36
(1H,d,
J= 12.5
Hz)
4.21
(1H,
AB)
4.21
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[150] 3 [153] 4 5 [152] 6 [157]
15A-
H
4.15
(1H,
ABq,
J=12
Hz)
4.03
(1H, d,
J=12.6
Hz)
4.39
(1H,
s(br))
4.39
(1H, m)
4.01
(1H, d,
J=12.4
Hz)
4.41
(1H, d,
J= 12.5
Hz)
4.21
(1H,
AB)
15B-
H
1.69
(3H, s) 1.69
1.86
(3H, m)
1.85
(3H,
s(br))
1.70
(3H, dd,
J=1.1,
1.1 Hz)
1.76
(3H, s)
1.74
(3H, s) 1.74
16-
H
5.75
(1H, qd,
J=1.4,
0.7 Hz)
1.93
(3H, s)
5.84
(1H, q,
J=1.2
Hz)
18-
H
5.67
(1H, s) 5.67
5.69
(1H,
s(br))
5.69
(1H,
s(br))
3.82
(1H,
ddq,
J=6.9,
0.5, 0.2
Hz)
5.64
(1H, s)
3.85
(1H, d,
J=7 Hz)
5.84
d
2’-H
2.64
(1H, d,
J=11
Hz)
2.63
(1H,
d(br),
J=12.5
Hz)
2.63
(1H, m)
2.61
(1H, d,
J=11
Hz)
2.24
(1H, m)
3.85
d
4’A-
H
2.26
(1H, dd
J=12.5,
8.5Hz)
2.26
(1H, m)
2.26
(1H,
d(br),
J=14
Hz)
5.24
(1H, d,
J=6.9
Hz)
2.66
(1H, dd,
J= 3.5,
12.0 Hz)
5.24
(1H, d,
J=7 Hz)
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4’B-
H
5.58
(1H, dd,
J=8, 3.5
Hz)
5.53
(1H,
dddd,
J=8.5,
3.4, 0.7,
0.2 Hz)
5.52
(1H, dd,
J= 8.3,
3.2 Hz)
5.52
(1H,
J=8, 4
Hz)
5.53
(1H,
dd, J=
3.5,8.5
Hz)
5.24
d
5’A-
H - - -
4.08
(1H,
dddd,
J=8.6,
2.7, 2.7,
0.7 Hz)
3.87
(1H, m)
5’B-
H
4.03
(1H, m)
4.05
(1H, d,
J=8.5,
2.7 Hz)
4.06
(1H, d,
J=8.5
Hz)
4.06
(1H,
d(br),
J=8 Hz)
5.91
(1H,
dddd,
J= 15.2,
2.6, 0.8,
0.8 Hz)
4.07
(1H,dt,
J= 2.5,
8.5 Hz)
5.8 (1H,
d, J=
15.5 Hz)
3.87
6’-H 5.9 (1H,m) 5.93
5.95
(1H, dd,
J=15.3,
15.3 Hz)
5.93
(1H, m)
7.64
(1H,
dddd,
J=15.2,
11.6,
2.2, 1.1
Hz)
5.96
(1H, dd,
J= 2.5
Hz)
7.70
(1H, dd,
J=15.5,
11.5 Hz)
5.80
d
7’-H
7.68
(1H, dd,
J= 15.5,
11 Hz)
7.68
(1H,
dddd,
J=15.3,
11.6,
2.2, 1.0
Hz)
7.70
(1H, dd,
J=15.3,
11.4 Hz)
7.70
(1H,
dddd,
J=15.2,
11.7,
2.2, 1.1
Hz)
6.54
(1H,
dddd,
J=11.3,
11.3,
0.7, 0.7
Hz)
7.65
(1H,
ddt,
J= 1.0,
11.5,
15.5 Hz)
6.54
(1H, dd,
J=11.5,
11.5 Hz)
7.70
dd
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8’-H
6.55
(1H, t,
J=11
Hz)
6.55
(1H,
dddd,
J=11.4,
11.4,
0.4, 0.4
Hz)
6.56
(1H, t,
J=11.4
Hz)
6.55
(1H, dd,
J=11.7,
11.1 Hz)
5.78
(1H,
dddd,
J=11.1,
1.1, 0.9,
0.9 Hz)
6.57
(1H, dd,
J= 11.5
Hz)
5.9
(1H, d,
J=11.5
Hz)
6.54 t
9’-H
5.79
(1H, d,
J=11
Hz)
5.79
(1H, dd,
J=11.1,
0.9 Hz)
5.80
(1H, d,
J=11.4
Hz)
5.79
(1H, dd,
J=11.1,
0.9 Hz)
2.26
(3H, d,
J=1.5
Hz)
5.80
(1H, dd,
J= 1.0,
11.5 Hz)
2.28
(3H, d,
J=1.2
Hz)
5.9 d
10’-
H
2.27
(3H, d,
J=1.5
Hz)
2.27
(3H,
s(br))
2.27
(3H, s)
2.26
(3H,
s(br))
3.64
(1H, dq,
J=8.8,
6.0 Hz)
2.28
(3H, d,
J= 1.0
Hz)
3.70
(1H, q,
J=6 Hz)
2.28
d
12’-
H
3.65
(1H, m)
3.66
(1H, m)
3.66
(1H, dq,
J=8.5,
6.0 Hz)
3.65
(1H, dq,
J=9, 6.0
Hz)
1.36
(3H, d,
J=6.0
Hz)
3.67
(1H,
dq, J=
6.0,8.5
Hz)
1.36
(3H, d,
J=6 Hz)
3.70
q
13’-
H
1.32
(3H, d,
J=6 Hz)
1.33
(3H, d,
J=6.1
Hz)
1.32
(3H, d,
J=6.0
Hz)
1.33
(3H, d,
J=6.0
Hz)
3.82
(1H, d,
J=5.1
Hz)
1.35
(3H, d,
J= 6.0
Hz)
3.85
(1H, d,
J=5 Hz)
1.36
d
14’-
H
2.46
(1H, dd,
J=15.3,
8.4 Hz)
2.48
(1H, dd,
J=15, 8
Hz)
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Figure 5.23: Chemical structures from the Calcarisporium arbuscula isolated roridins (1
− 6).
5.5.1.2 Fusidic acid
The mass spectra obtained from compound 7 in the negative mode showed an ion at m/z
515.2999 [M-H]−, pointing to a molecular ion of C31H48O6. The 13C NMR of this com-
pound confirmed the molecular formula derived by mass spectra by showing 31 resonances
and revealed that the eight double bound equivalents required for such a molecular for-
mula were formed by two double bonds with resonances at δC 151.20, 132.73, 129.34, and
123.04 and two carbonyl with 13C resonances at δC 173.15 and 170.70 (Fig. 5.24). Four
double bond equivalents remained demanding a tetracyclic compound. Careful inspection
of the 1H and 13C NMR spectra (Fig. 5.24 and Fig. 5.25) led to the conclusion that we
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were dealing with a rearranged sterol skeleton bearing six methyl groups. The six oxygen
atoms were located in the acetate unit revealed by its characteristic resonance at δH 1.96,
a free carboxyl group (δC at 173.15) and two hydroxyl groups with the adjacent carbons
at δC 71.42 and 68.33. The α-protons of the hydroxyl groups could be found at δH 3.75
and 4.34. Analysis of the 2D-NMR spectra (COSY-45 and HETERO-COSY) (Fig. 5.26
and Fig.5.27) and comparison with data from the literature [158] led to the identification
of the compound as fusidic acid 7 (Fig. 5.28). Fusidic acid 7 1H NMR and 13C chemical
shifts are found in table 5.12.
Figure 5.24: 600 MHz 1H NMR spectrum from compound 7, in CDCl3. This compound
was identified as fusidic acid.
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Figure 5.25: Fusidic acid 7 13C-NMR spectrum.
Table 5.12: 1H NMR and 13C chemical shifts for fusidic
acid 7, together with the data obtained from the litera-
ture.
Fusidic acid 7 [158]
No 13C 1H J 13C 1H
C-1 t 30,37 m 2,16 30,17 2,17
d 1,51 1,51
C-2 t 30,01 m 1,85 29,84 1,86
m 1,73 1,75
C-3 d 71,42 q 3,75 2 71,53 3,76
C-4 d 36,17 m 1,58 36,38 1,58
C-5 d 36,32 m 2,10 36,01 2,11
C-6 t 20,75 m 1,59 20,87 1,59
m 1,08 1,13
C-7 t 32,58 m 1,75 32,14 1,74
m 1,12 1,12
C-8 s 39,49 39,48
C-9 d 49,22 m 1,54 49,32 1,57
C-10 s 37,16 36,95
C-11 d 68,33 q 4,34 2 68,24 4,35
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C-12 t 35,59 dt 2,32 12,5; 3 35,58 2,33
m 1,83 1,85
C-13 d 44,38 d br 3,05 44,29 3,06
C-14 s 48,8 48,72
C-15 t 39,03 m 2,16 38,96 2,19
d 1,31 13,5 1,3
C-16 d 74,45 d 5,88 8 74,47 5,88
C-17 s 151,2 150,75
C-18 q 17,83 s 0,90 17,78 0,91
C-19 q 22,69 s 0,97 22,99 0,98
C-20 s 129,34 129,64
C-21 s 173,15 174,37
C-22 t 28,83 m 2,45 28,77 2,46
C-23 t 28,45 m 2,15 28,46 2,17
m 2,04 2,07
C-24 d 123,04 tq 5,09 7; 2 123,1 5,1
C-25 s 132,73 132,58
C-26 q 18,02 s 1,59 17,84 1,6
C-27 q 25,75 s 1,66 25,71 1,67
C-28 q 15,96 d 0,91 15,92 0,92
C-30 q 24,32 s 1,37 23,94 1,38
Ac-CO s 170,55 170,7
Ac q 20,69 s 1,96 20,7 1,96
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Figure 5.26: 2D NMR correlation spectroscopy (COSY) of fusidic acid 7.
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Figure 5.27: HMBC (Heteronuclear Multiple Bond Correlation) spectrum from fusidic
acid 7, produced by Calcarisporium arbuscula.
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Figure 5.28: Fusidic acid 7 chemical structure.
5.5.2 Compound isolated from the fraction CA_B1 of C. arbus-
cula cultivation.
C. arbuscula cultivation in 5L of medium yielded 1.5 mg of compound 8. The m/z of
was calculated to 180. 1H NMR spectra analysis pointed to a mixture, instead of a pure
compound. Further purification led to the isolation of 0.4 mg of compound 8. This sam-
ple was again subjected to 1H NMR (Fig. 5.29), however, compound insufficient amount
restrained additional NMR measurements. Therefore, structure of compound 8 remained
unsolved.
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Figure 5.29: 700 MHz 1H NMR spectrum from compound 8, in CDCl3. Structure of this
compound remained unsolved.
5.5.3 Compounds isolated from Coprinus comatus.
Compound 9 had a molecular mass of 128 with the composition C6H8O3. 1H NMR
showed an exo-methylene moiety at δH 6.34 and 5.98, a doublet of a methyl group at
δH 1.44 and two protons at δH 4.45 and 4.34 (Fig. 5.30). Using 1H-13C-correlated NMR
(Fig. 5.32) spectra structure elucidation led to the identification of 9 as 2-methylene-3,4-
dihydroxypentanoic acid 1,4-lactone. Trans-configuration of the compound was deduced
from the resonances of the methyl group at δH 1.44 instead of 1.40 and the 4-H at δH
4.34 instead of 4.7-5.0 reported for the cis-isomer (table 5.13) [159]. Absolute configura-
tion was deduced from the negative sign of the optical rotation to be 3R, 4S as reported
for this compound prepared by asymmetric synthesis [160]. Compound 9 was therefore
identified as (3R,4S)-2-methylene-3,4-dihydroxypentanoic acid 1,4-lactone and named co-
matuslactone 9 (Fig. 5.34). This molecule was hitherto only known from synthesis but
not reported as natural product.
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Table 5.13: 1H NMR and 13C chemical shifts for comatuslactone 9, together with the
data obtained from the literature.
2-methylene-3,4-
dihydroxypentanoic
acid 1,4-lactone
[159, 160]
Cis-2-
methylene-
3,4-di
hydroxy-
pentanoic
acid 1,4-
lactone
[159]
Compound 9 (comatuslactone)
13C 1H 1H 1H 13C 1H COSY CH-long
range
169.22 170.79 6.34,
5.98,
(4.34)
138.43 s 141.11 6.34
125.84 6.42
(1H, d,
J=2 Hz)
6.36
(1H, d,
J=2 Hz)
6.36
(1H, d,
J=2 Hz)
t 125.41 6.34
(1H, d,
J=2.4
Hz)
5.98,
4.46
-
5.98
(1H, d,
J=2 Hz)
6.00
(1H, d,
J=1.8
Hz)
6.00
(1H, d,
J=1.8
Hz)
5.98
(1H, d,
J=2.2
Hz)
6.34,
4.46
74.17 4.45
(1H, s)
4.3-4.6 4.7-5.0 d 75.32 4.45
(1H, dt,
J=4.6,
2.3 Hz)
6.34,
5.98,
4.34,
1.44
6.34,
5.98,
4.34,
1.44
82.10 4.40
(1H, q,
J=6.7
Hz)
4.3-4.6 4.7-5.0 d 83.37 4.34
(1H, dq,
J=6.5,
4.6 Hz)
4.46,
1.44,
1.36
4.46,
1.44
19.02 1.3 (3H,
d, J=6.7
Hz)
1.45
(3H, d,
J=6.4
Hz)
1.40
(3H, d,
J=6.0
Hz)
q 19.11 1.44
(3H, d,
J=6.4
Hz)
4.48 o.
4.46,
4.34,
1.21
-
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Figure 5.30: 400 MHz 1H NMR spectrum from compound 9, in MeOD3. This compound
was identified as 2-methylene-3,4-dihydroxypentanoic acid 1,4-lactone (comatuslactone
9).
Figure 5.31: Comatuslactone 9 13C-NMR spectrum.
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Figure 5.32: HMBC (Heteronuclear Multiple Bond Correlation) spectrum from comatus-
lactone 9.
Together with 9 a second small molecule was isolated with the mass of 130 and the
composition C6H10O3. Because of its NMR (Fig. 5.33) spectra this metabolite, com-
pound 10, proved to be the dihydro-derivative of comatuslactone 9. The relative config-
uration of the ring substituents were determined by comparison with NMR resonances
of known compounds. Using NMR data of (2R,3R,4S)- and (2S,3R,4S)-2-methyl-3,4-
dihydroxypentanoic acid 1,4-lactone [159], 5S, 3’R, 4’S, 5’S- and 5S, 3’S, 4’S, 5’S-hydroxy-
ancepsenolide as well as (2S*,3R*,4S*)-2-n-hexadecyl-3,4-dihydroxypentanoic acid 1,4-
lactone [161] it could be shown that a trans-configuration of the 3-OH to the 4-methyl
group causes a shielding of about δH 0.3-07 ppm and a deshielding of about δC 5 ppm
compared to a cis-arrangement. The 1H NMR and optical rotation data data of both the
(2R,3R,4S)-trans,trans- and (2S, 3R, 4S)-cis,trans-comatuslactone reported by Bernadi et
al. [160] led to the identification of 10 as (2S, 3R, 4S)-2-methyl-3,4-dihydroxypentanoic
acid 1,4-lactone. As for comatuslactone 9 its dihydro-derivative has not been reported as
natural product.
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Table 5.14: 1H NMR and 13C chemical shifts for compound 10 ((2S,3R ,4S)-2-methyl-3,4-
dihydroxypentanoic acid 1,4-lactone), together with the data obtained from the literature.
(2S,3R ,4S)-
2-methyl-3,4-
dihydroxypentanoic
acid 1,4-lactone
[164, 165]
Compound 10
1H 13C 1H COSY CH-long
range
181.06 4.46, 4.11,
2.89, 1.21
4.5 (1H, dq, J=5.9, 1.3 Hz) d 84.52 4.48 (1H,
qd, J=6.8,
1.4 Hz)
4.11, 1.36 4.11, 1.36
4.15 (1H, dd, J=5.9, 1.3 Hz) d 75.02 4.12 (1H,
dd, J=5.7,
1.3 Hz)
4.48, 2.89,
1.21
4.48, 1.36,
1.21
2.75 (1H, dq, J=6, 5.9 Hz) 39.70 2.89 (1H,
dq, J=7.3,
4.4 Hz)
4.11, 1.21 1.21
1.35 (3H, d, J=6 Hz) q 18.14 1.37 (3H, d,
J=6.8 Hz)
4.48, 4.46,
(4.34), 1.21
4.11
1.25 (3H, d, J=6 Hz) q 8.40 1.22 (3H, d,
J=7.3 Hz)
4.11, 2.89,
1.44, 1.36
2.89
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Figure 5.33: 400 MHz 1H NMR spectrum from a mixture comprising 2-methylene-3,4-
dihydroxypentanoic acid 1,4-lactone (comatuslactone 9) together with (2S, 3R, 4S)-2-
methyl-3,4-dihydroxypentanoic acid 1,4-lactone 10, in CD3OD.
Figure 5.34: Structures from comatuslactone 9 and its dihydro-derivative, (2S, 3R, 4S)-
2-methyl-3,4-dihydroxypentanoic acid 1,4-lactone 10.
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5.6 Biological activity displayed by the isolated com-
pounds
5.6.1 Planktonic cells
5.6.1.1 Minimal inhibitory concentration (MIC)
MIC values of six purified compounds (epiisororidin E 1, isororidin E 2 2, roridin H 3, 8α-
hydroxyl roridin H 4, roridin J 6 and comatuslactone 9) were determined using bacterial
and yeast strains listed on the sections 4.2.2 and 4.2.3. Compound 5 and compound 8
were not isolated as pure compounds (compound 5 was isolated as a mixture between a
roridin (8α-acetoxy roridin H 5) and a phenolic compound and compound 8 exhibited
impurities); nevertheless, their MIC values were determined as well. The only exception
here was fusidic acid 7. This compound is already used in the clinics against infections
caused by Gram-positive bacteria; therefore neither the antibacterial nor the antifungal
activity was tested. Due to quantities constraints, compound 5 was tested only against
C. albicans, P. aeruginosa and S. aureus.
All of the isolated roridins, inhibited the growth of Y. lipolytica. Interestingly, epiisororidin
E 1 and isororidin E 2 showed a fungicide activity, while roridin H 3 and 8α-hydroxyl
roridin H 4 worked as fungistatic compounds. Roridin H 3 showed the highest activity
between the isolated roridins (table 5.16). None of the roridins showed activity against
bacterial growth (table 5.15).
The mixture comprising compound 5 was active against C. albicans and S. aureus (table
5.15). Compound 8 showed antibiotic properties only against Gram-positive bacteria,
although no effect was verified when S. mutans cultures were employed (table 5.15).
Comatuslactone demonstrated a broad spectrum activity, inhibiting the growth of all of
the investigated bacteria. When the treated bacteria were incubated on fresh media, the
growth capacity was restored, revealing a bacteriostatic effect (table 5.15). A lack of
activity on yeast cells was verified (table 5.16).
MIC values established against bacteria are presented on table 5.15, as also compounds
showing bactericidal or bacteriostatic effects. On table 5.16, MIC values obtained against
yeasts as also their fungicide/ fungistatic effects are summarized.
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Table 5.15: Minimal inhibitory concentrations (µg mL −1) and growth effects from the
isolated compounds against bacterial strains.
B. E. M. P. S. S. S.
cereus coli roseus aeruginosa aureus epidermidis mutans
01 >250 >250 >250 >250 >250 >250 >250
02 >250 >250 >250 >250 >250 >250 >250
03 >250 >250 >250 >250 >250 >250 >250
04 >250 >250 >250 >250 >250 >250 >250
05 nt nt nt >250 125[1] nt nt
06 >250 >250 >250 >250 >250 >250 >250
07 nt nt nt nt nt nt nt
08 250 >250 125[1] >250 250[1] 125[1] >250
09 125[2] 125[2] 37.25[2] 150[2] 125[2] 125[2] 62.5[2]
Effect on growth: [1] Bactericide, [2] Bacteriostatic
nt - not tested
Table 5.16: Minimal inhibitory concentrations (µg mL −1) and growth effects from the
isolated compounds against yeasts.
C.
albicans
C.
guilliermondii
C.
krusei
C.
parapsilosis
C.
tropicalis
R.
glutinis
Y.
lipolytica
01 62.5 [2] 62.5 [2] 62.5 [1] 125 [2] 62.5 [2] 62.5 [1] 62.5 [1]
02 62.5 [2] 62.5 [2] 3 [1] >250 62.5 [1] 62.5 [2] 31.25 [1]
03 >250 >250 >250 >250 31.25 [2] >250 31.25 [2]
04 >250 >250 >250 >250 >250 >250 31.25 [2]
05 125[2] nt nt nt nt nt nt
06 >250 >250 >250 >250 >250 >250 31.25 [2]
07 nt nt nt nt nt nt nt
08 >250 >250 >250 >250 >250 >250 >250
09 >250 >250 >250 >250 >250 >250 >250
Effect on growth: [1] Fungicide, [2] Fungistatic
nt - not tested
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5.6.1.2 Effects of comatuslactone on bacterial cells
Since comatuslactone 9 showed bacteriostatic activity, transmission electron microscopy
(TEM) was applied to verify its effects on cellular structures. P. aeruginosa and S. au-
reus were grown overnight and treated with the established MICs of comatuslactone 9.
After 20 h of incubation, the cells were washed and submitted to microscopy procedures.
Controls were treated with identical MeOH concentration.
5.6.1.2.1 Pseudomonas aeruginosa Images from samples treated only with MeOH
(control) show cells in the late log phase, and cells with normal dense cytoplasm ex-
ist to an amount of roughly 30%. Ghost cells can be visualized (Fig. 5.35A, arrow 1).
When a higher magnification was used, cytoplasmic membranes revealed to be intact and
the cytoplasm showed normal densities and an adequate fibrillar meshwork of the bacte-
rial chromosome (Fig. 5.35B, arrows 1). Cells treated with comatuslactone 9 showed a
high amount of intracellular electron dense bodies (Fig. 5.35C, arrows 1- 5; 1D, arrows
2 and 3), which in general appear in contact with the cytoplasmic membrane. These
electron dense bodies are also present in the controls (Fig. 5.35B, arrows 2 and 3) but
here they are far less observed in the ghost-like residuals. Leakage of intracellular content
could be observed by the appearance of extracellular fibrillar matter, similar to that of
the cytoplasmic chromosome area (Fig. 5.35D, arrow 1), which undoubtedly represents
DNA.
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Figure 5.35: Effects caused by comatuslactone 9 on P. aeruginosa cells, visualized using
transmission electron microscopy. Fig. 5.35A, arrow 1 indicates a ghost cell observed in
the control samples (MeOH treated). Fig. 5.35B, arrow 1 shows the MeOH treated cells
(control) using a higher magnification. Intact membranes and cytoplasmic organization
can be observed. Fig. 5.35C and 5.35D demonstrate comatuslactone 9 treated cells.
Fig. 5.35C arrows 1-5, point to electron dense bodies. Fig. 5.35D arrow 1 indicates
extracellular fibrillar matter, caused by intracellular material leakage; arrows 2 and 3
indicate electron dense bodies. Photos: Dr. Heinrich Lünsdorf- HZI.
5.6.1.2.2 Staphylococcus aureus Micrographs obtained from late-log samples treated
only with MeOH (control) show about 75% of the cells with normal dense cytoplasm.
The overall cell size was obtained by the measurement of 10 cells and calculated to 0.8
± 0.11 µm. Dividing and ghost cells can be both recognized Fig. 5.36A, arrows 1, 2 and
3). When the cells were visualized using a higher magnification, intact membranes and a
normal cytoplasmic organization was noticed, with numerous cells in the state of division
Fig. 5.36B, arrow 1). After treatment with comatuslactone 9, a decrease of 31% of cell
91
diameter was observed Fig. 5.36C, arrow 1), clearly demonstrated by the comparison
of Fig. 5.36A with 5.36C. Interestingly, only very few cells were observed in the divi-
sion process Fig. 5.36C, arrow 2). Images obtained using a higher magnification show a
myelin-like organization of the cytoplasmic membrane Fig. 5.36D, arrows 2 and 3), which
can be taken as a characteristic feature of the lactone influence.
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5
Figure 5.36: Electron micrographs of S. aureus cells, using transmission electron mi-
croscopy. A and B represent cells treated with MeOH (control). Fig. 5.36A, arrows 1 and
3 show cells with a normal dense cytoplasm, and in the state of cell division. Fig. 5.36B,
arrow 1 shows the MeOH treated cells on a higher magnification, where intact membranes
and a normal cytoplasmic matrix can be observed. Fig. 5.36C and 5.36D indicate cells
treated with comatuslactone 9. Fig. 5.36C, arrow 1 indicates a cell with dense cytoplasm,
and a decreased diameter in comparison to the control. Fig. 5.36D, arrow 1 points to a
ghost cell, and arrow 2 indicates the myeline-like structures. This myeline-like structure
is shown in detail (arrow 3) in the inset. Photos: Dr. Heinrich Lünsdorf- HZI.
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5.6.2 Biofilms
5.6.2.1 Minimal biofilm inhibitory concentration (MBIC)
MBIC was determined using P. aeruginosa and S. aureus. Biofilm formation was evalu-
ated in polystyrene microtiter plates subsequently stained with crystal violet. Among the
nine compounds tested, epiisororidin E 1, roridin H 3 and compound 5 showed activity
against biofilm formation of S. aureus. 100% of biofilm inhibition was observed, when
the 250 µg mL−1 of epiisororidin E 1 was used and 50% of inhibition at the concentra-
tion of 125 µg mL−1. Roridin H 3 inhibited 80% of biofilm formation at 250 µg mL−1.
Compound 5 inhibited S. aureus biofilms formation at the concentration of 62.5 µg mL−1.
When higher concentrations were used, this compound mixture also displayed antibiotic
activity against S. aureus. None of the compounds could inhibit P. aeruginosa biofilm
formation.
5.6.2.2 Activity on in vitro established biofilms
Considering comatuslactone 9 activity against P. aeruginosa and S. aureus, the purity
and obtained quantity, the compound was selected for evaluation of its biofilm damag-
ing properties. Therefore, bacteria were allowed to grow on 8-well chamber slides, in
order to develop a biofilm. After the incubation time, medium was discharged and re-
placed by a medium containing serial dilutions of comatuslactone 9, with concentrations
ranging between 37.5 µg mL−1 and 300 µg mL−1 for P. aeruginosa biofilms and 37.5 µg
mL−1 to 150 µg mL−1 for S. aureus biofilms. Isopropanol (50 µL) was used to treat the
negative controls. Positive controls were treated with the same concentration of MeOH
used in the experiments. Chambers were re-incubated for 20 h. Subsequently, biofilms
were washed, fixed using a 2% paraformaldehyde aqueous solution and stained with a
Live/Dead®staining kit. In this case, living cells were visualized as green entities and
damaged cells as red. Slides were visualized under a confocal laser scanning microscope.
Z-stacks of P. aeruginosa biofilms were performed and biofilm volume was calculated us-
ing the program Fiji. Percentage of remaining live or damaged cells was calculated using
ImageJ. Treated samples were normalized to the control. For S. aureus, only the percent
of live and damaged cells was calculated.
5.6.2.2.1 Staphylococcus aureus biofilms Treatments with 100 µg mL−1 of comatus-
lactone 9 were effective in damaging 90% ± 10% of the staphylococcal biofilms. When 50
µg mL−1 were used, 65% ± 15% of the cells were red stained, demonstrating that even
in concentrations lower than the MIC, comatuslactone 9 can cause cellular disturbance
(Fig. 5.37). Images representing the control and treated samples of S. aureus biofilms
controls are shown in Fig. 5.38.
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Figure 5.37: Effect of different concentrations (50 and 100 µg mL−1) of comatuslactone 9
on S. aureus biofilms. Biofilms were stained using Live/Dead®staining kit. Areas covered
by live (green) and damaged (red) cells were quantified using ImageJ.
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Figure 5.38: Effects of different concentrations of comatuslactone 9 on S.aureus biofilms.
In vitro biofilms were stained using the Live/Dead®staining kit and visualized under a
confocal laser scanning microscope. Areas covered by live (green) and damaged (red) cells
were quantified using the software ImageJ. Fig 34A and 34B indicate the controls, positive
and negative, respectively; Fig 34C and 34D exhibit the consequence of treatments with
comatuslactone 9, using the concentration of 50 µg mL−1 (Fig. 5.38C) and 100 µg mL−1
(Fig. 5.38D).
5.6.2.2.2 Pseudomonas aeruginosa Treatments with the established MIC (150 µg
mL−1) of comatuslactone 9 against P. aeruginosa were effective in damaging 99.9% ±
0.3% of the in vitro developed biofilms. According to the results obtained after biofilm
volume quantification, only 1% ± 0.5% of the biofilm remained, in comparison to the
control. When biofilms were treated with 0.5 of the MIC, a severe damage was visualized.
In this case, a biofilm volume of 7.5 ± 1% was noticed, comprising less than 1% ± 0.6%
of living bacterial cells. Moreover, a treatment using the concentration of 37.5 µg mL−1,
was also effective, showing the biofilm volume decreased to 15% ± 2%. Nevertheless, in
this case 88% ± 5% of cells remained alive and 12% ± 7% were damaged (Fig. 5.39).
3D reconstructions of P. aeruginosa biofilms, including the positive control and samples
treated with different concentrations of comatuslactone 9 (37.5 µg mL−1, 75 µg mL−1 and
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150 µg mL−1) are represented in Fig. 5.40.
Figure 5.39: Effect of different concentrations of comatuslactone 9 on P. aeruginosa
biofilms. Biofilm volume was quantified using the software Fiji, control volume cor-
responded to 100%. Areas covered by live (green) and damaged (red) cells were also
quantified. Green columns correspond to living cells and red columns to damaged cells.
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Figure 5.40: 3D reconstructions of P. aeruginosa biofilms z-stacks, using Imaris software.
A-positive control, B-treatment with 37.5 µg mL−1 of comatuslactone 9, C-treatment
with 75 µg mL−1 and D-treatment with 150 µg mL−1 of comatuslactone 9.
5.6.3 Quorum sensing inhibition
As comatuslactone 9 showed to be efficient in biofilm damaging and dispersal, its influ-
ence on quorum sensing systems was also tested. Therefore, two mutants were selected:
(a) Escherichia coli MT102 (pSB403) - a reporter for genes lux, responding to short chain
AHLs and (b) Pseudomonas putida F117 (pKR-C12) - based on the las QS-system of P.
aeruginosa, responding to long chain AHLs. Both mutants were allowed to grow overnight;
the media was diluted with a new media containing the respective AHL and pipetted into
a 96-well black microtiter plate. Comatuslactone 9 was added on serial dilutions, with
concentration ranging between 60 µg mL −1 and 0.015 µg mL −1. Controls were treated
with MeOH and background controls were performed without AHL and comatuslactone
addition. Bioluminescence (for short chain AHL) and fluorescence (for long chain AHL)
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were quantified using a plate reader.
(a) E. coli MT102 (pSB403): bioluminescence quantification shows a complete abolish-
ment of the QS response at the concentration 3.75 ± 0.25 µg mL −1. At the concentration
of 60 µg mL −1, the compound displayed antibacterial activity against the mutant (Fig.
5.41).
Figure 5.41: Influence of comatuslactone 9 on E. coli MT102 (pSB403) QS, a reporter
for genes lux, responding to short chain AHLs. The black line corresponds to the control
and red line to the treated samples.
(b) P. putida F117 (pKR-C12): fluorescence measurement demonstrated that comatus-
lactone 9 was able to decrease by 80% ± 5% the QS response at the concentration 30
µg mL −1. Again, at the concentration of 60 µg mL −1, antibacterial activity against the
mutant was verified (Fig. 5.42).
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Figure 5.42: Influence of comatuslactone 9 on P. putida F117 (pKR-C12) QS,a mutant
based on the las QS-system of P. aeruginosa, responding to long chain AHLs. The black
line corresponds to control and red line to the treated samples.
5.6.3.1 Pyocyanin and rhamnolipid B inhibition
Pyocyanin and rhamnolipid B are synthesized via P. aeruginosa QS systems and are vir-
ulence factors. To verify the effect of comatuslactone 9 on these secondary metabolites
production, P. aeruginosa was incubated and serial dilutions of comatuslactone 9 were
added to 96-well microtiter plates. After 30 h of incubation, the cell-free supernatants
were extracted using ethyl acetate. Pyocyanin and rhamnolipid B concentration was mea-
sured using tandem mass spectrometry analysis (HPLC-MS/MS). Here, the target parent
ions m/z 211 [M + H]+ for pyocyanin and m/z 652 [M + H]+ for rhamnolipid B were
fragmented. After fragmentation, the two most intense product ions were chosen to per-
form the analysis of both metabolites present in the samples. Therefore, each individual
sample was always injected in triplicate and the product ions obtained from fragmenta-
tion of pyocyanin (m/z 168 and m/z 77) and rhamnolipid B (m/z 217 and m/z 70) were
monitored using the multiple reaction monitoring (MRM) mode, in order to avoid any
discrepancy originated from the equipment.
Pyocyanin concentrations were compared to a curve generated from a commercial stan-
dard (Fig. S3), using the MassHunter quantitative analysis software from Agilent Tech-
nologies. Rhamnolipid B quantities were normalized to the positive control and the rela-
tive concentrations calculated according to the area under the peaks.
Quantification of pyocyanin demonstrated that treatments using 75 µg mL−1 of comatus-
lactone 9 were able to reduce its production by 80%± 3% (Fig. 5.43), as well as 100% of
rhamonolipid B (Fig. 5.44). When 37.5 µg mL−1 of the active compound was applied to
the samples, 48% ± 5% of pyocyanin production was inhibited (Fig. 5.43). In the case
of rhamnolipid B, when the same concentration was used, an inhibition of 97.4% ± 2%
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was verified (Fig. 5.44). Surprisingly, treatments using 18.75 µg mL−1 of comatuslactone
9 allowed the production of only 44% ± 10% of rhamnolipid B (Fig. 5.44). On the other
hand, pyocyanin production was restored to almost 80% when this concentration was used
(Fig. 5.43).
Figure 5.43: Impact of comatuslactone 9 on pyocyanin production. Samples were treated
with serial dilutions of the active compound, using a concentration range of 4.68 µg mL−1
to 75 µg mL−1. Pyocyanin concentration (ng mL−1) was calculated according to the
values obtained from a curve generated with a commercial standard and analysed using
the MassHunter quantitative analysis software from Agilent Technologies.
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Figure 5.44: HPLC-MS/MS rhamnolipid B quantification (%), after treatment with se-
rial dilutions of comatuslactone 9. The results obtained using the concentrations of 75
µg mL−1, 37.5 µg mL−1 and 18.75 µg mL−1 are shown. Calculations were performed
according to the area under the peaks and normalized to the positive control.
5.6.4 Cytotoxicity
5.6.4.1 MTT assays
Comatuslactone 9, epiisororidin E 1, isororidin E 2, 8α-hydroxyl roridin H 4 and roridin
J 6 cytotoxicity was evaluated using the mouse fibroblast cell line L-929. Here the com-
pounds were serial diluted in a 96-well microtiter plate, in medium containing 5 x 104 cells
with a starting concentration of 30 µg mL−1. 8α-hydroxyl roridin H 4 and roridin J 6
showed the highest cytotoxicity, with IC50 value calculated to 1.1 ng mL −1 and 3.2 ng mL
−1, respectively. Both epiisororidin E 1 and isororidin E 2 exhibited an IC50 value of 50
ng mL −1. On the other hand, MTT assays of cell cultures treated with comatuslactone
9, show 10% of remaining cells, even when the highest concentrations were used.
5.6.4.2 Impedance measuraments
Cells treated with comatuslactone 9, epiisororidin E 1 and isororidin E 2 were submitted
to analysis on an xCELLigence™system, which measures time-dependent cell response
profiling. These measurements provide information about cellular status, as morphol-
ogy, cell number and viability. Therefore, cells were incubated in the presence of the
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IC90 concentration of each compound (30 µg mL−1 in the case of comatuslactone 9),
electrical-impedance was measured and obtained data were processed using the imple-
mented workflow. After results processing, a heatmap was constructed, and hierarchical
cluster analysis of the reference compounds together with the isolated compounds was per-
formed. Co-clustering of an isolated compound with a reference compound with known
mode of activity indicates the compounds mode of action. Here, cluster analysis shows
both roridins in the same group, which was separated from all of the reference compounds.
This result indicates that these metabolites display a different mechanism of action than
the class label compounds used in the assay (Fig. 5.45, group 1). Comatuslactone 9 clus-
tered together with the control (DMSO), suggesting no evidence of cytotoxic mechanisms
(Fig. 5.45, group 2).
Figure 5.45: Hierarchical cluster analysis of data from impedance curves obtained using
L-929 cells, incubated with epiisororidin E 1, isororidin E 2 and comatuslatone 9. Group
1 indicates epiisororidin E 1 and isororidin E 2 cluster. Group 2 indicates comatuslactone
9 clustering together with the control (DMSO).
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5.6.4.3 Eukaryotic cell morphology
In order to investigate morphological changes caused by comatuslactone 9, L-929 mouse
fibroblast cells were treated with the compound and subjected to immunofluorescence,
using anti-α-tubulin. The nucleus was stained with DAPI. Fig. 5.46A shows cells treated
with MeOH (as control) with a typical microtubular organization and nuclear appearance
(Fig. 5.46A, arrow 1). However, in comatuslactone 9 treated cells (Fig. 5.46B) an
increase of multinucleated cells (Fig. 5.46B, arrows 1 and 2) was visualized. Nevertheless,
the majority of the cells still presented a normal microtubular distribution and nuclear
morphology (Fig. 5.46B, arrow 3).
Figure 5.46: L-929 mouse fibroblast cells immunofluorescence images, stained with anti-
α-tubulin and DAPI. A - cells treated with MeOH, representing the control. B - cells
treated with comatuslactone 9. Here multinucleated and normal cells can be visualized.
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Chapter 6
Discussion
This study was focused on the exploitation of fungal secondary metabolites for their an-
tibiofilm, antifungal and antimicrobial properties. Thus, it was assumed that fungi possess
chemical self-defense mechanisms to prevent bacterial growth and/or biofilm formation
on their fruiting bodies, warranting a successful life cycle. Due to a lack of reports in the
literature about biofilm formation and bacterial composition associated with mushrooms
fruiting bodies and to provide a solid explanation about the hypothesis of this work,
bacterial communities of the surface of 49 mushrooms fruiting bodies were evaluated.
Furthermore, 5 isolated fungi, Calcarisporium arbuscula, Coprinus comatus, Macrolepiota
fuliginosa, Macrolepiota procera and Pholiota lenta were subjected to a screening per-
formed using different incubation conditions aiming bioactive compounds production.
Although the 5 studied fungal species were able to produce bioactive metabolites, not all
of the compounds could be successfully isolated. Occasionally, after a number of purifica-
tion steps, the biological activities were no longer detected. These findings may indicate
a synergistic effect between two or more compounds present in the crude extracts or even
very labile compounds, which were degraded during the experiments.
Nevertheless, the screening strategy used in this work led to the isolation and identifica-
tion of comatuslactone, a novel natural product from C. comatus, together with 6 roridins
and fusidic acid from C. arbuscula. Their respective biological activities and importance
will be discussed in the following sections.
6.1 Bacterial communities associated with
basidiomycetes fruiting bodies
Fungi and bacteria coexist for billions of years, sharing frequently the same ecological
niche and often depending on each other. In consequence, they have evolved complex
interaction mechanisms, which vary from beneficial symbiosis to deleterious diseases [68,
158, 159]. A number of secondary metabolites produced by fungi have the same function
as our immune system: protection of the producing organism. Thus, the goal of this work
was to exploit compounds produced by fungi capable of modulating pathogenic bacterial
biofilms. Fruiting bodies forming fungi are exposed to rain and moist climate, offering
ideal substrata for bacterial colonization. Therefore, those organisms are extremely de-
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pendent on their self-defense molecules to modulate their interaction with their friendly
and unfriendly environmental counterparts [158, 159]. Some efforts have been made be-
fore to characterize bacterial communities associated with fungi, as well as their possible
ecological role. Nevertheless, most studies concerning these associations are restricted to
culturable bacteria, isolated from fruiting bodies of symbiotic and economic important
species [159, 160, 161, 162]. Therefore, a combined investigation of their associated bac-
terial communities and the production of secondary metabolites with biofilm modulatory
properties is an interesting approach. Hence, bacterial communities composition of 49
basidiomycetes, both saprophytic and ectomycorrhizal, belonging to 7 genera, were anal-
ysed using SSCP fingerprinting.
Herein, it was demonstrated that 18 fungi showed no bacteria associated with their sur-
faces. Among those fungi, 14 individuals were identified as Coprinus comatus, 3 as Co-
prinopsis atramentaria, 1 as Macrolepiota procera and 1 as Laetiporus sulphureus. In-
terestingly, only Gram-negative bacteria were detected at the remaining 31 samples. In
2013, Zagriadskaia et al. [163], investigated the bacterial communities associated with
the hyphosphere soil and fruiting bodies surface and internal tissues of Laccaria laccata,
Lactarius aurantiacus, Gymnopus confluens, Lycoperdon perlatum, Coltricia perennis, and
Clavariadelphus ligula. In this case, Gram-negative bacteria showed prevalence among the
surface samples. Dahm et al. 2005 [164], published similar data, where Gram-negative
rods were the predominant bacteria isolated from the fruiting bodies of ectomycorrhyzal
fungi. Moreover, Kataoka et al. 2008 [165] evaluated bacterial communities associated
with root tips Pinus thunbergii mycorrhizae. A prevalence of Gram-negative microorgan-
isms, specially Burkholderia sp. and Bradyrhizobium sp. was observed. Comparison of
arbuscular mycorhizal fungi (AMF) associated bacteria, considering both attached and
non-attached communities, showed that the Gram-negative ones are better hyphae colo-
nizers [166]
In 2009, Warmink et al. [159] introduced the term fungiphile, to characterize bacte-
ria which are detected frequently in association with fungi. Here, Pseudomonas spp. and
Rhanella spp. were identified from several mycosphere samples using DGGE. In this work,
SSCP fingerprint analysis detected 118 phylotypes, distributed among 31 fruiting bodies
samples. Among those, 15 were identified as Rhanella spp., showing association with
specimens belonging to Boletus spp. 20 phylotypes belonging to Pseudomonas spp. were
detected, showing a broad distribution between the analysed fungal genera. Interestingly,
the two specimens at Russula emetica showed a very close association with Rhizobiaceae.
Regarding those individuals, 15 bacterial phylotypes were detected, 13 belonging to Rhi-
zobiaceae and 2 identified as Flavobacterium sp. Additionally, communities associated
with Boletus spp. showed a high prevalence of Enterobactereaceae. One incertae sedis
sequence was obtained from Amanita sp. In this case, there is the possibility of fungal
genomic fragment amplification, generating such sequence.
Warmink and van Elsas, 2008 [167], discussed the involvement of the type-III secretion
system (TTSS) on the bacterial cells binding to Laccaria proxima hyphae. TTSS are
virulence-associated systems, widespread among symbiotic and pathogenic Proteobacte-
ria, being related to interactions between bacteria with their respective hosts [168]. They
showed a selection of TTSS positive bacteria on those associations, particularly Pseu-
domonas spp. [167]. Within the data obtained in this work, only Gram-negative bacteria
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were detected in association with fruiting bodies. Many of those bacteria are known to
possess TTSS systems. Therefore, it can be hypothesized that these systems are required
for the establishment of those close interactions between the fruiting bodies of mushrooms
and bacteria. Moreover, the ectomycorrhizal evaluated individuals demonstrated a higher
diversity of bacteria, which can be explained by their ecological roles.
The results corroborate the initial hypothesis that fungi can control their biofilm com-
munities. In summary it can be predicted that appropriate knowledge about fungi and
bacteria interactions will be beneficial to determine approaches to screen for compounds
exhibiting biological activities.
6.2 Compounds isolated from Calcarisporium arbuscula
6.2.1 Roridins
The C. arbuscula strain used in this work was isolated from a Russula emetica fruiting
body and identified according to its ITS sequence. In 1955, C. arbuscula was already re-
ported living in symbiosis with Ascomycotina and Basidiomycotina fruiting bodies [142,
169]. From C. arbuscula fermentations, several cytotoxic compounds have been isolated,
like polyketides, named aureovertin D and B, [170, 171] as also trichothecenes [156].
Both aurovertins are very cytotoxic, and the mechanism of action is defined as potent
inhibitors of ATP-synthesis and ATP-hydrolysis. They have been used in studies about
H-translocating ATPases [172].
Trichothecenes are sesquiterpenoid metabolites, comprised of a tricyclic core. Many of
those compounds have an epoxide at C-12 and C-13, crucial for their toxicity [173, 174,
175]. More than 200 trichothecenes are known, and they were classified in non-macrocyclic
and macrocyclic compounds. The group of non-macrocyclic trichothecenes is divided in
three types: A, B and C. Examples are T-2 toxin, nivalenol, deoxynivalenol and tri-
chothecin, all produced by Fusarium [176, 177]. All of the macrocyclic trichothecenes
belong to type D compounds. They possess a cyclic diester or triester ring bound to the
trichothecene at C-4 and C-15. This division encloses satratoxins, verrucarins, roridins,
myrotoxins and baccharinoids [176, 178].
The production of roridins is extensively reported for fungi belonging to the Hypocre-
aceae family. Cylindrocarpon sp., Myrothecium roridum and Myrothecium verrucaria are
the most known producers, being the source of more than 20 roridins (table 6.1). For C.
arbuscula, production of roridin H, roridin J, 8α-hydroxy-roridin and 8α-acetoxy-roridin
H (as calcarisporin B1) was reported [156]. Herein, 6 roridins, epiisororidin E 1, isororidin
E 2, roridin H 3, 8α-hydroxy-roridin 4, 8α-acetoxy-roridin H 5 and roridin J 6 produced
by C. arbuscula were isolated and identified using NMR. Although most of these my-
cotoxins are already reported for this fungal species, the relative configuration at either
C-6’ and C-13’ for roridin H, and at 4’-H for roridin J was not determined. Therefore,
1H NMR data obtained from roridin H 3 was compared with 1,3-dioxolanes of erythro-
and threo-10,11-dihydroxy-trans-12-nornerolidol [151]. The chemical shifts of the threo-
compound 13-methyl group (δH = 1.25 ppm) together with a shielding of 11-H to δH =
3.72 ppm matched to the data obtained for roridin H 3. Consequently, its stereochemistry
at C-6’ and C-13’ was solved as a 6’S,13’S-configuration. 1H NMR spectrum analysis of
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roridin J 6 indicates a hydroxyl group at the 4’ position and coupling constant of J= 6.9
Hz between 4’ H and 5’ H. This value requires an dihedral angle of approximately 180◦
among those protons, which is only achievable if the 4’- hydroxyl group is in β-position.
Hence, its configuration is solved here, being 4’R.
Furthermore, the additional two roridin E isomers, epiisororidin E 1 and isororidin E 2
isolated from C. arbuscula were originally isolated from M. verrucaria and Cylindrocar-
pon sp. respectively [147,149]. It is important to emphasize that, for all of the isolated
roridins within this work, the stereochemistry at C-6’ was only found as 6’S configura-
tion. None of the compounds was detected as a mixture with the C-6’R isomers. The
biosynthesis of isororidin E (C-6’S and C-13’S) and epiisororidin E (C-6’S and C-13’R)
by Myrothecium spp. occurs, together with roridin E (C-6’R and C-13’R) and epiroridin
E (C-6’R and C-13’S). Generally, other roridins, e.g, roridin A were also isolated from the
same fermentation processes [179]. In most of the roridins, C-6’ is R whereas the C-6’S
configuration occurrence is less frequent. Moreover, roridins showing a C-6’S configura-
tion were always detected combined with their C-6’R isomers [147, 179]. The detection
of only C-6’S-configuration is the first report of such a stereospecificity. It may indicate
a biosynthesis which deviates from the one of Myrothecium sp.
Concerning trichothecenes biosynthesis, Fusarium spp., Trichoderma spp. and M. ror-
idium have been used to investigate gene clusters involved in those processes [173, 174,
175, 176, 180, 181]. The first step on the trichothecenes biosynthesis is the cyclization of
farnesyl pyrophospate to trichodiene by a trichodiene synthase, followed by a sequence of
oxygenations, cyclizations and esterifications, originating more complex structures. It was
shown that the genes involved in the biosynthesis of these compounds are organized in
clusters, designated TRI [173, 176, 180, 181]. While the non-macrocyclic trichothecenes
pathways are provided with more details, the macrocyclic biosynthetic pathways still re-
main obscure and only the last intermediates were already identified [181].
In 1982, Jarvis et al. [154] working with a strain of M. verrucaria, showed that trichover-
rins and isotrichoverrins (Fig. 6.1), are the macrocyclic trichothecenes precursors. From
the trichoverrins (C-6”S) or isotrichoverrins (C-6”R) to the macrocycles, ring closure re-
sults in an inversion of the configuration at the C-6”. After the inversion, the resulting
roridin is further transformed to other roridins. However, the sequence of the hydroxyla-
tion and esterification steps between trichodermol and trichoverrins remains unclear, as
well as the further steps needed for roridins modification [176, 181]. So far, only genes
controlling the initial stages of the trichothecenes macrocyclic biosynthetic pathway in M.
roridum (MRTRI4-6) have been characterized [173, 180, 181].
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Figure 6.1: Structure of trichoverrin.
6.2.2 Fusidic acid
Fusidic acid was isolated the first time in 1962 from Fusarium coccineum fermentations
[182]. In 2001, this same antibiotic was isolated from Stilbella aciculosa, a marine fungus
[183]. This steroid-like antibiotic is widely used to treat infections caused by Gram-
positive bacteria, including methicillin resistant Staphylococccus aureus [184]. A fusidic
acid analogue has been isolated from Acremonium crotocinigenum as well as cephalosporin
P1 - a triterpenoid antibiotic, related to fusidic acid, but not to cephalosporin - from Acre-
monium chrysogenum (Cephalosporium acremonium) [185, 186]. Besides demonstrating
the ability of producing fusidanes antibiotics, the common feature between these 4 genera
is that they all belong to the Hypocreales order. No literature correlating this order with
production of fusidanes has been encountered.
6.3 Biological activities of roridins
6.3.1 Yeasts growth inhibition
Inhibition of yeast and fungal growth was shown for roridin A and 8β-acetoxy ror-
idin H. For these two compounds, activity against C. albicans, Tricophyton rubrum
and Aspergillus niger was reported. Roridin A was also demonstrated to interfere with
Kluyveromyces fragilis growth [152, 187, 188]. Herein, fungicide and fungistatic activities
of epiisororidin E 1, isororidin E 2, roridin H 3, 8α-hydroxy-roridin 4 and roridin J 6
against a panel of 7 yeasts species was reported. All of these compounds were effective
against Y. lypolytica, acting as fungistatic (roridin H 3, 8α-hydroxy-roridin 4 and roridin
J 6) or fungicide (epiisororidin E 1, isororidin E 1) agents. Regarding Candida spp.,
epiisororidin E 1 inhibited the growth of all of the evaluated species, whereas isororidin
E 2 was not active against C. parapsilosis. Additionally, roridin H 3 showed a fungistatic
effect against C. tropicalis. Moreover, R. glutinis growth was inhibited only when epi-
isororidin E 1, isororidin E 2 were employed. Despite roridins structural similarities, the
displayed activities against yeasts demonstrate distinct features. Apparently, the ring
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conformation at C-6’S and C-13’S on roridin H 3, 8α-hydroxy-roridin 4 and roridin J 6,
conferred by the acetal moiety decreases their toxicity to yeasts cells. These observations
suggest that small changes on roridins macrocyclic ring conformation can cause variations
on their activity.
6.3.2 Cytotoxicity
Trichothecenes are phytotoxic and cytotoxic, causing several crop diseases and intoxica-
tions. However, antifungic and antileukemic activities are also reported [147, 152, 176,
189, 190]. Inhibition of protein, DNA and RNA synthesis, interference with mitochondrial
function, effects on cell division and on membrane are some known cytotoxic responses in
eukaryotic cells. Nevertheless, the exact mechanism of toxicity is not completely clear [176,
191]. Most of the investigations on trichothecenes mechanisms of toxicity are restricted
to the non-macrocyclic type. Within this class, anguidin achieved phase II in clinical
trials, but those investigations were discontinued due to toxic effects heterogeneity and
inadequacy of the observed biological activity. Furthermore, anguidin demonstrated to
be non-selective between murine and tumor cells [176, 192].
In 2003, Amagata et al. [192], investigated the cytotoxic effects of several trichothecenes,
including non-macrocyclic (anguidin, 13’-acetyltrichoverrin B, trichoverrin A and tri-
choverrin B) and macrocyclic compounds (roridin A, isororidin A, epiroridin E, 3-hydroxy-
roridin E, roridin L, roridin M, miophytocen C, verrucarin A and verrucarin M). Here,
a disk diffusion soft agar colony formation assay and a NCI screen, consisting 60 cancer
cell lines were employed. Regarding those assays, a substantial variation on the cytotoxic
effects displayed by the tested compounds was observed. Here, miophytocen C showed
the lowest toxicity, which is explained by the absence of the C-12 and C-13 epoxide. The
epoxide ring has been shown to be essential for trichothecenes toxicity [176, 193]. There-
fore, in 1984, Jarvis et al. [193] used a semi synthetic approach in order to introduce
a 9β-10β epoxide at some trichothecenes, including roridin A, roridin J and roridin H.
Their activitiy was tested in vivo against P388 mouse leukemia. Herein, the addition of an
epoxide increased selectivity and potency for roridin A and roridin H. Contradictorily, the
modified roridin J was less active against leukemia. Moreover, reported experiments using
roridins imply on a broad toxicity, which is cell strain and roridin structure dependent.
On a general manner, it is suggested that a 2’-OH substituent on the macrocyclic ring
increases tumor cells selectivity and potency, as well as the stereochemistry at C-6’ and
C-13’ [192]. On the other hand, Oda et al. 2010 [194] demonstrated that the cytotoxicity
of 12′-hydroxyroridin E was more than 1000 fold reduced when compared to roridin E.
Here, the cytotoxicity of epiisororidin E 1, isororidin E 2, 8α-hydroxy-roridin H 4 and
roridin J 6 was evaluated against a mouse fibroblast cell strain (L-929). The obtained
IC50 values demonstrated that 8α-hydroxy-roridin H 4 and roridin J 6 displayed a higher
cytotoxicity than epiisororidin E 1, isororidin E 2. Hitherto, the roridins showing a 13’
-OH (epiisororidin E 1 and isororidin E 2) demonstrated a decreased toxicity of approxi-
mately 10 fold when compared to 8α-hydroxy-roridin H 4 and roridin J 6. Epiisororidin E
1 and isororidin E 2 were also subjected to an impedance measurement in order to predict
their toxic mechanisms. Within this assay, both roridins clustered together, establishing
a new group, not related to the standard references. This indicates a peculiar mode of
action. In table 6.1, data about roridins producer organisms along with their biological
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activities are summarized.
Besides of all of these observed effects on eukaryotic cells, almost no biological activity
on prokaryotes was reported. In fact, these compounds showed a preference for eukary-
otic systems [176]. For bacteria, studies showed de-epoxidation of the non-macrocyclic
trichothecenes deoxynivalenol caused by Clostridiales, Anaerofilum sp., Collinsella sp.,
and Bacillus spp. [195, 196]. Nevertheless, data obtained within this work, revealed that
epiisororidin E 1 and roridin H 3 are capable of inhibiting S. aureus biofilm formation.
The mechanisms underlying this activity remain to be investigated.
Table 6.1: Roridins producer organisms and biological activities,
together with the respective refences.
Compound Formula Producer organism Biological activity Ref.
Roridin A C29H40O9 Cylindrocarpon sp.
Myrothecium
roridum
Myrothecium
verrucaria
Growth inhibition of
Candida albicans, Kluyveromyces
fragilis, Tricophyton rubrum,
Aspergillus niger.
Cytotoxicity against L1210,
NCI-H226 NCI-H522, COLO205,
M14, UACC-62 SK-MEL-2,
786-0, A498, RXF 393, MDA-N and
MDA-MB-435 cell lines.
Inhibition of Arabidopsis thaliana
pollen development.
Plasmodium falciparum
Junin virus
192,
197,
198,
199,
200,
201,
202
Isororidin A C29H40O9 Myrothecium
verrucaria
Acremonium
neo-caledoniae
Cytotoxicity against KB, NCI-H522,
COLO205, M14, UACC-62, A498,
RXF 393, MDA-N and
MDA-MB-435 cell lines
179,
192,
203
8β-
hydroxyroridin A
C29H40O10 Semisynthetic P388 mouse leukemia
(in vivo)
193
9β, 10β -
epoxyroridin A
C29H40O11 Semisynthetic P388 mouse leukemia
(in vivo)
193
8β-hydroxy-9
β,10 β -
epoxyroridin A
C29H40O11 Semisynthetic P388 mouse leukemia
(in vivo)
193
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Compound Formula Producer organism Biological activity Ref.
16-hydroxy-9
β,10 β
-epoxyroridin A
C29H40O11 Semisynthetic P388 mouse leukemia
(in vivo)
193
Roridin D C29H38O9 Myrothecium
roridum
Myrothecium
verrucaria
Cytotoxicity against primary
soft-tissue sarcoma cells
198,
204,
205
Roridin E C29H38O8 Myrothecium
roridum
Myrothecium
verrucaria
Phytotoxicity
Cytotoxicity against H4TG, MDCK,
NIH3T3, KA31T and primary
soft-tissue sarcoma cells.
Activity against
Plasmodium falciparum
Activity against Junin virus
147,
197,
198,
206,
207
Epiroridin E C29H38O8 Myrothecium
verrucaria
Cytotoxicity against HL-60, NCI-H226,
HCT-116, M14, UACC-62, 786-0,
A498, RXF 393 and
MDA-MB-435 cell lines.
149,
192
Epiisororidin E C29H38O8 Calcarsiporium
arbusculaa
Myrothecium
verrucaria
Fungicide againstC. krusei,
R. glutinis andY. lypolytica;
Fungistatic againstC. guilliermondii,
C. parapsilosis andC. tropicalisa
Phytotoxicity
Cytotoxicity against L929, H4TG,
MDCK, NIH3T3, KA31T and primary
soft-tissue sarcoma cells.
147,
198,
207,
a
Isororidin E C29H38O8 Calcarsiporium
arbusculaa
Cylindrocarpon sp.
Myrothecium
roridum
Myrothecium
verrucaria
Fungicide against
C. krusei, C. tropicalis
andY. lypolytica;
Fungistatic against
C. parapsilosis andR. glutinisa
Cytotoxicity against L929 cellsa.
147,
149,
a
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Compound Formula Producer organism Biological activity Ref.
12,13-
deoxyroridin E
C29H38O7 Myrothecium
roridum
HL-60 and L1210 cell lines 208
7β - 8β-
Epoxyisororidin E
C29H36O9 Cylindrocarpon sp. 149
3-hydroxy
roridin E
C29H38O9 Myrothecium
verrucaria
Cytotoxicity against HL-60,
NCI-H226, HCT-116, M14,
UACC-62, 786-0, A498, RXF 393
and MDA-MB-435 cell lines.
192
12’- hydroxy
roridin E
C29H39O9 Myrothecium
roridum
Cytotoxicity against cells L1210. 199
16-hydroxy
roridin E
C29H39O9 Myrothecium
roridum
Cytotoxicity against primary
soft-tissue sarcoma and high-grade
leiomyosarcoma tumor cells.
209
Roridin J C29H36O9 Calcarisporium
arbuscula
Myrothecium
verrucaria
P388 mouse leukemia (in vivo)
Growth inhibition of
Yarrowia lipolyticaa.
Cytotoxic against L-929 cellsÃć
157,
193,
a
9 β,10 β-
epoxyroridin J
C29H38O9 Semisynthetic 193
Roridin H C29H36O8 Calcarisporium
arbuscula
Myrothecium
roridum
Myrothecium
verrucaria
Phytotoxicity
Cytotoxicity against H4TG, MDCK,
NIH3T3, KA31T, L1210 and primary
soft-tissue sarcoma cells.
Cytotoxic against L-929 cellsa
P388 mouse leukemia (in vivo).
Fungistatic againstC. tropicalis
andY. lipolyticaa
150,
193,
207
8 α -
hydroxy roridin H
C29H36O9 Myrothecium
sp. GS-17
Calcarisporium
arbuscula
Growth inhibition of
Rhizoctonia solani Fusarium
oxysporum andYarrowia
lipolyticaa.
Cytotoxic against L-929 cellsa
153,
156
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8β -
Acetoxy-roridin H
C31H38O10 Myrothecium
sp. Z16
Growth inhibition ofCandida
albicans, Tricophyton
rubrum, Aspergillus niger
153
7β, 8β, 2’, 3’-
Diepoxyroridin H
C29H34O10 Cylindrocarpon sp. 149
7β - 8β-
Epoxyroridin H
C29H34O9 Cylindrocarpon sp. 149
9 β,10β-
epoxyroridin H
C29H38O9 Semisynthetic P388 mouse leukemia (in vivo). 193
Isororidin K C29H38O9 Myrothecium
verrucaria
153
Roridin L C29H38O9 Myrothecium
verrucaria
Cytotoxicity against P388, NCI-H226,
NCI-H522, COLO205, M14, UACC-62,
SK-MEL-2, A498, MDA-N and
MDA-MB-435 cell lines.
210
Roridin M C29H36O9 Myrothecium
verrucaria
Cytotoxicity against P388, NCI-H226,
NCI-H522, HCT-116, HCT - 15, M14,
UACC-62 SK-MEL-2, A498, RXF 393,
MDA-N and MDA-MB-435 cell lines.
192,
210
Roridin Q C35H47O11 Myrothecium
roridum
Cytotoxicity against L1210 cells. 199
Roridin R C29H39O9 Myrothecium
roridum
Cytotoxicity against L1210 cells. 199
6.4 Compounds isolated from Coprinus comatus
Coprinus comatus, the shaggy ink cap, is an edible mushroom of cosmopolitan occurrence
(Fig. 6.2). Its cultivation was established in China and Taiwan, generally in sawdust
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plastic bags [215, 216]. It is known as a medicinal fungus and a number of biological
activities have been reported, including anticancer, due to blocking the androgen recep-
tor, antioxidant [216, 217], nematocidal [218, 219, 220] and analgesic activities [221].C.
comatus fruiting bodies have also been found possessing antimicrobial activity [222, 223]
but the underlying chemical compounds have not yet been identified.
Figure 6.2: Fruiting bodies of C. comatus.
Within this work, a specimen of C. comatus was collected in Braunschweig, Germany
and isolated in PDA media. The obtained mycelium was subjected to growth under
different stress conditions, in order to produce bacterial biofilm modulators. Regarding
this activity, (3R,4S)-2-methylene-3,4-dihydroxypentanoic acid 1,4-lactone was isolated.
This compound was produced in BAF and YEM media, adjusted to pH 5.0, 7.0 and 9.0
and at both temperatures tested. No production was detected when the fungi was incu-
bated in PDB. The aforementioned molecule was already described as synthetic derivative
[159, 160], being characterized here, for the first time as a natural product. Therefore,
it was denominated comatuslactone 9 (Fig. 6.3A). Moreover, a second lactone, named
(2S,3R,4S)-2-methyl-3,4-dihydroxypentanoic acid 1,4-lactone 10 (Fig. 6.3B) was also iso-
lated. Nevertheless this compound did not exhibit any of the tested biological activities.
Alpha-methylene-gamma-butyrolactones are generally isolated from plants [224]. Few
cases are reported for fungi, including 2-methyl-pentene-olide (Fig. 6.3C), a flavor iso-
lated from C. comatus fruiting bodies [225] and (3S,4R)-3-carboxy-2-methylene-heptan-4-
olide (Fig. 6.3D), produced by the plant pathogen Lasiodiplodia theobromae, responsible
for black spots induction on bananas [226]. Tulipalin A and B (Fig. 6.3E) were first
isolated from Tulipa gesneriana. Tulipalins are recognized as chemical self-defense com-
pounds, acting against microbial infection and insects predation. Interestingly, tulipalin
A demonstrates a higher antifungal activity than tulipalin B, whereas tulipalin B inhibits
bacterial growth more efficiently than tulipalin A. Tulipalin A was also shown to cause
contact allergies in mammals [227, 228, 229].
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Figure 6.3: Chemical structures of: A - (3R,4S)-2-methylene-3,4-dihydroxypentanoic
acid 1,4-lactone (comatuslactone 9); B - (2S,3R ,4S)-2-methyl-3,4- dihydroxypentanoic
acid 1,4-lactone 10; C- 2-methyl-pentene-olide, isolated from C. comatus; D - (3S,4R)-3-
carboxy-2-methylene-heptan-4-olide, isolated from L. theobromae and E- tulipalins A and
B, isolated from T. gesneriana.
Kato et al. have been working on the biosynthesis of tulipalins [230, 231]. Thus, glucose
esters, named tuliposides (Fig. 6.4) were identified as tulipalins precursors. So far, seven
analogs have been characterized: 1 - tuliposide A and B; 6 - tuliposide A and B; and
tuliposides D, E and F. Tulipalins are the result of a lactonization of a released aglycone,
which can occur spontaneously as a result of a pH change, due to tuliposides instability
on pH above 5.5, or as a result of enzymatic liberation [232].
Figure 6.4: Tulipalin A synthesis. Tuliposide A is hydrolysed under alkaline conditions,
or enzymatically yielding tulipalin A and glucose.
In 2012, Nomura et al. [227] purified a tuliposide-converting-enzyme (TgTCE1) from
tulips bulbs. This enzyme belongs to the lactone forming carboxylesterases and catalyzes
the reaction from 6-tuliposides A, yielding tulipalin A. It is proposed that tuliposides
possess a storage function, being compartmentalized in vacuoles and acting as prodrugs.
The TgTCE1 enzymes are organized in plastids, both in intact tulips tissues. Due to
cellular damage by infection or wounding, those molecules are released, finally converting
6-tuliposide A to tulipalin A and glucose. Some other examples of prodrugs are the fatty
acid esters of some sesquiterpenes. In this case, some Russula spp. produce sesquiterpene
alcohols which are esterified with fatty acids. These fatty acid esters do not display strong
antibiotic activities. However, when the fruiting body is injured esterases are activated
which cleave the ester bond and release the free alcohols. These alcohols are either very
labile and react to a number of products or they are the substrates for enzymes which
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transform them into a multitude of products. These products are chemically very reac-
tive, hence toxic on the one hand but instable on the other hand [233, 234].
Comatuslactone and tulipalins possess a very similar structure, and it would not be a
surprise if both are derived from a similar precursor. Comatuslactone was always de-
tected after 35 days of incubation, which would corroborate to a mycelial storage derived
product. Moreover, due to long incubation periods, the cells are normally lysed, liberat-
ing the glycol-complex, which is hydrolysed through enzymatic activity or environmental
conditions, yielding glucose and comatuslactone. No antimicrobial activity was detected
in fruiting bodies and mycelia extracts.
Although bacterial community analyses from C. comatus fruiting bodies demonstrated
an efficient infection control mechanism, it improbable that comatuslactone is responsible
for those regulations. This was already demonstrated by Stadler and Sterner, 1998 [69],
when several Basidiomycotina fungi were tested for biological activities before and after
their respective fruiting bodies injury. In this case, C. comatus mushrooms did not exhibit
any activity or changes in their chemical profiling after injury. Nevertheless, it is still not
clear if comatuslactone 9 is a self-defense agent, stored as a glyco-complex, in the cells of
C. comatus vegetative mycelia.
6.4.1 Biological activities
6.4.1.1 Antimicrobial activity
Comatuslactone exhibited bacteriostatic properties against both Gram-positive and Gram-
negative bacteria. To provide more details about the possible mechanism of action of this
compound, P. aeruginosa and S. aureus cells treated with comatuslactone were subjected
to ultrastructural analysis, using TEM. Membrane damage, causing extracellular leakage,
is clearly observed in P. aeruginosa micrographs, together with black dots of unknown
origin. Regarding S. aureus, myelin-like structures could be seen in the treated cells, as
well as a substantial reduction on the cellular diameter.
In 1982, Wecke et al. [235] investigated ultrastructural changes on S. aureus cells treated
with lysozyme. Among several alterations observed, myelin-like structures were also rec-
ognized. Lysozyme catalyses the hydrolysis of the β-1-4 bond between N-acetylmuramic
(NAM) acid and N-acetylglucosamine (NAG), the building blocks of the bacterial cell wall
peptidoglycan. The lysozyme mechanism of action was described on 1969, by Chipman
and Sharon [236].
Peptidoglycan biosynthesis is catalyzed, in its first step, by the UDP-N-acetylglucosamine
1- carboxyvinyltransferase (MurA). This enzyme has been evaluated as a target for an-
tibacterial drug discovery. Fosfomycin is the only MurA inhibitor in clinical use [237, 238].
In 2010, Mendgen et al. [238] have described MurA inactivation by tulipalin B and 1-
tuliposide B. Interestingly, no enzyme inhibition was detected when tulipalin A was em-
ployed. All of those compounds showed antimicrobial activity against a broad range of
bacteria [239]. Further assays using a fosfomycin resistant MurA E. coli mutant revealed
no resistance against tulipalin derivatives, demonstrating other targets than MurA [251].
Considering the ultrastuctural modifications of the bacterial cells towards the presence of
comatuslactone and its similarity with tulipalin B, two mechanisms of action are proposed
to comatuslactone 9:
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a Membrane destabilization. In this case, comatuslactone would interact with nega-
tively charged lipids, causing membrane permeabilization;
b Inactivation of MurA.
Both proposed mechanisms remain to be investigated in detail.
6.4.1.2 Biofilm damaging and dispersal
S. aureus biofilms are commonly associated with osteomyelitis, periodontitis and peri-
implantitis, endocarditis, chronic rhinosinusites, ocular and chronic wound infections.
Furthermore, those biofilms characterize chronic polymer-associated infections, where in-
dwelling devices are colonized, causing a chronic condition [240, 241]. Infections caused
by S. aureus biofilms are related to a mortality rate of 25% in the USA [254].
Despite its bacteriostatic activity, comatuslactone 9 was effective in P. aeruginosa and S.
aureus biofilm damage as well as in P. aeruginosa biofilm dispersal, although no inhibi-
tion on biofilm formation was detected. Even when concentrations below the MICs were
employed, those activities were further observed.
Compared to planktonic bacterial cells, biofilms are much more resistant against antibi-
otics, heavy metals and disinfectants [32, 242]. Considering S. aureus biofilms, it was
already demonstrated that oxacillin, cefotaxime and vancomycin diffusion is deficient into
the matrix [243]. Moreover, in 2011, Thurlow et al. [244] showed that inflammatory me-
diator production and macrophage invasion are attenuated by S. aureus, when growing
on biofilms.
P. aeruginosa biofilms are associated with urinary tract, ocular, ears and burned wound
infections and most of the lung infections in cystic fibrosis patients. As S. aureus, P.
aeruginosa also colonizes medical devices, leading to a chronic condition [245, 246]. A
number of studies have been performed in order to understand the mechanisms underlying
biofilms resistance against antibiotics. In 2013, Hengzhuang et al. [247] showed accumu-
lation of beta-lactamases in P. aeruginosa biofilms matrix. Increased resistance was also
demonstrated against tobramycin. In this case, extracelluar DNA was suggested to bind
the aminoglycosides, decreasing their penetration into the biofilm [28, 248]. Moreover,
the low growth rates of the cells embedded in the lowest biofilm layers, also contributed
to an increased resistance against antibiotics [1, 28, 32].
One novel approach to control biofilm infections is the interference with the QS systems,
quorum quenching (QQ), which have been correlated with virulence factors production
as well as biofilm formation [53, 61]. Following this rational, a number of natural prod-
ucts which exhibit the capacity of inhibiting or dispersing bacterial biofilms were already
identified. Furanones from the macroalga Delisea pulchra (Rhodophyta) are such QQ
compounds and are capable of inhibiting a number of QS-controlled phenotypes, includ-
ing virulence factors. Moreover, those compound scaffolds inspired a number of research
for their synthetic derivatives [53, 54, 55, 56, 57]. Plants such as carrots, garlic, habanero
(chili), and water lily also produce compounds that interfere with bacterial QS systems.
Garlic extracts were demonstrated to be able to clear pulmonary P. aeruginosa infections
in mouse models, and ajoene was recognized as the major QS inhibitor [62, 63, 64, 65, 66].
Therefore, comatuslactone 9 quorum quenching properties was evaluated using two mu-
tants: (a) E. coli MT102 (pSB403) - a reporter for genes lux, responding to short chain
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AHLs [130] and (b) P. putida F117 (pKR-C12) - based on the las QS-system of P. aerug-
inosa, responding to long chain AHLs [131]. Our results showed an inhibition of both
QS systems. Additionally, it was demonstrated that comatuslactone 9 inhibits the QS
products pyocyanin and rhamnolipid B, in an assay using P. aeruginosa PA14.
P. aeruginosa AHL-mediated QS system is based on the V. fisheri luxIR homologous sys-
tem, consisting of LasI and LasR (responding to 3-oxo-C12-HSL) and and RhlI and RhlR
(responding to responsive to C4-HSL). Those systems control the expression of several
virulence genes, such as alkaline protease (aprA), exotoxin A (toxA), pyocyanin, pyover-
dine, the Xcp translocation machinery, cyanide, lipase, rpoS, twitching motility, azurin
(azu), alginate and chitinase, as well as catalase and superoxide dismutase (katA, sodA
and sodB) [249, 250]. Biofilm formation is essential for P. aeruginosa pathogenicity and
persistence. However, its relation with QS systems is not yet fully understood. Davey et
al. 2003 [251], working with a P. aeruginosa PAO1 mutant strain uncapable of synthesize
rhamnolipids, demonstrated that those molecules regulate biofilm architecture, without
affecting initial biofilm formation. Furthermore, rhamnolipid B displayed hemolytic and
biosurfactant properties. In 2007, it was demonstrated by Jensen et al. [252] that rham-
nolipid B affects polymorphonuclear leukocytes (PMNs), causing necrosis and enabling
P. aeruginosa persistence in the lungs. HPLC-MS-MS experiments using P. aeruginosa
cultures treated with comatuslactone 9 demonstrated rhamnolipid B production inhibi-
tion. 3D reconstructions of the in vitro treated biofilms showed a volume decrease of
approximately 85% with the employment of 37.5 µg/ml of comatuslactone. Besides QS
and rhamnolipid B inhibition, no initial biofilm inhibition was detected.
Moreover, inhibition of pyocyanin production was also investigated using comatuslac-
tone. Pyocyanin causes alterations of calcium concentrations in the cytoplasmic matrix
of the epithelial cells, inhibiting their ciliary activity and leading to lung damage. It
was demonstrated that pyocyanin also inhibits the expression of interleukin (IL)-2 and its
receptor and stimulates IL-8 release in human epithelial cells [253]. Usually, a spectropho-
tometric method, described by Essar et al. [254] is used to perform this assay. Here, a
HPLC-MS-MS method was developed for pyocyanin quantification in culture media. Co-
matuslactone 9 inhibited pyocyanin production by 80%. Synthetic autoinducer-mimics
were investigated by Morkunas et al. 2012 [255] who found that most compounds antago-
nized pyocyanin production, whereas no structure activity relations could be established.
Raloxifene, an oral selective oestrogen receptor modulator was also reported to inhibit
pyocyanin biosynthesis [256].
The results of interference with QS systems were dispersed and thinner biofilms, together
with the decrease of virulence factor expression. Hence, biofilms become more accessible
to antibiotic therapies and to the host immune system.
6.4.1.3 Cytotoxicity to eukaryotic cells
Results obtained with an impedance method assay, showed no cytotoxic mechanisms
associated with comatuslactone. Moreover, cell morphology visualized by fluorescence
microscopy suggested that comatuslactone acts as a cytostatic compound. Interestingly,
despite their structural similarities, it was reported that tulipalin A possesses an IC50
value of 0.8 µg ml−1 [257]. This compound is known for causing contact allergies among
workers in the tulip fields. Guinea pigs have been used for sensitization against aller-
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genic compounds and both (+)-tulipalin A, and (-)-tulipalin A showed positive reactions.
On the other hand, when tulipalin B was evaluated, the positive reactions were enan-
tiospecific, while (-)-tulipalin B showed no such effect. The synthetic (+)- and (-)-beta-
hydroxy-gamma-methyl-alpha-methylene-gamma-butyrolactones were also evaluated by
Papageorgiou et al. 1988 [228]. Here it is critical to emphasize that (-)-beta-hydroxy-
gamma-methyl-alpha-methylene-gamma-butyrolactone was isolated in this work as the
natural product comatuslactone 9. As (-)-tulipalin B it did not sensitize the tested ani-
mals [228, 229].
Nevertheless, further characterization of comatuslactone 9 regarding its impact on eu-
karyotic systems is required in order to evaluate possible applications concerning human
health.
Moreover, with the data obtained within this work in combination with the literature
reports about tulipalins on their biological activities it is possible to propose:
a The hydroxy group decreases the toxicity of tulipalin B and comatuslactone against
fungi and increases at the same time the toxicity against bacteria; on the other
hand, the lack of this hydroxyl-group (tulipalin A) increases the toxicity against
eukaryotic cells.
b The methylene group is essential for the biological activities, since (2S, 3R, 4S)-2-
methyl-3,4-dihydroxypentanoic acid 1,4-lactone did not show any of the evaluated
activities.
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Chapter 7
Concluding remarks
Fungi are known as a rich source of bioactive compounds. Therefore the present study
aimed the use of those organisms to produce metabolites with biofilm modulatory prop-
erties. The rationale employed was based on fungal self-defense mechanisms, since their
sporocarps offer ideal substrata for bacterial colonization with subsequent biofilm forma-
tion. Moreover, fungal vegetative mycelia share ecological niches with bacteria, insects
and other fungi, which imposes successful competition strategies for survival. Here, for the
first time, bacterial communities associated with mushrooms were evaluated addressing
biofilm modulators compounds research. The obtained results demonstrated interesting
data, as the lack of bacterial attachment on the surface of certain fungi, particularly
C. comatus. From this species, a compound, named comatuslactone, showing bacterio-
static, biofilm and quorum sensing modulating properties was successfully isolated. Co-
matuslactone was demonstrated to be cytostatic against eukaryotic cells. Nevertheless,
its effects on such cells should be further characterized in order to evaluate its possible
uses in the clinics. Regarding the interactions of fungi with their bacterial neighbours,
the exploitation of such synergies may be a valuable approach on drug discovery pro-
grams. Additionally, 6 roridins and fusidic acid were purified from the parasitic fungus
C. arbuscula. Roridins have been evaluated as anticancer compounds and show selectiv-
ity for eukaryotic organisms. However, their applicability on human therapy is still not
clear, since the exact mechanism of cytotoxicity is unknown. Nevertheless, a number of
roridins show specificity against cancer cell lines, but again the structure requirements
which could improve such feature are still unidentified. Studies on their structure activity
relationships are highly recommended. All of the roridins produced by C. arbuscula pos-
sessed C-6’S-configuration. This is the first report of such stereospecificity. C. arbuscula,
which parasites other fungi, shows two faces: it produces at the same time compounds
responsible for human and animal intoxications and crop diseases, as well as an antibi-
otic already used in the clinics, especially against methicillin resistant S. aureus. These
findings demonstrate that ecological considerations can be useful in drug discovery.
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Chapter 8
Supplementary material
8.1 Screening
Figure 8.1: Fruiting bodies of some mushrooms used in this work. A-Macrolepiota fuligi-
nosa, B-Laetiporus sulphureus, C-Pholiota lenta and D-Russula emetica.
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Figure 8.2: Fruiting bodies used for the SSCP fingerprint analysis. A-Boletus edulis,
B-Boletus edulis, C-Coprinopsis atramentaria and D-Boletus edulis.
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8.2 Quantitavive HPLC-MS/MS
Figure 8.3: Pyocyanin standard curve.
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